|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/7/15 ¤W¤È 08:08:23
|
¤½¥q¬ãµoµ¦²¤¦b©ó»P¤@¯ëÃļt°µ©úÅã°Ï¹j¡A ¤£¥HÄvª§¿E¯P¤§©ú¬PºZ¾PÃÄ¥«³õ¬°¾É¦V¡A ¦Ó¥H³Ð·s«äºû¿ï¾Ü§Q°ò¥«³õ¤Á¤J¡A«Ø¥ß¨ã¯S¦â¤Î·s ¿o©Ê¤§»sÃÄÃöÁä§Þ³N¥¥x¡A¨Ã¤À¬ãµo¤è¦V¶i¦æ¡K ¦h¦~¨Ó¤½¥q¦b¨S¦³¦W¤H¥úÀô¥[«ù¤Î¤j°]¹Îª÷´©¤U ¤´¤@¨B¤@¸}¦Lªº¥H§xÃø¾Ç¦WÃĤΤfªA§Þ³N·sÃÄ¥¥xÂù¥D¶b¦P¨Bµo®i ¦b10¦h¦~ªº§V¤O¤U¡Aº¥º¥ªº¤]¬Ý¨ì¤F¤@¨Ç¦¨ªG ¥¼¨Ó1~3¦~¤ºÈ±o´Á«Ýªº¶i®i¦³: ¹Å¦h©ú¨ú±o¬ü°êÃÄÃÒ ¦]¸¿Õ¥X³f¤g¦Õ¨ä¤Î¥Ó½Ð¬ü°êÃÄÃÒ Carvedilol CR ¶i¦æ30¤H¥ÍÅé¬Ûµ¥©Ê¹êÅç¡B±ÂÅv¤Î¥Ó½Ð¬ü°êÃÄÃÒ Gemcitabine Oral ¶i¦æÁ{§É¤G´Á¤Î±ÂÅv µu´Á«h¬O¦³´¶Àù¨O¡B¹Å¦h©ú¡B¹Å¦hµø«Ø¡B¦]·ü¹çµ¥ÃĪ«°^Äm°ò¥»À禬 °£°ê¤ºÀ禬«ùÄò¦¨ªø¥~¥ç³°Äò»P¦U°ê¬¢Ã±¸g¾P¦X¬ù¡K ´Á¬ß¤½¥q¯à°÷¤@¨B¤@¸}¦L¿v¹Ú½ñ¹ê§¹¦¨ªÑªF·|³q¹L¤§¦U¶µÁZ®Ä«ü¼Ð |
|
·|û¡GJacK10145269 µoªí®É¶¡:2018/1/29 ¤U¤È 04:46:17²Ä 133 ½g¦^À³
|
ÁÂÁ¦ÌÄ_¤j¤j´£¿ô¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2018/1/29 ¤U¤È 01:42:30²Ä 132 ½g¦^À³
|
Hi Jack¤j «e¨â¤Ñ¥t¥~Á¿¨ìªº¨º¤@ÀɪѲ¼ ±zn¯S§O¤p¤ßºO ±ÀÂ˨é°Ó쥻´N¶È³Ñ¨â®a ¤µ¤Ñ¦³¤@®a¨é°Ó¦³¬Û·íªø¤@¬q®É¶¡³£¨S¦³³ø½æªºµP»ù¥X¨Ó¤F..... §Æ±æ¤£¬O¤p§Ì·Qªº¨ººØ±¡ªp........ |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2018/1/28 ¤U¤È 10:20:39²Ä 131 ½g¦^À³
|
ÁÂÁÂcstang¥Î¤ß¤ÀªR»¡¡A§V¤Oªº·sÃĤ½¥q¡A¤j®aÁÙ¬O·|¤ä«ùªº¡A¥[ªo! |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2018/1/28 ¤U¤È 09:25:17²Ä 130 ½g¦^À³
|
³o¨â©P«ùªÑ¶q¤jªºªÑªFÁÙ¬OÄ~Äò¦b¶R¤J¦]µØªÑ²¼ªº,¦p¤U(²Îp¼Æ¦r¬O10±i¥H¤W) ³\¤UªL¤Wªº¤é´Á¬OW03 2018/1/16 800~1000±iªÑªF 1000±i¥H¤WªÑªF 2018W04 5,390 ( 6¤H) 26,290 ( 8¤H) «ùªÑ800±i¥H¤WªÑªF¼W¥[120±i 2018W03 6,370 ( 7¤H) 25,190 ( 7¤H) «ùªÑ800±i¥H¤WªÑªF¼W¥[ 50±i 2018W02 6,370 ( 7¤H) 25,140 ( 7¤H) «ùªÑ800±i¥H¤WªÑªF¼W¥[130±i 2018W01 6,350 ( 7¤H) 25,030 ( 7¤H) «ùªÑ800±i¥H¤WªÑªF¼W¥[ 10±i 2017W52 6,350 ( 7¤H) 25,020 ( 7¤H) «ùªÑ800±i¥H¤WªÑªF¼W¥[140±i 2017W51 7,340 ( 8¤H) 23,890 ( 6¤H) 2017W50 7,280 ( 8¤H) 23,890 ( 6¤H) 2017W49 7,270 ( 8¤H) 23,910 ( 6¤H) 2017W48 7,280 ( 8¤H) 23,930 ( 6¤H) «ùªÑ¶}©l½æ¥Xªº«o¬O«ùªÑ¼Æ¤Öªº¤pªÑªF¤F,§Æ±æ¤jªÑªF¯à°í«ù¤U¥hÄ~Äò¶R¦^ªÑ²¼,¥[ªo! ÁöµM¤§«e´£¨ì¥þÅ鸳ºÊ«ùªÑ¶q¦³³v¤ë¤U°ªºª¬ºA(½æ9±i¨Æ¥ó),¤£¹L¤ñ¸û¤@¤Uª¬ªp¦p¤U, «D¿W¥ß¸³ºÊ«ùªÑ¤ñ¨Ò 2017/12 25.2% 2017/11 25.4% 2017/10 25.7% 2017/06 29.6% ¦]µØ¥H¨CªÑ18¤¸¼W¸ê 2017/05 22.8% 2017/03 22.8% ¥H«D¿W¥ß¸³ºÊ«ùªÑ¤ñ¨Ò¨Ó¬Ý²{¦bªº«ùªÑ¤ñÁÙ¬O¤j©ó18¤¸¼W¸ê«e,©Ò¥H¸³ºÊ·íªì¬°¤FÅý¦]µØ¼W¸ê¦¨¥\(¬°¤F¦]µØ¥i¥HÄ~ÄòÀç¹Bªº²{ª÷)¦Ó¦Y¶i¥hªºªÑ²¼ÁÙ¤j³¡¤À¬O¯d¦b¤â¤Wªº,²{¦bªÑ»ù§C©ó18¤¸,§Ú·Q«D¿W¥ß¸³ºÊ(À³¸Ó¬O¦b°·X¤â¤W)À³¸Ó¨S¦³¿ìªk¦b¥X³f¤F,µÛÓ·|p±bÀ³¸Ó¬O°µ¤£¥X¨Ó......... ¦b¥Ø«e¦]µØ³Ì»Ýn¸êª÷ªº®É¨è(¥Ó½ÐÃÄÃÒ,1/2´Á¥þ²y¤HÅé¸ÕÅç,·sÃĶ}µo,¤Ñ¤Ñ³£¦b¿N¿ú), ¦p¦P¤p¦a¤W¤W¦¸©Ò´£ : ¦]µØ¦b 106¦~²{ª÷¼W¸ê¤½¶}®ÑP57~P58,(106/107¦~¤½¥q²{ª÷¦¬¤ä¹w´úªí)´£¥X107¦~1¤ë¤½¥q²{ª÷±b±N·|p³]©w³Ì§C¦w¥þ²{ª÷¬y°Ê¶q,·|pªºpµe¬O¦A¼W¸ê¥H´£¨Ñ107¦~«×²{ª÷©PÂà,¥Ø¼Ð¬O3»õ,¨Ñ107¦~¦U¶µ¬ãµo¤Î¥Ó½Ð³W¶O¨Ï¥Î ,³o»òÃe¤jªº²{ª÷¦pªGn¦A¥Î²{ª÷¼W¸ê©Î¬O¥Ó½Ð¤WÂdªº¤è¦¡¨Ó¶Ò¶°,¥H²{¦æ½\»ù¨Ópºâµ´¹ï¬O¤@¥ó,«D±`XXXXªº¨Æ¥ó(¬ù·í¼W¸ê18,000±i) ©Ò¥H¥H°Ó³õ¦Ñ«e½úªL¸³©Ü¾Ô³T¨Ó¹F¦¨¶°¸ê(¨p¶Ò,µ²·ù,Åv§Qª÷,»È¦æɶU...........),µ´¹ï¬O¤ñ¹L¥h¨Óªº®e©ö¹F¦¨,¦Ó¥B¬O«D¹F¦¨¤£¥i!!!!! ¤p§Ì¬OÃÙ¦¨¦b³oÓ®ÉÔ ³\¤UªL¤W ¨¯WªL¸³!!¥[ªo!!¤p§Ì¤ä«ù§A,¥»©PÁÙ¬O¦³«ùÄò¶R¶i!! |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2018/1/28 ¤U¤È 07:17:09²Ä 129 ½g¦^À³
|
§YµMªL¸³¨C¤Ñ½æ9±i¡A¨º¤p´²¤á§ä±o¨ì©T¦u¤Q¦æÜ®wªº²z¥Ñ¶Ü¡H½T¹êÅý¤H·P¨ì¥i±¤¤]·P¨ì¥¢±æ! |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2018/1/26 ¤U¤È 11:49:57²Ä 128 ½g¦^À³
|
ÁÂÁ¦ÌÄ_¤j¤j´£¿ô¡A§Ú·|¦AÁA¸Ñ¬Ý¬Ý!§Ú¶RªÑ²¼¨S¦³«Ü¥Î¤ß¬ã¨s¡Aı±o¤£¿ù´N¶R¤F¡A¥H«á§Ú·|§ó¥Î¥\¨Ç¡C |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2018/1/26 ¤U¤È 11:21:34²Ä 127 ½g¦^À³
|
³Ìªñ¦b¬Y½g¬ã¨s³ø§iªººKnùجݨì¦]µØ¤´³Qµø¬°Left Ventricular Dysfunction(¥ª¤ß«Ç¥\¯à¤£¥þ)ªºtop players¤§¤@, ·íµM¬O«üCarvedilol CR¥Ø«eªº¬ã¨s¦¨ªG. µM«á¥h¦~©³Coreg CR ªº¾Ç¦WÃijQ¬ü°êFDA approved¤F,¸ÓÃļt(Sun Pharma)pºâì¼tÃÄ12Ó¤ë¤j·§¦³2.08»õ¬üª÷ªº¾P¶q. (¥h¦~¦~³ø¦]µØ«ü¥XCarvedilol CRnÄvª§ªº¬O¤T»õ¬üª÷ªº¥«³õ,¥i¯à¬O¥]¬A«DCRª©¥») ÁöµM¾Ç¦WÃĪº¥X²{¾ÉP°â»ù¥i¯àÅÜ®t,¦ý¥Ñ¤§«e¬Ý¨ìªº¬ã¨s³X½Í(2014¦~¤é²±§ëÅUªº³X½Í)¥iª¾¦]µØªºCavedilol CRÃĮĬO¤ñCoreg CR¦n, ¤W¥««áÀ³¸ÓÁÙ¬O¯à·m¤U¤£¤Ö¥«³õ. ³Ì«á§Æ±æªL¸³¦Ü¤Ö¥X¨ÓÁ¿Ó¸Ü»¡©ú¦]µØªº²{ªpÅý§ë¸êªÌ©ñ¤ß,¨C¤Ñ9±i¤]¤£n¦A½æ¤F,³£¤w¸gÁ«¥»¤F. ´Á«ÝªÑ»ù¦¤é¦^Ã,Åý§ë¸êªÌ¹LÓ¦n¦~. |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2018/1/26 ¤U¤È 09:34:52²Ä 126 ½g¦^À³
|
JacK¤j±z«È®ð¤F ²{¤µ¥Í§ÞªÑ¦ü¥G¤w¸g¬Ý¨ì¤F¤@¨Ç¬K¿P¤F ¦b¾¤©ú¤]³\§Y±N¨ì¨Óªº®ÉÔ ¿ï¾Ü¶^²`¥B¨ã³Æ3°](¤H¤~ ÃD§÷(Ãħ÷) ¿ú°])ªºÁZÀu¥Í§ÞªÑ¤]³\¬O¥i¥H¦Ò¼{ªº¿ï¶µ ¤£¹L´N¦]µØ¨ÓÁ¿¥Ø«e¬O¦³ÂIÂøµªº ¤p§Ì¦]өʤñ¸ûÀt¤ò ¥Ø«e¬O¥ýÆ[±æ...... ¥t¥~®e¤p§Ìµy·LÂû±C¤@¤U ±z³o¨â¤Ñ¦b¬Yª©§OÀɪѲ¼¦ü¥G¤]¦³¸ß°Ý¸ÓªÑÃþ¦üªº°ÝÃD ¤p§Ì¦n©_µy·L¬Ý¤F¤@¤U ¸ÓÀɪѲ¼°ò¥»±¤p§Ì¬O¨S¦³²`¤J¬ã¨s ¤£¹L¸ÓªÑ³Ìªñ¤½§iºI¦Ü02¤ë02¤é¹wp²{ª÷¤Î»È¦æ¦s´Ú¾lÃB¶È³Ñ·s¥x¹ô3,126¥a¤¸ ¦Ó¤U©Pn¤ä¥Iªº±b´Ú¬°·s¥x¹ô1,089¥a¤¸¥i¥H»¡¦b´X©P¥i¯à±b¤W²{ª÷´N¤£°÷¤äÀ³¤F.... ¸ÓªÑªñ´Áªº²{ª÷¼W¸ê¬Û·íªºÃöÁä....¦pªG¦³©Ò°{¥¢©Î¿ð©µ¨º´N¬Û·íªº¦MÀI.... ¥t¥~À³¦¬±b´Ú¬Û¸û¥h¦~¬O¦³Ãk¤Éªº±¡§Î¤]¬On¯d·Nªº..... (¥H¤W³o¬q¬O¤p§Ì²Ê²Lªº»{ÃÑ ¹ï¸ÓªÑ¤p§Ì¬ã¨s¨Ã¨S¦³«Ü²` ¦pªG¦³Á¿¿ù©|½Ð¦U¦ì¤j¤j¤£n¨£©Ç).... |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2018/1/26 ¤U¤È 03:45:28²Ä 125 ½g¦^À³
|
ÁÂÁ¦ÌÄ_¤j¤j¸Ô²Ó»¡©ú¡C§Ú¤µ¤Ñ¦]¤âÄo¤£¤p¤ß¶R¤F¦]µØ¡A©Ò¥H¤~½Ð±Ð±z!ÁÂÁ±z¸ÑºÃ¡A®¦! |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2018/1/26 ¤U¤È 03:30:12²Ä 124 ½g¦^À³
|
¦]µØªÑ»ù·|³o»ò®z¶Õªñ¦]¬°Á`¸g²zÃã¾ ³o¶¡¤½¥q¥i¥H»¡¬O³\Á`¸ò°q°ÆÁ`¤@¤â³Ð¿ìªº ¥L̨â¸òªL¸³¥i¥H»¡¬O³o¶¡¤½¥qªºÆF»î¤Hª« ¦Ó³Ð¿ì¤H«o¦b¤½¥q¦U¶µ·~°È±À®iÃöÁä®É¨è ¥Bè©Û³{¤@¨Ç°f·ªº®ÉÔÃã¥ô ¦U¶µ·~°È±À®i¤Î¸gÀç¤è¦V¬O§_·|¨ü¨ì¼vÅT? ¤Î¬O§_·|¦³·s¤@ªiªº¤H¨Æ²§°Ê³£¬O»Ýn®É¶¡Æ[¹îªº¡C ¦Ó¤¤´Áªº¦]¯À«h¬O¦Û¥h¦~8¤ë¥H¨Ó¾D¹Jªº¤@³s¦êªº¤£¶¶§Q ±q8¤ë°_¦X§@¹Ù¦ñªFoo¤½¥q°ª¦åÀ£ÃĵL¹wĵªººM¥ó ªñ¤@¨B¤Þµo¤F12¤ë©³¤WÂd¥Ó½Ð®×µLªk¦p´Á´£¥X ¾ÉP¤½¥q¦bªñ´Á¥²¶·¥t´MºÞ¹DÄw¸ê¡K..¦b¦bªº³£·|À£§íªÑ»ùªºªí²{ Ó¤Hı±o¤½¥qµu´Á¦]¸¿Õ¸òÅã¼v¾¯³£¬O¦³¾÷·|ªí²{ªº«~¶µ ¤£¹L¥Ø«e¤½¥q½T¹ê¤]¦³¤£¤ÖÃøÃö¥²¶·§JªA (¤Hûªº§ó¡ Àç¹B¤è°wªº©µÄò ¸êª÷ªºÄw±¹ ¬ÛÃö«~¶µ¬O§_¥i¦p´Á¨ú±oÃÄÃÒµ¥µ¥) ¦Ó³o¨Ç³£¬O»Ýn¤@¬q®É¶¡ªºÆ[¹î¸òµ¥«Ýªº¡K¡K.. |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2018/1/26 ¤U¤È 02:34:29²Ä 123 ½g¦^À³
|
¦U¦ì¤j¤j¦n¡A½Ð°Ý¦]µØ¬°¤°»ò¤@ª½¶^?§Ú°O±o¦]µØ¥H«eªÑ©Ê«Ü¬¡¼â¡A¦ý¦Û±q30¤¸±¼¤U¨Ó¦Ü¤µ¤w«Ü¤[¡A«o¤£¨£¦³°_¦â?¤£ª¾¤°ì¦]?½Ð±Ð¦U¦ì¤j¤j¡A³o®a¤½¥q«e´º¦n¤£¦n?¦]§Ú¦L¶H¤¤¥L¬O¦n¤½¥q¡AªÑ»ù³o¼Ë¦³ÂI¤£¦X²z§r? |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2018/1/19 ¤U¤È 05:06:12²Ä 122 ½g¦^À³
|
«i´±ªº³{§C¶R¶i¡A¬Ý¬Ý¯q±o³Ìªñªº®ð¶Õ¡AªL¸³¤µ¦~¤U¥b¦~·|µ¹¦]µØ¤@Ó¦X²zªº¥æ«Ýªº¡A¤p§Ì¥Ø«e¨C¶g³£ÁÙ¦b¶R¶i¤¤ |
|
|
·|û¡G¤Ñ¦æ10138985 µoªí®É¶¡:2018/1/19 ¤U¤È 01:08:39²Ä 121 ½g¦^À³
|
ªÑ»ùÁÙ¬OÅý¤H¥¢±æ, §Æ±æ¤½¥q¯à¦³¦n®ø®§¶Ç¥X |
|
|
·|û¡GBiotech Ki10145805 µoªí®É¶¡:2018/1/17 ¤U¤È 01:42:54²Ä 120 ½g¦^À³
|
¬O¦p¦¹¶Ü? |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2018/1/17 ¤W¤È 11:54:02²Ä 119 ½g¦^À³
|
¤p§Ìı±oÀ³¸Ó¤£¬Oµo¥Í¤°»ò¤j¨Æ¡AÀ³¸Ó¬O¥ÑªL¸³n¦Û¤v¸õ¥X¨Ó¶Ò¸ê§ä¿ú¥[¤W«e±´X¦¸¤£¶¶§Qªº¨Æ¡AªL¸³·Q¥X¨Ó§ß¤@¤U |
|
|
·|û¡G¤Ñ¦æ10138985 µoªí®É¶¡:2018/1/17 ¤W¤È 10:36:32²Ä 118 ½g¦^À³
|
¤£ª¾¹Dµo¥Í¤°»ò¨Æ? ªÑ»ù«ùÄò¦b¯}©³ |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2018/1/16 ¤U¤È 07:11:42²Ä 117 ½g¦^À³
|
¤½§i¥»¤½¥q¸³¨Æ·|³q¹LÁ`¸g²z²§°Ê 1.¸³¨Æ·|¨Mij¤é´Á©Îµo¥ÍÅܰʤé´Á:107/01/16 2.ÂÂ¥ôªÌ©m¦W¤Î²¾ú:³\ªø¤s ¦]µØ¥Í§Þ»sÃĪѥ÷¦³¤½¥qÁ`¸g²z 3.·s¥ôªÌ©m¦W¤Î²¾ú:ªL´¼·u ¦]µØ¥Í§Þ»sÃĪѥ÷¦³¤½¥q¸³¨ÆªøÝ¥ôÁ`¸g²z 4.²§°Ê±¡§Î¡]½Ð¿é¤J¡uÃ㾡v¡B¡u¾°È½Õ¾ã¡v¡B¡u¸ê»º¡v¡B¡u°h¥ð¡v¡B¡u¦º¤`¡v©Î¡u·s ¥ô¡v¡^:Ãã¥ô 5.²§°Êì¦]:¥»¤½¥q107/01/16¸³¨Æ·|³q¹L¥ô©R¡C 6.·s¥ô¥Í®Ä¤é´Á:107/01/16 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL¡C ¦³¤j¤j¤F¸Ñµo¥Í¤°»ò¨Æ¶Ü??? |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2018/1/16 ¤U¤È 01:15:20²Ä 116 ½g¦^À³
|
Hi cstang¤j, ¤p§Ìµy·L§â³o¤@°}¤lªºÄw½X¤ÀªR¤@¤U (1)¥Dn¶R¤è¬O²Î¤@·s¥x¤¤³oÓ±b¤á,¦ôp¥L´N¬O·s¼Wªº¤d±i¤j¤á,¤£¹L³o´X¤Ñ¥L¤Ï¤â½æ¥X¤F (2)¥Dn½æ¤è¬O±d©M,¤j·§¸ò²Î¤@¶R¶iªº¦P®É¶¡¶}©l˳f (3)¥t¤@¶R¤è¬°¤¸´I«°ªF,¤j·§¤W§«ô¥½¶}©l¶R¤J ®Ú¾Ú§Úªø´ÁÆ[¹î,²Î¤@³oÓ¤áÀY±`±`¤j¶q¶R¤JµM«á¹L¤£¤[´N½æ¥X,·PıÁ«¿ú©~¦h ±d©M¤§«e¤]ºCºC¦³¦b¶i³f,¦ý¦b18¶ô¤W¤U˳f·Pı¤]¬OÁ«¿ú. ¤¸´Iªº¶R¶i¥i¥HÆ[¹î¥L·|¤£·|¬Oªø´ÁĹ®a ,²¦³º¥L¼È®É¶R¦b¥»ªi§CÂI §Ú¤´µM¤Q¤À·P´n³o¦¸¤WÂd®×³QºM¦^,¦pªG¯à¤Þ¶i·sªº¸êª÷À³¸Ó·|¹ïªÑ»ù¦³©Ò§U¯q,¦b³oªÑ¥«¤j¦hÀYÁÙ³o»ò·|À£ªÑ»ùªº¥D¤O¯u¬O¤£¦h¨£, ¤×¨ä¬Ý¨ì¯q±o¤w¸g©¹50¥H¤WÁÚ¶i§ó¬O·P¨ì¤£³Ó®D¼N. ÁÙ¬O§Æ±æ¤½¥q¦U¶µ·~°È¯à¦³¦n®ø®§¥X¨Ó. |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2018/1/14 ¤W¤È 11:48:09²Ä 115 ½g¦^À³
|
ÁöµM¸³ºÊ¨Æ¦b2016/7¶}©l±N¤§«e¬°¼W¸ê¦Y¦hªºªÑ²¼¦b¥«³õ¥H¥¼¥Ó³ø¨C¤é9±iªº¼Ò¦¡½æ¥X¬ù1115±i(ºI¦Ü106/12)..................¦ý¬OÁÙ¬O¦³¦nªºª¬ªp¥X²{ ³o¨â©P«ùªÑ¶q¤jªºªÑªF¤w¸g¦³¶R¤JªÑ²¼ªºªí²{,¦p¤U(²Îp¼Æ¦r¬O10±i¥H¤W) 800~1000±iªÑªF 1000±i¥H¤WªÑªF 2018W02 6,370 ( 7¤H) 25,140 ( 7¤H) 2018W01 6,350 ( 7¤H) 25,030 ( 7¤H) 2017W52 6,350 ( 7¤H) 25,020 ( 7¤H) 2017W51 7,340 ( 8¤H) 23,890 ( 6¤H) 2017W50 7,280 ( 8¤H) 23,890 ( 6¤H) 2017W49 7,270 ( 8¤H) 23,910 ( 6¤H) 2017W48 7,280 ( 8¤H) 23,930 ( 6¤H) «ùªÑ¶}©l½æ¥Xªº«o¶}©l¦¡«ùªÑ¼Æ¤Ö¶qªº¤pªÑªF¤F,§Æ±æ¤jªÑªF¯à°í«ù¤U¥h ¤£n¦A½æªÑ¤F |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2018/1/7 ¤U¤È 10:41:41²Ä 114 ½g¦^À³
|
·PÁ¦ÌÄ_¤j¦p¦¹¨³³tªº¦^À³¡A§Æ±æ¦]µØ¦U¶µ·~°È¯à¶¶§Q¶i¦æ |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2018/1/7 ¤U¤È 10:14:23²Ä 113 ½g¦^À³
|
Hi mogwai¤j ¤fªA§ÜÀùÃij¡¤ÀÁ{§É¹êÅç¬ÛÃö¸ê®Æ¤w¸gµn¿ý©ó¥xÆWÃĪ«Á{§É¸ÕÅç¸ê°Tºô www1.cde.org.tw/ct_taiwan/search_case2.php 11/29®Öã¡@¢°¢±/30µn¿ý¡@¬Û¸û©ó¬ü°ê¬ÛÃö¸ê°T©|¥¼µn¿ý¡@¥xÆWªºÁ{§É¹êÅçµn¿ý¬Û·í¨³³t¡@À³¸Ó¬O¸ò¤½¥q§Æ±æ¦h¦¬ÂI¥xÆWªº¯f¤H´î¤Ö¶}¤ä¦³Ãö ¡]¤£¹L´Nµn¿ý¸ê®Æ¨Ó¬Ý¥Ø«e¶i¦æªº¦ü¥G¤ñ¸û°¾¦V©ó¬O1b/2´Á¦³Ãö¾¯¶q¾Ü©w¤Îªì¨BÀø®ÄªºÁ{§É¹êÅç¡A¥¼¨Ó°£«DÀø®Ä¦nªº¤£±o¤F¤£µMÀ³¸Ó§@§¹«áÁÙ·|»Ýn¶i¦æ¤@ӼϯùêÅç¡A¤£¹L³æ´N±ÂÅv¨ÓÁ¿²z½×¤W§¹¦¨1b/2 ´Á¹êÅç¬Æ¦Ü¥H³oÓÃĪ«¨ÓÁ¿§¹¦¨¢°¢ê³o¤@³¡¤À«áÀ³¸Ó´N¨ã³Æ¤ñ¸û¥R¤Àªº±ÂÅv±ø¥ó¤F¡K..¡^ °w¹ï¦]¸¿Õ³¡¤À³oÀ³¸Ó¬O¥Ø«e¤½¥q²£«~¤¤¸ß°Ý«×¤ñ¸û°ªªº 1.«e°}¤lñ¬ùªº¨ºÓ¥«³õ´N¤p§Ì¤F¸Ñ¥Ø«e·|¥ý¶i®Æ¸Õ²£¡@¸Õ²£¶¶§Q«á¶i¦æÃÄÃҥӽмf¬d¬yµ{¬ù¢µÓ¤ë¡ã¢°¦~¡A¸Ó¥«³õ¤£¤p 2.¬ü°ê¥«³õ¤§«e¸ß°Ýªºµ²ªG¬O¤½¥q§Æ±æ¤O«÷¦b¤@¦~¤º¥Ó½ÐÃÄÃÒ¡]¬O§_·|¢ì¢í¢ô¢é£B´N¤£ª¾¤F¡^¡A´N¤p§Ì¥»¤Hªº²z¸Ñ¦]¬°¦]µØ¬O¤p¤½¥q¬G¥Ó½ÐÃÄÃÒ«e²z½×¤W¤@©w·|±ÂÅv¡]¦]¬°³o¬O¢Þ¢³ªº®×¥óì¼t¬°¤F®Â½Ã¸ÓÃÄ¥¨¤jªº¾P°â§Q¯q¡A¥²©w·|¥H¶D³^¤è¦¡¨Ó±À©µÄvª§ªÌÃĪ«ªº¤W¥«¡A¦Ó¦]µØ¬O¤p¤½¥qµL¤H¤O¸ò°]¤O¸ò¤jÃļt¶D³^¡A¬G¤@©w·|§ä±aÀY¤jô¨ÓÀ°¦£¡^¡A¨º¦pªG¸ÓÃĦ]¬°³o¼Ë³Qì¼t§Q¥Î¶D³^¤â¬q±À¿ð¨ì¢±¢¯¢±¢¯¦~«á·|«ç¼Ë¡H¦pªG¤½¥qªºÃĬO¦³Ävª§¤O¥B³Ì«á¶D³^µ²ªG¨S¦³«I¥Ç¨ìì¼t±M§Q¨º¼Ë¤½¥q¥i¥H¸òì¼tn¨D¦]¬°¶D³^¤zÂZ¦Ó³y¦¨©µ«á¤W¥«¤§Àç·~·l¥¢(³o³¡¤À¤]¬O¬Û·í¸Éªº)¤§«á´N¬Ý©¼¦¹²£«~ªºÄvª§¤O¤F....¡A¤£¹L¦]¬°³oÓÃħt¦]µØ¸òì¼t¦b¤ºÁ`¦@¤]¤~4®a¼t°Ó¹è¥e¡A¬G²z½×¤W¨ÓÁ¿¥un±ÂÅv¹ï¶H¤£n¤Ó®tªº¸ÜÀ³¸Ó¤]¬O¥i¥H·m±o¤@®u¤§¦aªº 3.°£¦¹¤§¥~´N¤p§Ì¤F¸Ñ¸ÓÃĪ«À³¸Ó¦b¨ä¥L¥«³õ¸ß°Ý«×¤]¬O¬Û·íªº°ª¡A¦pªG¤µ¦~¦b¨ä¥Lªº¤j°Ï¥i¥H¦A±ÂÅv¥X¥hªº¸ÜÀ³¸Ó¤]¬Û·í¦³¥i¬Ý©Ê Á`µ²´N¦]¸¿Õ³o¤@Ó²£«~¨ÓÁ¿ À³¸Ó·|¬O³o´X¦~¬Û·í·m²´ªº¤@Ó²£«~¡A«e±3Ó°Ï°ì³o¨â¦~¥un¥ô¦ó¤@°Ï¥i¥H¶¶§Q¨ú±oÃÄÃÒ¤W¥«¡A¤W¥««á¤@°}¤l¥i°^ÄmªºÀ禬À³¸Ó·|»·°ª©ó±z¦ôªº6000¸U¤F(«Y«ü¤W¥«À禬éw«á¡A¦p³æ¬Ý107¦~¤µ¦~ªº¸ÜÅܼƴN¬Û·íªº¤j....) C08001³oÓ²£«~¤§«e¤½¥qªk»¡¦³¹w¦ô¥¦ªº²L¤O¬ù2»õ¬üª÷ ¤p§Ì»{¬°¦p¯à¶¶§Q¤W¥«À³¸Ó´N¬O¤½¥q¤jµoªº®ÉÔ ¤£¹L¦]¬°¦b8¤ë«áµo¥Íªº¤@³s¦ê¨Æ¥ó¤p§Ì¬O¼È®É¥ý«O¦¬¦ôºâ¥¦ªº»ùÈ ¦ý¤]§Æ±æ¥i¥H¦b2¦~¤ºÅ¥¨ì¬ÛÃöªº¦n®ø®§©Ô Åã¼v¾¯: °O±o¤§«eªºµ§°O¦³¼g¹D ³æ¹Å¦h©ú³oÓ¶µ¥Ø¦b¬ü°ê¥«³õì¼t´N¦³8000¸U¬üª÷ªºÀç·~ÃB¦Ó¥Ø«e³oÓ«~¶µ¦b¬ü°ê°£ì¼t¥~¬O¨S¦³Ävª§ªÌªº(¬OªºDMF¥DÀÉ¥u¦³µn¿ýì¼t¨ÑÀ³°Ó¸ò¤C¬P)¦pªG¦³©¯¥i¥H¦b¤µ¦~¨ú±oÃÄÃÒªº¸Ü ¨Ì¾Ú²Îp¸ê®Æ¦bì¼t¨S¦³±Ä¥Î¥É¥ÛѵI¦¡ªº±þ»ùÄvª§±¡ªp¤U¥H©¹ªº¨Ò¤l¥t¤@®a¾Ç¦WÃļt¬ù¥i¨ú±oì¼t30%ªºÀç·~ÃB(¦]µØ¦b¬ü°ê¦X§@ªºAkron«YÄÝnasdaq±¾µP¤½¥q¥«È40»õ¬üª÷¹ê¤OÀ³Äݤ£¿ù «O¦u¦ô15~20%Àç·~ÃB¨Ã¦©°£¼È¦ô50%³q¸ô°Ó§Q¼í«á¨Ó»{¦C¬ÛÃöÀç·~ÃBÀ³¸Ó¬O¥i´Á¤] ¦Ó¥B²z½×¤W¨ÓÁ¿¥un¬ü°ê¥i¥H¶¶§Q¨úÃÒ¨ä¥L°Ï°ìn¨úÃÒÀ³¸Ó¶È¬O®É¶¡ªº°ÝÃD) ¦¹¥~¤½¥q©|¦³¦h¶µ¬ãµo¤¤ªºÅã¼v¾¯¥«³õ»ùȤ£¨£±o¤ñ¹Å¦h©ú¤p.... ´¶Àù¨O: ¨Ì¤½¥q©xºô¤½§i¥Ø«e¥¿¦b¦V°·«O§½¥Ó½Ð±N·s¾AÀ³¯g¯Ç¤J°·«O®Ö»ù¤¤ ²z½×¤W¨ÓÁ¿À禬n¦A¦¸¤j´T¦¨ªøÀ³¸Ó¬On«Ý°·«O§½¥¿¦¡®Ö»ù³q¹L ¤p§ÌÓ¤H¬O´Á±æ¥i¥H¦b¤µ¦~¤¤¥¿¦¡¨ú±o°·«O®Ö»ù©Ô.... ¦Ü©ó¤½¥q·l¯q¨â¥ªºÂI°Ñ¦Ò¤½¥q³o¦¸ªÑªF·|û¤u»{ªÑÅvªº±ø¥ó ¤½¥q¬O¦ô¤j¬ùÀ禬¹F¨ì2»õ6¤d¸U¥ª¥k´N¦³¾÷·|¦³¤p´T¬Õ¾l ¤p§ÌÓ¤H¬Oı±o¥unÅã¼v¾¯©Î¬O¦]¸¿Õ¨ä¤@¯à°÷¶¶§Qµo®i¨Ã¨ú±oÃÄÃÒªº¸Ü¦b¸Ó«~¶µ¨ú±oÃÄÃҫ᪺2¦~¤ºÀ³¸Ó·|¦³¾÷·|Á«Âà¬Õ ¦pªG©¯¹Bªº¸Ü¨âÓ³£µo®i¤£¿ùÀ³¸Ó´N¥i¥H¦³ÁÙ¤£¿ùªº¬Õ¾l ¤£¹L«e´£¬O¤½¥qn¯à°÷¶¶§Q¦p´Á¨ú±o¥Dn¥«³õªºÃÄÃÒ.... |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2018/1/7 ¤U¤È 07:25:57²Ä 112 ½g¦^À³
|
¶¢¨ÓµL¨Æ·j´M¤F¤@¤UFDA®Ö¥iªºÁxºÞÀù©t¨àÃĪº¦W³æ¦p¤U Generic Name Designation Date Contact Company NV196 2008/1/10 Marshall Edwards, Inc. ARQ087 2015/11/19 ArQule, Inc. Yeliva 2017/3/30 RedHill Biopharma Ltd. gemcitabine 2016/1/11 InnoPharmax, Inc. Ivosidenib 2017/4/26 Agios Pharmaceuticals, Inc. liposomal oxaliplatin 2017/3/30 KC Specialty Therapeutics, LLC melphalan 2015/7/14 Delcath Systems, Inc. Porfimer sodium 2004/11/18 Concordia Laboratories, Inc. Redaporfin 2017/4/12 Luzitin, S.A. Silmitasertib 2016/12/22 Senhwa Biosciences, Inc. Varlitinib 2015/8/5 ASLAN Pharmaceuticals fimaporfin 2017/10/4 PCI Biotech ¤j·§10¨ÓÓ,¤j·§¤]¯à²z¸Ñ¬°¦óD07001ÁÙ®³¤£¨ì«Ü¦nªº±ÂÅv±ø¥ó,¦]¬°Ävª§ªÌ»¡¦h¤£¦h»¡¤Ö¤]¤£¤Ö, ¦³¹ê¤O½Í±ÂÅvªº¼t°ÓÀ³¸Ó·|¥ýÆ[±æ©Î¬O§Æ±æ¥Î«Ü¤Öªº¥N»ù¨Ó½Í,§Æ±æ¤½¥q¯àºÉ§Ö³q¹LIRB¼f¬d,»°§Ö°µ¥X¤@¨Ç¼Æ¾Ú¨Ó»¡ªA¥LÌ, ¥t¥~¹ï¨Ó¦~¦³¤@¨Ç¬Ýªk½Ð¦ÌÄ_¤j¤©¥H«ü±Ð ¦]¸¿Õ: Ãö©ó¤g¦Õ¨ä¤¤°ê°¨¨Ó¦è¨È¥«³õ,§Æ±æ¯à¾¨¦«Ø¥ß²£½u, ¬ü°ê¤è±PAR¤w»Pì¼t©M¸Ñ¹wp2020¦~¥i¥H¤W¥«, §Úı±o°£«D¦]µØ±o¨ì«Ü±jªº¤ä¬W,¤£µM¥u³Ñ¨â¦~n»Pì¼t¶D³^¤Î¥Ó½ÐÃÄÃÒ¦ü¥G¤£¤Ó®e©ö. ì¼t¬JµM¤w¦P·N2020¦~ÅýPAR¤W¥«,¦ôp±M§Q³oÃäÁÙ¤£·|©ñ. ³oÃÄ¥ý¥Î¦~¦¬6000¸U(²£½u«Ø¥ß§¹¦¨«á)¨Ó¬Ý. C08001 : ´N¤§«e¤½¥qªº»¡ªk,ÃĮĤñì¼t½wÄÀ«¬ÁÙ¦n,´N§Æ±æ¤½¥q¦b¬ü°êÁ{§É¹êÅ糡¤À¯à¦³¶i®i. ³oÃä¤]¸É¥R¤@Ó·s»D,D¤½¥q»P¥ÃX¤½¥qªºÃĪ«ªÈ¯É³Ìªñ¸¨¹õ,¥Ñ¥Ã¤½¥qªá¿ú¶R¦^Åv§Q,§Ú¦b·QD¤½¥qÀ³¸Óµ¦²¤¦³ÅÜ,·Q¦^¦¬¤§«eªº§ë¸ê¦Ó ¤£·Q¦Aªá¿ú,³o¼Ë¤]ÆZ¯à¸ÑÄÀ¤§«e©ñ±ó¥Ó½Ð¥xÆWÃÄÃÒªºì¦]. Åã¼v¾¯: §Æ±æ¤µ¦~¯à®³¨ì¬ü°êÃÄÃÒ,§Ú¦ôp³oÀ³¸Ó¥i¥H´£¨Ñ¤@¦~¤@»õµ¥¯Åªº¦¬¤J ´¶Àù¨O: Y¨Ì¦ÌÄ_¤j±o¨ìªº®ø®§,¶¶§Qªº¸Ü¨C¦~¥i¥H´£¨Ñ¤K¤d¸U¥ª¥kªºÀ禬(¥[¿) ¦pªGµu´Á¦]¸¿Õ,Åã¼v¾¯,´¶Àù¨Oªº¥Ø¼Ð¦³¹F¦¨,¤½¥qÀ³¸Ó´N§Ön¥i¥H·l¯q¨â¥¤F. |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/28 ¤U¤È 10:07:35²Ä 111 ½g¦^À³
|
Hi mogwai¤j °ò¥»¤W¦b¤½§iºM¥ó¤§«á¤p§Ì´¿¦h¦¸¸ò¨â®a¤½¥q¥æ¤e¤ñ¹ï½T»{ì¦] ¥ý»¡µ²½×¦n¤F:¨â®a¤½¥q¹ï©ó¦b¬ü°êÁ{§É©ê«ù§Æ±æ ¦ý¹ï©óºM¥óì¦]Á¿ªk¦U²§ ¨ä¤¤D¤½¥q¤p§Ì°Ý¤F¨â¦¸ ¥[¤W§A¨ºÓºô§}Á¿±oºâ°_¨ÓÁ`¦@3¦¸ µM«á¨C¦¸»¡ªk³£¤£¤Ó¤@¼Ë ¤S¥H§A¤Þzªº¨ºÓºô§}»¡ªk³Ì¬°Â÷©_ ´N³s¤p§Ì³oӥͧޥ~¦æ¤H³£Ä±±o¬Û·íªºÂ÷©_..... ¦Ü©óI¤½¥qªºÁ¿ªk¶Ü«h¬O¦Ü©l¦Ü²×³£¬O¤@Pªº..... ¤ñ¹ïI¤½¥qªk»¡¸ê®ÆÁÙ¦³±q¥h¦~ªÑªF·|¨´¤µªº»¡ªk¤p§Ì¬O¤ñ¸û¶É¦VI¤½¥qªº»¡ªk©Ô...... ¤£¹L¤£ºÞ«ç»ò»¡³oÓ«~¶µ½T¹ê¦]¬°8¤ë¥÷ªººM¥óÅܱo¤ñ¸û¦³Âøµ ¤p§ÌÓ¤H¦bµû»ù®É¬O¥ý±N³oÓ«~¶µªº·ÀI¶K¤ô½Õ°ª(¥Õ¸Ü¤@ÂIÁ¿´N¬O¥ý«O¦u¦ô¥¦ªº»ùÈ)µ¥¤§«á¦pªG¸Ó«~¶µ¦³·sªº¶i®i(±ÂÅv ©Î¬OÁ{§É¤S¶i¤@¤j¨B®É)¦A¨Ó½Õ¾ã¥¦ªº·ÀI¶K¤ô.... (·íµM¤½¥q¤µ¦~¨Ó¦b¨ä¥L³¡¤À¤ñ¦p»¡¬O ¤fªA§ÜÀùÃÄ ¦]¸¿Õ ´¶Àù¨O ¬Æ¦ÜÅã¼v¾¯¸É¥óµ¥³£¦³·sªº¶i®i ³o¤@³¡¤À¬O¹ï¤½¥qªº»ùȦ³¥¿±ªº¥[¤Àªº....) |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/12/28 ¤U¤È 04:53:33²Ä 110 ½g¦^À³
|
¦ÌÄ_¤j,§Ú¬O±q³o¨â½g¬Ý¨ì¤F,À³¸Ó¬OªF¤½¥qªk»¡·|«áªºQ&A´CÅé©Ò´£¥Xªº°ÝÃD www.genetinfo.com/investment/featured/item/10794.html www.genetinfo.com/investment/featured/item/10791.html?start=2 ´N¤£ª¾¹D¬O´CÅé»~¸Ñ©Î¬OªF¤½¥q¬G·N»~¾É,¤£¹L§Ú¹ïÁ{§É¹êÅç¨S¨º»ò¼ô,¦³¨S¦³¥i¯à¹êÅç²Õ©M¹ï·Ó²Õ¯f±¡³£¦³§ïµ½. ¦pªG¬O³o¼Ë´N¥i¯à¬O«Ü¤£¥©©Î¹ï·Ó²Õ¹êÅç¥X¤F°ÝÃD. ¤£¹L¤£ºÞ«ç¼Ë,ÁÙ¬O´Á«Ý¤½¥q¦b¬ü°êÁ{§É¹êÅç¥i¥H¦³¦nµ²ªG. ¥tY·ÓªF¤½¥q©Ò»¡,¦¹ÃĦ³7¤C¤d¸Uªº¼ç¤O(¥xÆW¥[¤j³°¥«³õ?),¨º¨ú±o¬ü°êÃÄÃÒ«áÀ³¸Ó¤]·|ª¥¤â¥i¼ö. ·PÁ¦ÌÄ_¤jªº¦^À³¤F |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/28 ¤U¤È 04:27:46²Ä 109 ½g¦^À³
|
mogwai ¤j ±z¨ºÓ»¡ªkÀ³¸Ó¬O¬Y´CÅéÂàzªº ¤p§Ì¤£ª¾¬O¤£¬O¸ÓÂàz¦³©Ò¸¨®t©Î²¨º| ¤£¹L¤p§Ì¤F¸Ñ¤½¥q¹ï©ó«e¬qªº»¡ªk¬O¬Û·í¤£¯à»{¦Pªº ¦Ó¥B¦pªG¸ÕÅç²Õ¨S¦³¤ñ¦w¼¢¾¯²ÕÀø®Ä§ó¦n¥Nªí§ïÁ{§É¹êÅç¨S¦³¹F¼Ð ³o¼Ë¸ÓÃĪ«ÁÙ¥i¥H¤½§i¦b¥h¦~©³¸òTFDA¥Ó½ÐÃÄÃÒ? ¦Ó¥B¥Ó½Ð¤FÁÙ¨S¦³°¨¤W³QÅF¦^¨Ó¦Ó¬O¤@ª½¨ì¤µ¦~8¤ë¥÷¤~¤½§i¦]¬°°Ó·~µ¦²¤ì¦]ºM¦^¸ÓÃÄÃÒ? ³o¼Ëªº²z¥Ñ¬O¬Û·í¥O¤H¤£¸Ñªº...... |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/12/28 ¤W¤È 03:06:45²Ä 108 ½g¦^À³
|
¦^¥h½¤@¤UªF¥ÍµØcrta04ªº説ªk¡]§YC08001) ·íªì°µ§¹Á{§Éµo²{¹êÅç²ÕÁö¦³¹F¼Ð¡A¦ý¦w¼¢¾¯²ÕÀø®Ä§ó¦n¡A¬G¥ýºM®×¡C ¦ý¥L̤´´Á«Ý¦]µØ¦b¬ü°êÁ{§Éªº¼Æ¾Ú¯à±a¨Ó¦nµ²ªG¡C ªF¥ÍµØªk»¡¤´µM§âcrta04¤W¥«¤é´Áq¦b2018¦~ ´N¦¹¸É¥R»¡©ú |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/12/26 ¤W¤È 12:40:46²Ä 107 ½g¦^À³
|
¯uªº«Ü·PÁ¦ÌÄ_¤jªø´Á¥H¨Ó³o»ò¼ö¤ß¦a¦^µª³\¦h°ÝÃD,¨C¦¸³£Åý§Ú¨ü¯q¨}¦h. ¤£¹L§Ú·Q±j½Õªº¬O,¤£¬O¨CÓ§ë¸êªÌ³£¦³©¯¯à§ä¨ì³oÓ°Q½×°ÏÀò±o±zªº«üÂI, (¨ä¹ê§Ú¤W¤@½g©Ò´£ªº°ÝÃD«Ü¦h±z³£¦^µª¹L,§Ú¤]³£¦³°O±o) §Úºâ¬O«Ü»{¯uªº¦b°lÂܦ]µØªº·s»D(°ê¤º¥~),¦~³ø,°]³ø,ªk»¡·|¤º®e,¬ã¨s³ø§i(¤]«Ü¤[¨S¦³·sªº³ø§i¤F),¬Æ¦Ü¦]µØ°ê¥~°Ñ¥[ªº·|ij§Ú¤]ºÉ¶q¥h§ä³ø§i²¤¶. §Y«K¦p¦¹,§Ú¤Wz´£¨ìªº°ÝÃD¤]¨S¦³µª®×,©Ò¦³°ÝÃD³£»Ýn±zªºÀ°¦£¦^µª. ¨º¤£ª¾¹D³oÓ°Q½×°Ïªº¤@¯ë§ë¸êªÌ«ç»ò¿ì?¦b¤£²M·¡¦]µØªºª¬ªp¤U·|¨Ó§ë¸ê¶Ü? Y¦]µØ§ë¸êªÌÃö«Y³B²z±o¦n,·d¤£¦nÄ@·N§ë¸êªÌ´NÅܦh¤F,ªÑ»ù´£¤ÉÄw¸ê®e©ö,¤]¥i¥H©Û¶Ò§ó¦h¤H¥[³t¬ã¨sªº¶i¦æ. ¦³·P¦Óµo,³Ì«á¦A¦¸·PÁ¦ÌÄ_¤jªº¦^À³. |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/25 ¤U¤È 11:09:19²Ä 106 ½g¦^À³
|
«D±`·PÁ¦̤jªº¥Î¤ß¦^µª¡A±zªº¼ö¸Û»P@¤ßµÛ¹ê¥O¤H·P°Ê¡A¥xÆW¥Í§Þ¥[ªo!! |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/25 ¤U¤È 10:13:15²Ä 105 ½g¦^À³
|
Mogwai¤j±zªººÃ°Ý¦³¨Ç¬O¯uªº¤½¥q¨S¦³»¡²M·¡ ¦³¨Ç¥i¯à¬O¦³ÂI»~·| ¤p§Ì´N§Ú©Òª¾ªººÉ¤O¦^µª ¦]¤p§Ì¤]«DÂå¾Ç¥»¬ì¦p¦³¤£ºë½T©Î¬O¦³¿ù»~ªº¦a¤èÁٽЦU¦ì¤j¤j¸É¥R 1.§K¤ã°w¦å¿}¾÷,«á¨Ó¤½¥q´N¨S¦³¥ô¦ó»¡©ú ¢Ï¡G°O±o¦n¹³¬O2¦~«eªºªÑªF·|¦³ªÑªF´£°Ý ¦]¬°¥DºÞ¾÷Ãö¼Ð·Ç¦³ÅܰʬG¥Ø«e³o¤@Ó«~¶µÀ³¸Ó¬O¦C¬°¦¸nªº¶µ¥Ø(²{¦b¸êª÷¤Î¤H¤O§ó¤£¨¬¤p§Ì¬Oı±oµu´Á¶¡¤£n§â¥L¦C¤J¦Ò¼{¤ñ¸û¦n)(¥t¥~³o¤@Ó«~¶µ±q¤@¶}©l¤p§Ì¦Û¦æ¦bµû¦ô®É´N¨S¦³§â¥L¦C¤J¦Ò¶q¡A¦]¬°¥xÆW¦å¿}¾÷¦P·~¦p¤¹© ®õ³Õ µØ¼s¡@°T¬Mµ¥¬Û·íªºÀu¨q¥H¤@®aÁÙ¬O¯ó³Ðªì´Áªº·sÃĤ½¥q n¸ò¦ÑµPªº¦å¿}¾÷¼tÄvª§À³¸Ó¤£¬O«Ü®e©ö) 2.Åã¼v¾¯±q2014¦~°e¥ó¥H¨Ó¤½¥q¤]¨S¥D°Ê»¡©úª¬ªp ¢Ï¡G¬ÛÃö¶i«×½Ð°Ñ¦Ò¤§«eªºPO¤å 3.Carvedilol CR, ªF¥ÍµØºM¾PÃÄÃҥӽФ]¨S¨£¤½¥q»¡©ú,¬Æ¦Ü³o·s»DÁÙ¬O±qªF¥ÍµØ¬ÛÃö·s»D¥h±ÀºV±o¨Ó,Carvedilol CR¦ó¥h¦ó±q§Ṳ́]¤£ª¾¹D. ¢Ï¡G´N¤p§Ì¤F¸ÑCarvedilol CR¥Ø«e¤½¥q¤´«ùÄòªºµo®i¸ò¬¢½Í±ÂÅv¤¤ 4.Gemcitabine Oral,¤§«e¬O»¡¤@´Áµ²§ô«á¥i¸g¥Ñ505(b2)ÁYµuÁ{§É®É¶¡,¦ýµ¥¤F«Ü¤[«oÅܦ¨¥Ó½ÐÁxºÞÀù©t¨àÃÄ,¤]¬O¬°¤FÁYµuÁ{§É®É¶¡,µM«á³Ìªñªº¨â«h·s»D´N¬O¬ü°ê¥xÆW¦P·NÁ{§É¹êÅç¤F,¦ý¦ó®É¶}©l¤]¤£ª¾¹D ¢Ï¡G³o¤@ÃD´Nnªá¤@ÂI½g´T¤F¡@°w¹ï·sÃĪº¬ãµo ¥DºÞ¾÷Ãön¼f®Ö¬Û·í¦hªº¤å¥ó¸ò¶µ¥Ø¡@¦Ó 505(b2)»{ÃÒªí¥Ü³oÓÃĪ«¬O°w¹ïì¥ý¤w¤W¥«ªºÃĪ«¶i¦æ§ï¨}(¦h¼Æ¬O¾¯«¬ªº§ï¨})¡A¦]¬°¬OÃĪ«ªº§ï¨}¬G¹ï³¡¤Àì§ï¨}«eÃĪ«¤w¸g°µ¹Lªº¸ê®Æ¤¹³\¼t°Ó¥i¥H¤Þ¥Î¸Ó¸ê®Æ¡A¤£¥Î°µ¬ÛÃö¹êÅç¡A¬G¨ú±o505(b2)½T¹ê¥i¥HÁYµuÁ{§É¶µ¥Ø¤Î®É¶¡¨Ã¸`¬ÙÁ{§Éªºµo¶O¡A¦Ó©t¨àÃĪº¥Ó½Ð¨ÓÁ¿«h¬O¤½¥qµo®iªº¤@¶µµ¦²¤¡A©t¨àÃÄ«Y¥DºÞ¾÷Ãö°w¹ï³¡¤À¯f±w¤H¼Æ¸û¤Öªº¯e¯fµ¹¤©ÃĪ«¿W¦û´Á¤Îµ|°È¤è±µ¥µ¥ªºÀu´f ¦Ó¥B©t¨àÃĦb«OÀI®Ö»ù¤W¤]·|¤ñ¸û°ª¡A¥t¥~¦]³o¤@Ãþªº¯f±w¤H¼Æ¤ñ¸û¤Ö©Ò¥H¬Û¹ï¦a¹ï©óÁ{§É¦¬®×¤H¼Æªºn¨D·|¤ñ¸û¤Ö¡A°ò¥»¤W505(b2)¸ò©t¨àÃĪº¨ú±o¨âªÌ¨Ã¤£¤¬¬Û½Ä¬ð¡A¬Æ¦Ü¹ï©ó¤@®a¤£ºÞ¬O¦b¸êª÷¸ò¤H¤O³£«Ü¯Ê¥Fªº¤p¤½¥q¨ÓÁ¿¥ý¨ú±o505(b2)ÅýÁ{§É¹êÅç»Ýn°µªº¶µ¥Ø´î¤Ö¦b°w¹ï©t¨àÃÄ¥«³õ¥ý¶i¦æ¬ãµo¥HÁY´îÁ{§É¤H¼Æ¨ú±o°ª«OÀI®Ö»ù¤Î¸ûªøªº¥«³õ¿W¦û´Á¬O°È¹ê¥BÁo©úªºµ¦²¤¡C ¦Ó°w¹ïÁ{§É¹êÅç¶}©lªº®É¶¡¨ÓÁ¿°ò¥»¤W¥DºÞ¾÷Ãö®ÖãIND«á¤£¬O°¨¤W´N¥i¶i¦æÁ{§É¹êÅç¡A¨ì¦UÂå°|«áÁÙn¸g¹L¦UÂå°|ªº¬ã¨sÛ²z©eû·|(IRB)¼f¬d³q¹L¤~¥i¥H¶}©lÁ{§É¹êÅç¡A¦Ó¦UÂå°|¼f¬d´Á¶¡ªøµu¨Ã¤£¬O¤½¥q¥i¥H´x±±ªº¡A¬G¦P·NIND«á¹j´XÓ¤ë¤~¶}©l¦¬¯f¤HÀ³¸Ó¬O¥¿±`ªº¡]²{¦bÁxºÞÀù¤G´Á¦b¬ü°ê¬O¥¿³B©ó¢×¢à¢Ðªº¬yµ{¡A¤½¥q¬O¹w´Á³oÓ¤ë¥i¥H¨«¦¨¢×¢à¢Ðµ{§Ç¶}©l¦¬¯f¤H¦ý±ß¢°¡ã¢±Ó¤ë¤]¤£ºâ¤Ö¨£ªº±¡ªp¡^ 5.½Ñ¦h¦X¬ù·s»D,¦ý¤ñ·Ó°]³ø,¤½¥qÀ禬¤j©vÁÙ¬O¥N²z¦Ó¨Óªº´¶Àù¨O°^Ämªº ¢Ï¡G°ò¥»¤W¤½¥qªñ´ÁÁöµMñ¤F¤@¨Ç¦X¬ù¤£¹L¦]¬°³o¨Ç³£¬O¨Ï¥Î¦b¤HÅ骺ÃĪ«¡A°£¤F¤@¨Ç©Ó»{¥xÆWÃÄÃÒªº°ê®a¥i¥Hª½±µ½æ¥H¥~¡A¨ä¥Lªº°Ï°ìÁÙ¬On§¹¦¨¸Ó°ê¥DºÞ¾÷Ãöªº¦U¶µn¨D¥Ó½Ð¨Ã¨ú±oÃÄÃÒ«áÃĤ~¥i¥H¶}½æ¡A¬GÀ禬n¤j´T¦¨ªøn¬Ý¦b¦U±ÂÅv°Ï°ì¦ó®É¨ú±oÃÄÃÒ¡]¤p§Ìı±o¦X¬ù¤¤¤ñ¸û«nªº¬°¬ü°êÅã¼v¾¯¡@¸ò³Ìªñ±ÂÅvªº¦]¸¿Õ³¡¤À¡^ ¢µ. Åã¼v¾¯¨Ó½Í,±q³Ì¦ªº·s»D¨Ó¬Ý,¥»¨Ó¬O©e°U¸gFDA¼f®Ö³q¹LªºÁp¨È¥Í²£,¦pªG¦³«D±o´«¦¨¤C¬Pªº²z¥Ñ,¬°¤°»ò¤£¥ýÂÔ·V³B²z¦A°e¥ó,¦Ó¬O¤£Â_¸É¥ó ¢Ï¡GÅã¼v¾¯ªº³¡¤À¤C¬P¬Ot³dì®ÆÃĪº¥Í²£¡AÁp¨È¬Ot³d»s¾¯ªº¥Í²£¡A¨Ã¨S¦³§ïÅÜ¡A¨âµÛªºÃö«Y´N¦n¤ñ¦b°µÄÑ¥]¡A¤C¬P¬O°µÄѯ»ªº¡AÁp¨È¬O®³¤C¬PªºÄѯ»°µ¦¨ÄÑ¥]¡A¦ÓÄÑ¥]¶}½æ«en°eµ¹¢Ô¢Ò¢Ï¼f¬d¡A¢Ô¢Ò¢Ï°w¹ï¤C¬P¸òÁp¨Èªº¥Í²£¬yµ{³£·|Àˬd¦³µL°ÝÃD¡A¥t¥~¢Ô¢Ò¢Ï¸É¥óªº°ÝÃD¡A³oÓ¦ü¥G¨CӥӽЮ׳£·|¹J¨ì®t§O¥u¦b©ó°ÝÃD¤j©Î¤p¦h©Î¤Ö¦Ó¤w¡A¥H¹Å¦h©ú¨Ó¬Ý½T¹ê¸É¥óªº®É¶¡¤ñ§O¤Hµy·L¤[¤@ÂI¡A¤£¹L¤p§Ìªºªº¸ÑŪ¬O¦]¬°¦]µØ¬O¤p¤½¥q¤£ºÞ¦b¤H¤~ ¸gÅç ¸êª÷¬Æ¦Ü¬O¬ÛÃö¦X§@¹Ù¦ñ¤W¨Ã¨S¿ìªk¸ò¤@¨Ç¤j¤½¥q¬Û¤ñ¡A¤S¦]¬°³o¬O¤½¥q²Ä¤@¥ó¸ò¢Ô¢Ò¢Ï¥Ó½Ð¢Ï¢Ü¢Ò¢Ï®×¤l¬Gµy·LºC¤@ÂI¤]µL¥i©`¦ó¡A±z¥i¥H¬Ý¬Ýªñ´Á¤¤¸Î¸òÃĵتº¨Ò¤l³o¨â®a¤½¥q¥i»¡¬Oªñ´Á¥xÆW¥Í§ÞªÑªºÁZÀu¥Í°}®e°í±j¡]·íµMµû»ù¤]«ÜÁZÀu¡^¤£¹L¦bÃÄÃҥӽФW¤]¬O¹J¨ì¤F¿ð©µªº°ÝÃD¡K ³Ì«á¤p§Ì»{¦P±z¤½¥qÀ³¦h§â²£«~¶i«×¸ò§ë¸êªÌ»¡©ú¥H¦w²³¤ßªº¬Ýªk¡A¤p§Ìı±o¦³®É´Nºâ¤½¥q¨S¦³±µ¨ì¤@¨Çªk»¡·|ªºÁܬù¦Ü¤Ö¥i¥H§â¤@¨Ç·sªº¶i®i¸ò®ø®§¤½§i¦b©xºô¤W³o¼Ë¦Ü¤Ö¤pªÑªF¥i¥H¤ñ¸û¦Yªº¦nºÎªº¦n©êªº¦íªÑ²¼¡K¡K |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/12/25 ¤U¤È 02:18:59²Ä 104 ½g¦^À³
|
¦ÌÄ_¤j¤Î½Ñ¦ì¤j¤j¦n, Åý¤p§Ì¤]©ê«è¤@¤U, ªø´Á¥H¨Ó¤½¥q¹ï©ó¦U¶µ¶}µo¶i«×(§t³o¦¸¤WÂd®×ªº³B²z)³£¬O¬Û·í¤£³z©úªº,¥H¤U§ÚÁ|¨Ò(¦³¨Ç¦ÌÄ_¤j¤w¸g¦³°l¬d§i¶Dºô¤Í), 1.§K¤ã°w¦å¿}¾÷,«á¨Ó¤½¥q´N¨S¦³¥ô¦ó»¡©ú 2.Åã¼v¾¯±q2014¦~°e¥ó¥H¨Ó¤½¥q¤]¨S¥D°Ê»¡©úª¬ªp 3.Carvedilol CR, ªF¥ÍµØºM¾PÃÄÃҥӽФ]¨S¨£¤½¥q»¡©ú,¬Æ¦Ü³o·s»DÁÙ¬O±qªF¥ÍµØ¬ÛÃö·s»D¥h±ÀºV±o¨Ó,Carvedilol CR¦ó¥h¦ó±q§Ṳ́]¤£ª¾¹D. 4.Gemcitabine Oral,¤§«e¬O»¡¤@´Áµ²§ô«á¥i¸g¥Ñ505(b2)ÁYµuÁ{§É®É¶¡,¦ýµ¥¤F«Ü¤[«oÅܦ¨¥Ó½ÐÁxºÞÀù©t¨àÃÄ,¤]¬O¬°¤FÁYµuÁ{§É®É¶¡, µM«á³Ìªñªº¨â«h·s»D´N¬O¬ü°ê¥xÆW¦P·NÁ{§É¹êÅç¤F,¦ý¦ó®É¶}©l¤]¤£ª¾¹D 5.½Ñ¦h¦X¬ù·s»D,¦ý¤ñ·Ó°]³ø,¤½¥qÀ禬¤j©vÁÙ¬O¥N²z¦Ó¨Óªº´¶Àù¨O°^Ämªº ¥t¥~¥ÑÅã¼v¾¯¨Ó½Í,±q³Ì¦ªº·s»D¨Ó¬Ý,¥»¨Ó¬O©e°U¸gFDA¼f®Ö³q¹LªºÁp¨È¥Í²£,¦pªG¦³«D±o´«¦¨¤C¬Pªº²z¥Ñ,¬°¤°»ò¤£¥ýÂÔ·V³B²z¦A°e¥ó, ¦Ó¬O¤£Â_¸É¥ó. ÁÙ¦n¦³¦ÌÄ_¤jÄ@·N¦b³oÓ¥¥x»¡©ú¦U¨Æ¶µ,¤£µM§Ú¤]¬Oº¡µÄºÃ°Ý. ³Ì«á¦^¨ì¤@¯ë§ë¸êªÌ¹ï¤½¥q·|«ç»ò¬Ý ¦³«Ü¦h¦n²£«~,¦ü¥G¤]ñ¤F«Ü¦h¦X¬ù,¤]¦³«Ü¦h±ÂÅv¥¿¦b½Í,¦ý¦~À禬ÁÙ¬O¬Ý´¶Àù¨Oªíºt. ¦U¶µ²£«~¶}µo°£«D¦³¥¿±µ²ªG¤~·|¤½¥¬,¨S³Q´£°_ªº¤£ª¾¹D¬O²×¤î¤FÁÙ¬O¶i«×½wºC¦Ó¤w. (¤j®a¥i¥H¬Ý¬Ý8/21ªº³o«h·s»D ¡¨¦]µØÃĪ«±ÂÅv ³ø¨Îµ, Carvedilol CR¨S¦³³Q´£°_) §Ú·Q¤½¥q¬JµM¤w¸g¤W¿³Âd,À³¸Ó§ó«µø»P§ë¸êªÌªºÃö«Y,¦b¤£¯A¾÷±K°ÝÃDªº±¡ªp¤U¦h§â²£«~¶i«×¸ò§ë¸êªÌ»¡©ú¥H¦w²³¤ß. ³o¼Ë§ë¸êªÌ¤~¤£·|¤@¦³·§j¯ó°Ê´N·Q½æªÑ,ªÑ»ù°ª,Äw¸ê®e©ö,¶}µo¶i«×¤]·|§Ö,³o¬O¤@Ó¥¿´`Àô. |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/25 ¤W¤È 07:52:50²Ä 103 ½g¦^À³
|
§ë¸êªÌ¤j ¦]µØ¤½¥qµ¹§Úªº·Pı«Ü¹³¥xÆW¤ô¤û°w¹ï¦Û¤v¥»·~ªº³¡¤À®IÀYW·F¡A¦ý°w¹ï¥«³õ± °]°È± ·s»D±¤§¾Þ§@¸òµo¥¬µ¥´N¤ñ¸û¤£¨º»ò¦b¦æ(¥xÆW·sÃĤ½¥q¦n¹³¬O¨âÓ·¥ºÝ¦b¤Ñ¥¨âºÝ¦n¹³³£¤£¤Ö¤½¥q)¡K¡K ³o¤@¦¸ªº°e¥ó´N§Úªº¤F¸Ñ¨ä¹ê¤½¥q쥻»{¬°¦]¬°¦]¸¿Õ ´¶Àù¨O ¸ò¤fªA§ÜÀùÃĦbªñ¥b¦~¬Æ¦Ü¥¼¨Óªº¥b¦~¶i®i¬Û·íªº¦n¡AÀ³¥i©è¾P°ª¦åÀ£ÃĦX§@¹Ù¦ñºM¥óªº¤£¨}¼vÅT¡A¬G¤´¤@ª½¿n·¥·Ç³Æ¤WÂd¦U¶µ§@·~ª½¨ì³Ì«á¤@¨è¡A³Ì«á¬OX´I¤@ª½¸ò¤½¥q¤ÀªR§Q¹ú±o¥¢³Ì«á¤½¥q¤~±µ¯Ç»²¾É¨é°Ó·N¨£±Ä¨ú¤ñ¸ûÃ·íªºµ¦²¤(·Q·Q¤]¬O¦pªG³Ì«á¦b¤WÂd¼fij¤¤³Q¨ê¤U¨Ó¨º´N§óÁV¿|¤F¡K¡K) ¥t¥~°ª¬ì§Þ¨çªº³¡¤À¦bì¥ý¨ç¨ì´Á«e±ÀÂˮĤO¬O¦s¦bªº ¬G¤p§Ì¤]¤£½T©w¦bì¨ç¥¢®Ä«e¦A¥h¥Ó½Ð¤@¦¸¥DºÞ¾÷Ãö±µ¤£±µ¨ü¡K¡K ¦Ü©ó¤WÂd°ò¥»¤W¤p§Ì»{¬°¬Oµu¦h¤¤ªÅ µu´Á¥i¥HÅý¤½¥q¨ú±o¬ãµo¸êª÷¥B¦]¬°®ø®§±Ãö«Y¹ï©óªÑ»ù·|¦³¤@©wªº¿EÀy®ÄªG ¦ý¤¤´Á´N¹³cstang¤jÁ¿ªº¦bªÅÀY®É´ÁÄw½X±N¬Û·íªºâ¶Ã ¤Ï¦Ó¹ïªÑ»ù·|¦³¤£§Qªº¼vÅT ¨ä¹ê¤p§Ì¬O»{¬°¬JµM³£n¥Î¤WÂd¥H¥~ªº¤è¦¡¶Ò¸ê¤F¡A¤½¥qÀ³¸Ón«ä¦Òªº¬O»P¨ä¦bªÅÀY¥«³õ«æµÛ¦A¦¸¥Ó½Ð¤WÂd¡A¤£¦p¥þ¤ßÅý¦U¶µ·~°È«ùÄò±À¶iµ¥¤½¥qÅé½è§ó°·¥þ(À³¸Ó¦b³o¨â¦~¦³¾÷·|À禬¤jÃzµo)¿ï¾Ü¤@Ó¦nªº®É¶¡ÂI¦nªº¥«³õ¦b¤W¡K |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/24 ¤U¤È 09:19:26²Ä 102 ½g¦^À³
|
¦Ì¤j¡Bcstang §ÚÁÙ¬On©ê«è¤@¤U¡A¨ä¹ê«Ü¦h¨Æ±¡¤½¥q¤£¬O¦´Nª¾¹D¤F!!¹³¬O carvedilol CR ¥xÆWÃÄÃÒªº°ÝÃD¡A8¤ë´Nª¾¹D¤F!!¦ý¬O¤½¥qÁÙ¬OÁnºÙ¤µ¦~©³·|¤WÂd¡C¤º±±¤]¬O°µ¼Ë¤l°e¥ó¡A¥~¦æ¤H¯uªº³£¬OÃú¸Ì¬Ýªá¡C ·íªìÁpXÃĤ]¬O³o¼Ë¡A¤]¬O¤¸XÄU°h¤½¥q¡A¥HºÞ²zªº¨¤«×¨Ó¬Ý¡Aµo²{°ÝÃDÀ³¸Ó»°ºò¸Ñ¨M¡A¤ñ¦p»¡ ¦]µØ Q4 ´N¥i¥H¶}©l«°e¬ì§Þ¨Æ·~³\¥i¡A¦Ó¤£¬O²{¦b¤~¦b»¡«°e¼f¬d¦æ¬F¦Ü¤Ön 3-6 Ó¤ë¡C¦A»¡ 2014 ¦~¤½¥q¬ì§Þ¨Æ·~´N³Q°h¹L¤F¡A²Ä¤G¦¸¾÷·|¤FÁÙ¿ù¹L¡A¯uªºn¥´§¾ªÑ¡C ²{¦b¤WÂd¬O¦n¬OÃaªº½T¬OÓ¥¼ª¾¼Æ¡A²¦³ºÀô¹Ò¨Ã¤£¤Íµ½¡A¦ýÂd¶R¤¤¤ß/FDA þÓÃø·d? ¥ú¤@ÓÂd¶R¤¤¤ß³£¥i¥H·d¦¨³o¼Ë¡A«ÜÃø·Q¹³ NDA n©ì¦h¤[¡C ÁÙ¦n¦³¥x¤¤/®ç¶éªºªB¤Í¼µ¦í¡A¤½¥q¥[ªo!! |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/24 ¤U¤È 07:25:34²Ä 101 ½g¦^À³
|
cstang¤j ¤p§Ì§¹¥þ»{¦P±zªº½×ÂI §Æ±æ³o¤@¦¸Äw±¹¸êª÷¤½¥q¥i¥H¶¶§Qªº¥Î¨p¶Òªº¤è¦¡§ä¨ì»{¦P¤½¥qªºµ¦²¤§ë¸ê¤H ¥t¥~°w¹ïÀç¹B¸êª÷³¡¤À¤p§Ìı±o¤½¥q¤j·§´N³o¨â¦~¤ñ¸û»Ýn¹ï¥~Äw±¹¸êª÷ ¤§«áÀ³¸Ó´N¦³§Æ±æ¦Ûµ¹¦Û¨¬¤F ¨ä¹ê¥«ªp¤£¦n¤£¤@©wn¦b¦¹®É¤WÂd ¬Æ¦Ü©ú«á¦~¦¨ÁZ°µ¥X¨Ó«á¦pªG³o¸Ì¤£Åwªï§Ṳ́]¤£¨£±on¦b³o¸Ì¤WÂd ¹³¬O»´ä©Î¬O¬ü°ê¨ä¹ê¤]³£¬O¤£¿ùªº¿ï¾Ü ¤£¹L²{¦bÁ¿³oÓ¥i¯à³£¤Ó¦¤F ²{¶¥¬q¥u´Á±æ¤½¥q¶¶§Q§¹¦¨¶Ò¸ê¤@¨B¤@¸}¦L¦a§¹¦¨¦U¶µ²£«~¶i«× |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2017/12/24 ¤U¤È 03:32:27²Ä 100 ½g¦^À³
|
¦ÌÄ_¤j¤j, ·PÁ§Aªº¸ê°T,µÛ¹êÅý¤p§ÌÃP¤F¤@¤f®ð,¤]·PÁ¨é°Ó°±¤î¤F¤½¥q²{®ÉÂIªº¤WÂd,쥻¤p§ÌÁÙ®¼¾á¤ß¤½¥q¯uªº·|¥Ó½Ð¤WÂd,¤£¹L¥H²{¦b¤½¥qªºª¬ªp(¦h¼Æªº¬ãµo³£®tÁ{ªù¤@¸})¥[¤W¥xÆW ¥Í§Þ§ë¸ê¦B«Ê´Á,¿ï¾Ü¦¹®É¯uªº¬O³Ì¤£¦nªº¤èªk¨Ó¸Ñ¨M¬ãµo¸êª÷¦Yºòªº°ÝÃD,¤WÂd¼W¸êªº½T¥i¥H¼W¥[«D²{¦æì©lªÑªF°Ñ¥[»{ªÑ,¦ý¬O±a¨Óªº°ÝÃD§ó¦h,²{¦bªÑ»ù§C,¤WÂd¦ÛµM¤£¯à¦³¦n»ù¿ú¦Ó¥B©âÅÒ¥u·|³y¦¨Äw½X§óâ¶Ã,©Ò¥HÁÙ¬Oµ¥©ú¦~¤U¥b¦~À禬¸òÃÄÃÒ©ú½Tªº®ÉÔ¦b¤WÂd·|¤ñ¸û¦n§a! ¿³Âdº¦´T¥i¥H¦³50%,Äw½X¤S¶°¤¤,¦Ó¥B·|¶R¿³ÂdªÑ²¼ªÌ¦h¬O«ùªÑ·|¤ñ¸ûªø´Áéwªº§ë¸ê,¹ï¥¼¨Ó·|¦³¦n®ø®§ªº¦]µØ¨Ó»¡¿³Âd¥ý«ÝµÛ·|¤ñ¸û¦nªº............. ¸Ñ¨M¬ãµo¸êª÷¦Yºòªº°ÝÃD,§Æ±æ¤½¥q°]°È¤Î¤jªÑªF¯à¶XµÛ³Ìªñ¤£Â_¦³¥~¸ê¹ï¥xÆW¥Í§Þ¤½¥q©Û¤â¤§»Ú(»´äÃÒ¨÷¥æ©ö©ÒÅwªï¥xÆW¥Í§Þ¤½¥qu´ä¤W¥«,¤é°ÓSJR·¸»ù100%¦¬ÁÊ«a¬ì...............)¨ä¹ê¥xÆW¥Í§Þ¤½¥q¯uªº«Ü«K©y,¦]µØ¤×¨ä«K©y,¥xÆW¤]¦³«Ü¦h¹q¤l¤½¥q¦ÑÁó¶}©l§ë¸ê¥Í§Þ¤½¥q¤F,´Á«Ý¦]µØ¯à¥Î¤O¦a¥hn¨D¨é°Ó¼g³ø§i¤¶²Ð¦Û¤v,±q¹q¤l¤j¦Ñ¨ºÄw¸êÓ1~2»õµ´«DÃø¨Æ,¥u¬O¤½¥qn¦h¥h¤¶²Ð¦Û¤v¦³¦h¼F®` ·PÁÂ¥»¶g¤U±þªÑ²¼ªº¦n¤Í,¤p§Ì¤w¸g§¹¥þ¦^¸É¤§«eªº¥X²æÁÙ¼W«ù¨Ç³\, |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/24 ¤W¤È 12:53:54²Ä 99 ½g¦^À³
|
Hi ¦Ì¤j ÁÂÁ±zªº¸ê°T¤À¨É¡C¨Æ¤w¦Ü¦¹¡A¤]¥u¦³³o¼Ë¤F¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/23 ¤U¤È 10:15:53²Ä 98 ½g¦^À³
|
³o°}¤l¦n¦ü¦^¨ì¤FÁp¦ÒÁÙ¦s¦bªº¨ºÓ¦~¥N ¤Ñ¤Ñ¤Wºô¸ô¬dº] «o¤Ñ¤Ñ¤£¨£¥ì¤HªºªÚÂÜ¥X²{¦bº]¤W ¯u¬O¦n¨Æ¦h¿iªü ¨¥Âk¥¿¶Ç¥»¦¸¬°¦ó¨S¦³¦p´Á°e¥X¤WÂdªº¥Ó½Ð? ¾Ú¤p§Ì°¼±ªº¤F¸Ñ ¨ä¹ê¤½¥q¤Q´X½cªº¸ê®Æ³£¤w¸g·Ç³Æ¦n¤F ¦ý´N¦b¸ê®Æ°e¥X«eªº³Ì«á¤@¨è³Q¥D¿ì»²¾É¨é°Ó¤¸´IÄUªý¤F ì¦]§Y¥X¦b8¤ëªìªº¨ºÀɳ¾¨Æ¨¤W ¸Ü»¡·íªì¦V¤u·~§½¥Ó½Ð°ª¬ì§Þ¨çªº®ÉÔ¥¿È°Ï°ª¦åÀ£ÃħY±N¦b¥xÆW¥Ó½ÐNDAªº®É¨è¡A¬G¥Ó½Ð¸ê®Æ¤¤¤£¥iÁקK¦a±N¦¹¤@«~¶µ¦C¤J¥Dn¥B«nªº«~¶µ¡A¶à«á¤]¶¶§Qªº¨ú±o¤F¤u·~§½ªº±ÀÂ˨ç¡Aþª¾´N¦b¤½¥q¥þ¤O±À°Ê¤WÂd¦U¶µ¶i«×®É¦X§@¹Ù¦ñ³º¦b8¤ë3¤éºM¦^¤FNDAªº¥Ó½Ð¡K¡K ¦Ó¥H²{¹êªºª¬ªp¤Î¸Ó¦X§@¹Ù¦ñªñ¨Ó¤@³s¦ê½Ñ¦h¨Æ¥óªºµo®i¨ÓÁ¿¡A¥LÌÂ_¤£¥i¯àÀ°¤½¥q¥h¦VÂd¶R¸ÑÄÀÂç²MºM¦^NDAªºì¦]¡A¬G´X¸g¦Ò¶q³Ì«á¤½¥qÁÙ¬O±µ¯Ç¤¸´Iªº·N¨£«°e°ª¬ì§Þ¨ç¨Ã©ó¨ú±o«áºÉ³t¦A¦¸¥Ó½Ð¤WÂd¡K ¬Ý¨ì³o¸Ì¤j®a¬O§_¸ò¤p§Ì¤@¼Ëı±o¦³ÂI³¾OOXXªº?¨SÃö«YÅý§ÚÌÄ~Äò¬Ý¤U¥h °]°È± ¤½¥q¤]¤F¸Ñ¨ì²{¦b¥Í§Þ¥«ªp¤£¨Î²{ª÷¼W¸ê¦³¨äÃø«×¸ò¯ÊÂI¡A¬Gªñ¨Ó¤]¿n·¥±µÄ²¤@¨Ç¥i¯à¦³·Nªº¹ï¶H±´¸ß¦UºØÄw±¹¸êª÷ªº¥i¯à©Ê¡A¥¼¨Ó¤½¥qÀ³¸Ó·|¦ôºâ¥i¯àªº¸êª÷»Ý¨D¨ÃÀÀ§´¥]§t¦ý¤£©ó²{ª÷¼W¸êªº¦UºØ¿ï¶µ¶i¦æ°Q½×¥B¦]¥¼¨ÓÀ³¸Ó·|¦³¬ÛÃöÀ禬¤Î±ÂÅvª÷µ¥¦¬¤J¬G»ÝnÄw±¹ªº¸êª÷À³¨S¦³·Q¹³¤¤ªº¤j¡F¥t¥~¥À¤½¥q°·³ì¨´¤µ¬°¤î³£«Ü¤ä«ù¤½¥qªº¦U¶µµo®i¡C ·~°È± 1.´¶Àù¨O·s¾AÀ³¯g·~¸gTFDA®Öã¬ÛÃö°T®§·~¤w¤½§i¦b¤½¥qªººô¯¸¤W ·s¼Wªº³¡¤À¥«³õ¼ç¤O¸ò¬J¦³ªº¥«³õ®t¤£¦h¤j 2.¦]¸¿Õ¦b°ê»Ú¥«³õ¤¤¸ß°Ý«×¬Û·í°ª¡A¦b³¡¤À¤j°Ï¦³¼t°Ó·¥¦³·NÄ@¡A¦Ü©ó¸Ó«~¶µ¦b¬ü°ê¥«³õ²£«~ªº¶i«×¨ÓÁ¿¥Ø«e¬OON SCHEDULE(°Ñ¦Òì¼t³Ìªñ¤@¦¸°]´ú ì¼t¹w¦ô¥L̤µ¦~¥þ²y¾P°âÃB¥i¦¨ªø¨ì¹F4»õ¬üª÷) 3.¦P¼Ë¬O¦]¸¿Õ³o¤@¦¸Ã±¬ùªº¥«³õ¼ç¤O¤£¤p¡A¥Ø«e¸Ó¦X§@¹ï¶HÀ³·|¤Uq¥D¦¨¤Àì®Æ¶i¦æ¸Õ²£¡AÁö¶È¬Oì®Æ¦ý»ù®æ¬Û·í©ù¶Q¡C 4.¤fªA§ÜÀùÃĥثe¶i«×¥ç¬OON SCHEDULE¡C 5.¦Ü©ó¤j®aÃö¤ßªº¹Å¦h©ú»s¾¯³¡¤Àªº¸É¥ó·~©ó´XÓ¤ë«e§¹¦¨¦ÓÃö©ó¤C¬Pì®Æ¥Í²£ªº¸É¥ó¥ç¤w©ó¥»¤ë§¹¦¨¡C 6.Ãö©ó¦U²£«~±ÂÅv½Í§P¬Ò«ùÄò¶i¦æ¤¤¡A¥un±ø¥ó¦¨¼ô§Y·|ñ©w¨Ã¨S¦³¯S©wªº¹w³]±ø¥ó¡C Ó¤H·P·Q:ÁöµM¤WÂd¦³©Ò©µÌX¥O¤H¦³ÂI¤p¥¢±æ¡A¤£¹L³o¬O¤@¶¡¦A°µ¨Æªº¤½¥q¡A¥Ñ·~°È±¶i®i¨Ó¬ÝÀ禬°_¸À³¸Ó´N¦b©ú¦~¤F¡A¦pªG©¯¹B¤@ÂI¹Å¦h©ú¶¶§Q¦b©ú¦~¨ú±oÃÄÃÒ¨º«á¦~À³¸Ó´N¦³Âà¬Õªº§Æ±æ¤F¡F¤£¹L©ú¦~À³¸Ó·|¦³¤@¦¸¶Ò¸êªº°Ê§@¡A¨Ì¾Ú±Ä¦æ¶Ò¸ê¤è¦¡ªº¤£¦P(¨p¶Ò¡B²{¼W©Î¨ä¥L)±N²o°Ê¤½¥qµu¤¤´ÁªÑ»ù¨«¶Õ¡A¦ý¥un¸êª÷¨ì¦ì«á·f°tÀ禬¤j´T¦¨ªø¡A¬Û«HÁ`¦³¤@¤ÑªÑ»ù±N·|°l¤W°ò¥»±ªº¡C ³Ì«á§Æ±æ¦]µØ¤½¥q¯à°÷¥[ªo ¤£n¦AÅý³\³\¦h¦hªø´Á¤ä«ùªºªÑªF¥¢±æ¤F..... |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2017/12/19 ¤U¤È 06:57:55²Ä 97 ½g¦^À³
|
³sÄò2¤Ñ¼W¤j¶q±þ§C¡A§C¯}18¡A¦³¤j¤j¥i¥H¶}¥Ü¶Ü¡H¸ò23¸¹¦³Ãö¶Ü¡H |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/12/18 ¤U¤È 10:34:39²Ä 96 ½g¦^À³
|
¤½¥q§Y±N©ó©ú¦~¤T¤ë°Ñ¥[ ²Ä¤G©¡¨È¤Ó¦a°ÏÁxºÞÀù·|ij apcurecc.com/program.php ²Ä¤G¤Ñ·~¬Éªº¤£¤½¶}·|ij Industry Forum (Closed Session ¡V By Invitation Only) Session Chairs: Milind Javle, MD Anderson, Texas, USA and Virote Sriuranpong, Chulalongkorn University, Bangkok Thailand Industry Speakers/Presenters Jerry Huang, Taiho (Japan) Bertil Lindmark,Aslan (Singapore) Kelly Lin, Innopharmax (Taiwan) Kai Wang, Origimed (China) Crystal Genomics (South Korea) °ò¥»¤W¤½¥q±`±`°Ñ¥[³oÃþ«¬ªº·|ij,¤]¤£´Á«Ý·|±a¨Ó¤°»ò¦n®ø®§, ¤£¹L¦³½ìªº¬O¥xÆW°Ñ¥[ªº¼t°Ó¬O¦]µØ¦Ó¤£¬O¶i¤J¤G´Áªº¥ÍµØ,¬O§_ªí¥Ü¦]µØ¤ñ¸û¨ü´Á«Ý©O?(¬ÝªÑ»ù¤S¤£¬O³o»ò¤@¦^¨Æ) |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/13 ¤U¤È 08:41:09²Ä 95 ½g¦^À³
|
«Ü´Îªº¶i®i¡A¦ý¬O¤½¥q¦ü¥G¤]¨S¦³¤½§iµ¹¤j®aª¾¹D...... |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/13 ¤U¤È 06:15:53²Ä 94 ½g¦^À³
|
è¤W¹Ãĸpºô¯¸¬d¸ß ´¶Àù¨O·s¾AÀ³¯g·~©ó11¤ë14¤é¸g¹Ãĸp®Öã²{¨Ã¥¿¦¡¤½§i¦b12¤ë¥÷ªºÅܧó³\¥iÃÒ¤ë³ø¤¤ ·s¼Wªº¾AÀ³¯g¬O¤°»ò©O? ¤ñ¹ï«e«áªº¥é³æ¬°·s¼W³o¤@Ó¾AÀ³¯g 3.Bendamustine¦X¨ÖRituximab¾A¥Î©ó¥ý«e¥¼´¿±µ¨üªvÀøªºCD20¶§©Ê¡B²Ä III / IV ´Á©M½w©Ê«D¦óªNª÷¤ó²O¤ÚÀù(non-hodgkin lymphoma, NHL)¡CBendamustine¦X¨ÖRituximab¾A¥Î©ó¥ý«e¥¼´¿±µ¨üªvÀø¥B¤£¾A¦X¦ÛÅé·F²ÓM²¾´Óªº²Ä III / IV ´Á³Q®M²ÓM²O¤ÚÀù(mantle cell lymphoma, MCL)¡C (¬Ý¨Ó¬O¥Ñ¨Ö¥ÎRituximab©¹«e±À¶i¨ì¤@½uªºªvÀø...) ´Á¬ß´¶Àù¨O³oÓ«~¶µ¯à¦b¨Ó¦~¬°¤½¥q¦A«×³Ð³y·sªºÀ禬...... |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/11 ¤U¤È 10:18:37²Ä 93 ½g¦^À³
|
ÁÂÁ§A@¤ßªº¦^ÂСA¦Ì¤j¡C ¥t¥~¡Aȱo¤@´£ªº¡A¤µ¤Ñ¯q±o³q¹L¤WÂd¼fij©eû·|¼f¬d¤F¡A¥¿¦¡¤WÂd¡C±µ¤U¨Ó´Nµ¥¦]µØ°e¥ó¤F¡C¤Ñ¤Wn±¼®ø®§¹Æ!! www.chinatimes.com/realtimenews/20171211005452-260410 |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/11 ¤U¤È 10:05:56²Ä 92 ½g¦^À³
|
§ë¸êªÌ¤j ¦³Ãö¦¹¦¸Ã±¬ùªº¼t°Ó°ò©ó¤½¥q¹L¥h©Òµo¥¬ªº¤@¨Ç¸ê°T¤p§Ì¤£¥iÁקKªº¤ß¤¤¬O·|¦³¨Ç²q´ú¦W³æ ¤£¹Lµu´Á¤ºµLªkÃÒ¹ê¬O§_¥¿½T,¬JµM¤½¥q¤½§i»¡°ò©ó«O±K¨ó©w²£«~©|¥¼¤W¥««e¤£±o´¦ÅS«´¬ù¬Û¹ï¤H ¤p§Ì¬Oı±o¤j®a´N@¤ßªºµ¥«Ý²£«~¤W¥«¥Ñ¤½¥q´¦ÅS§a, ¤£¹L¥i¥H½T©wªº¬O¤½¥q«Ü¬Ý«¦]¸¿Õ³o¶µ²£«~ ´X¦¸ªÑªF·|³£¦³ÆU¤½¥q´£¨ì³oÓ«~¶µ, ¦Ü©ó¸ò¬ü°ê Glenmark Pharmaceuticals Inc. ñqªº±ÂÅv¤Î¨Ñ³f Non-binding term sheet °ò¥»¤W³oÓ¤½§iªº«ÂI¦b©ó«e±ªº Non-binding¨âÓ¦r ¥L¶È¥Nªí¤F¨â®a¤½¥q¹ï©ó¦X§@®×¦³ªì¨Bªº·NÄ@ ¥B¹ï©ó¦X§@±ø¥ó¦³ªì¨Bªº¦@ÃѬG¥ýñq§ë¸ê·N¦V®Ñ(Non-bindingªí¥Ü¨S¦³±j¨î¤Oªº) ³o¶Èªí¥Ü Glenmark Pharmaceuticals¬O¥i¯à¦X§@¹ï¶H¤§¤@¥BÂù¤è½Í¨ì¤@©wµ{«×¤F ¦ý©|¥¼§¹¥þºV©w¥¼¨Ó¤´¥i¯à¦³ÅܼÆ(±z¥i¥H¥h¬Ý¤@¤U105¦~¸òAvir PharmañqBinding term sheet¤ñ¸û¤@¤U®t²§) °ò¥»¤W³oÓ¬ù¤´¥¼½T©w¬G¤p§Ì¶ÈÃöª`¦ý¨S¦³²`¨s.... (·íµM¤]¨Sªk²`¨s «¢«¢.. ³o¤j·§¥u¦³¤½¥qt³d½Í§Pªº°ª¼h¤~·|ª¾¹D¤º®e¤F....) |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/11 ¤U¤È 07:42:20²Ä 91 ½g¦^À³
|
Hi ¦ÌÄ_ ÁÂÁ±zªº¦^´_³á¡C ¤§«e¦³¤@«h·s»D¦p¤U:¦]¸¿Õ¤g¦Õ¨ä¤è±¡A¤w¸g»P·í¦a M Ãļtñq¾P°â·N¦V®Ñ¡C±zª¾¹D¤å¤¤ªº M Ãļt¦³¥i¯à¬O«ü½Ö¶Ü?? ¦Ü©ó±ÂÅvªº±ø¬O§_³\¥i¥H°Ñ¦Ò¤§«e©M¬ü°ê Glenmark Pharmaceuticals Inc. ñqªº±ÂÅv¤Î¨Ñ³f Non-binding term sheet ©O?? ±zª¾¹D¤§«e©M Glenmark Pharmaceuticals Inc.ªº¦X¬ù±ø¥ó¶Ü?? ÁÂÁ§A³á!! ¨ä¹ê¤½¥q°w¹ï¦X¬ùªº¤º®e¬O¤£¬O³£¤ñ¸û¤Ö¤½§i?·Pı±o¬O¬YºØµ¦²¤¦Ò¶q? |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/11 ¤U¤È 07:29:01²Ä 90 ½g¦^À³
|
§ë¸êªÌ¤j,¥H¤U¬°¤p§Ì²Ê²Lªº¤F¸Ñ ¨î±ø´Ú(¸Ñ°£ªÌ¤£¾A¥Î):¦]Âù¤èñq«O±K«´¬ù¡A²£«~©|¥¼¤W¥««e¤£±o´¦ÅS«´¬ù¬Û¹ï¤H¡C Q: ±ÂÅvµ¹½Ö³£¤£¯à»¡©ú¡A³oºØ case ±`¨£¶Ü?? A:¥H¤p§Ì¹L©¹¬Ý¹Lªº¤@¨Ç¨Ò¤l¨Ó¬Ý¦h¼Æ¬O·|´¦ÅS±ÂÅvµ¹½Ö,¦ý°w¹ï±ÂÅvª÷¦h¹èÁÙ¦³»{¦Cªº±ø¥óµ¥µ¥´N¤£¨£±o·|¦b²Ä¤@®É¶¡¦³©Ò´¦ÅS,¤£¹L¥H¦]¸¿Õªº¨Ò¤l¨ÓÁ¿,³o¤@¦¸ªº±ÂÅv¥]§t¤F¼Ú¨È¦a°Ï,¦Ó¦]¸¿Õ¦b¬ü°êµ¥ªk³W°ê®a«YÄݱM§Q¥¼¨ì´ÁªºP4®×¥ó(¬ü°ê©|¥¼¨ì´Á ¼Ú¬w©|«Ý½T»{),¬G¤]³\Âù¤è¦]¬°¤@¨Ç°Ó·~µ¦²¤ªº¦Ò¶q¤£´¦ÅS¬ÛÃö°T®§,¤p§Ì¬Oı±o¥i¥Hµ¹¤½¥q¤@¨ÇªÅ¶¡©Ô ¹ï¤½¥q°]°È¡B·~°È¤§¼vÅT(¸Ñ°£ªÌ¤£¾A¥Î):¦³§U©ó¤½¥q¸Ó«~¶µ¼Ú¨È¦a°Ï·~°È¤§±À°Ê¡C Q: ³o¼Ëªº±ÂÅv®×¡A·|¦³±ÂÅvª÷¥i¥H»{¦C¶Ü? A:´N¤p§Ìªº¤F¸Ñ¤@¯ë±ÂÅv®×«Y¥Ñ¤U¦C´XÓ¦¨¤À²Õ¦¨: ñ¬ùª÷(ñ¬ù§Y¨ú±o) ¨½µ{ª÷(§¹¦¨¯S©w¶i«×©Î±ø¥ó¦p¤W¥« ©Î¬O¾P°âÃB¹F¤@©wª÷ÃB¥i¨ú±o) ¾P°â¤À¼í(¨Ì¾P°âÃB¤@©w¦Ê¤À¤ñ©â¶Ä) ¤TªÌªºÃö«Y´N¦n¤ñ¬OÃßÃߪO¤@Ó°ª¥t¤@Ó´N§C, ¹ê»Úºc¦¨ªº±ø¥ó¤Î¤ñ²v´N¬ÝÂù¤è¨ó°Óªºµ²ªG(¥H¥xÆWªº¨Ò¤l¨ÓÁ¿ ´¼Àº¬O¨½µ{ª÷°ª ¤¤¸Î¬O¿ï¾Ü¾P°â¤À¼í°ª),¦Ó´N§ÚÌ®aªº¨Ò¤l¨ÓÁ¿ ¥H©¹¦]µØ¦ü¥Gñ¬ù¬O±Ä¤T¶µ§¡¿Åµo®iªº¼Ò¦¡,¬G¤p§Ì¬Oı±oÀ³¸Ó¥i¥H»{¦C¤@¨Çñ¬ùª÷©Ô,¤£¹L¬O°ª¬O§C´N¬ÝÂù¤è¨ó°Ó¤ñ²vªº°t¸m¤F(¤£¹L´N²{¦b¥Í§Þ¥«ªp¨º»òÁVÄw¸ê¤£©öªº±¡§Î¤U¤p§Ì¬O§Æ±æ¤½¥q¥i¥H¦hn¤@¨Çñ¬ùª÷©Ô......,) |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/11 ¤W¤È 10:34:09²Ä 89 ½g¦^À³
|
Hi ¦Ì¤j ½Ð±Ð´XÓ°ÝÃD: ¨î±ø´Ú(¸Ñ°£ªÌ¤£¾A¥Î):¦]Âù¤èñq«O±K«´¬ù¡A²£«~©|¥¼¤W¥««e¤£±o´¦ÅS«´¬ù¬Û¹ï¤H¡C Q: ±ÂÅvµ¹½Ö³£¤£¯à»¡©ú¡A³oºØ case ±`¨£¶Ü?? ¹ï¤½¥q°]°È¡B·~°È¤§¼vÅT(¸Ñ°£ªÌ¤£¾A¥Î):¦³§U©ó¤½¥q¸Ó«~¶µ¼Ú¨È¦a°Ï·~°È¤§±À°Ê¡C Q: ³o¼Ëªº±ÂÅv®×¡A·|¦³±ÂÅvª÷¥i¥H»{¦C¶Ü? ±q2016¦~¦~³ø¤WºI¿ý (8)D07002 ¨u¨£¯e¯f-fଧ¿¯g-¦]¸¿Õ-¥|²B¥Íª«³ãËïÆQ»ÄÆQªº»s³Æ¤èªk¨ú±o¿D¬w¤Î¾¥¦èô±M§Q³\¥i¡C D07002 ½T¹ê¬O¦]«D¿Õ¨S¿ù¡C |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/12/11 ¤W¤È 08:50:03²Ä 88 ½g¦^À³
|
¦ÌÄ_¤j±z²q´úªº¨S¿ù, ±q¦]µØ2014¥ø·~ªÀ·|³d¥ô³ø§i®Ñ¤¤¸Ì±¦³´£¨ì, ¥»¤½¥q¨Ã2014¦~8¤ë¨ú±o¸Ó«~¶µ¤Î¥t¤@fଧ¿¯g¨u¯f¥ÎÃÄ(D07002)¤§¬ü°ê±M§Q¡A¦ÓD07002¤]¦b2014¦~©³¶}©l¶i¦æ¤p§å¶q¤§¥~¾P¡A¨¬¨£¤½¥q¦b¹L¥hªº¬ãµo³vº¥®i²{¦¨ªG, ³o´N¬O¦]¸¿Õ. ¦]µØ¥[ªo |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/11 ¤W¤È 07:37:45²Ä 87 ½g¦^À³
|
Á¿µÛÁ¿µÛ´N±¼¤U¨Ó¤@Ó±ÂÅv¦X¬ù¤F ¤½§i¥»¤½¥q»P¼Ú¨È¦a°Ï³q¸ô¤Î²£«~»s³y°Óñq¨Ñ³f¤Î ¦X§@¦X¬ù¡A±Ò°Ê·~°È©Ý®i »¡©ú 1.¨Æ¹êµo¥Í¤é:106/12/11 2.«´¬ù©Î©Ó¿Õ¬Û¹ï¤H:¼Ú¨È¦a°Ï³q¸ô¤Î²£«~»s³y°Ó 3.»P¤½¥qÃö«Y:µL 4.«´¬ù©Î©Ó¿Õ°_¨´¤é´Á(©Î¸Ñ°£¤é´Á):106/12/11 5.¥Dn¤º®e(¸Ñ°£ªÌ¤£¾A¥Î): 1.°w¹ï¥»¤½¥qªºD07002¤§¥D¦¨¤À¨Ñ³f»P»s¾¯§Þ³N±ÂÅv¦X¬ù¡C 2.±ÂÅv°Ï°ì¡G¼Ú¨È¦a°Ï¤§¿W®a±ÂÅv¡C 3.¦X¬ù¥Dn±ø´Ú¡G§Ú¤èt³d¥D¦¨¤À¨Ñ³f¤Î»s¾¯§Þ³N²¾Âà¡A³q¸ô¤Î²£«~»s³y°Ót³d »s¾¯²£«~¥Í²£¡B¬dµn¡B¾P°â¡C 4.¦X¬ù´Á¶¡¡G¥»¦X¬ù¦³®Ä´Á¬°10¦~¡CY¨ì´ÁµL¥D°Ê´£¥X²×¤î¦X¬ù¡A«h¦Û°ÊÄò¬ù5¦~¡C 6.¨î±ø´Ú(¸Ñ°£ªÌ¤£¾A¥Î):¦]Âù¤èñq«O±K«´¬ù¡A²£«~©|¥¼¤W¥««e¤£±o´¦ÅS«´¬ù¬Û¹ï¤H 7.¹ï¤½¥q°]°È¡B·~°È¤§¼vÅT(¸Ñ°£ªÌ¤£¾A¥Î):¦³§U©ó¤½¥q¸Ó«~¶µ¼Ú¨È¦a°Ï·~°È¤§±À°Ê¡C 8.¨ãÅé¥Øªº(¸Ñ°£ªÌ¤£¾A¥Î):©Ý®i¥»¤½¥q¸Ó«~¶µ«áÄò°ê»Ú·~°È¤§±À°Ê¡C 9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL D07002©xºô¤¤¬O§â¥LÂkÃþ¦¨¨u¨£¯e¯f¥ÎÃÄ ¤£¹LÂI¶i¥h«o¸õ¨ì¥t¤@Ó²£«~.... ¤p§Ì¬O±À´úÀ³¸Ó¬O¦]¸¿Õªº¼Ú¨È¦a°Ï±ÂÅv¦]¬°«´¬ù±ø´Ú¤¤¦³¼g¨ì: ³q¸ô¤Î²£«~»s³y°Ót³d»s¾¯²£«~¥Í²£¡B¬dµn¡B¾P°â¡C ¦pªG¯u¬O¼Ú¨È¦a°Ïªº±ÂÅv¨ºªí¥Ü¦]¸¿Õ¦b¤@°}¤l«áÀ³¸Ó¬O¤j¦³¥i¬° °O±o1~2¦~«eªº·s»D³ø¾É¤g¦Õ¨ä¦a°Ï¦b²Ä¤@¦~¥i¥H¦³6000¸U¥ª¥kªºÀ禬..... ¤£¹L«á¨Ó¦]¬°·í¦a¬F©²§Æ±æ¥H¸¨¦a²£¤è¦¡¾ÉP®Éµ{µy¦³©µ¿ð.... ¦pªG¯u¬O¦]¸¿Õªº¼Ú¨È±ÂÅv¨º´N¤Ó´Î¤F.... ¥[ªo¥[ªo.... |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/10 ¤U¤È 09:50:19²Ä 86 ½g¦^À³
|
Hi §ë¸êªÌ¤j ´¶Àù¨O¦L¶H¤¤¶i³f¤ë¥÷¤£¤Ó¤@©w¤£¹L¥H©¹¬ù5~9Ó¤ë·|¦³¤@¦¸ªº§å¦¸¶i³f ³o¤@¦¸¶i³f®É¶¡¤w¸g¶¡¹j¶W¹L10Ó¤ë¤F(¤£¹L¤W¦¸³sÄò¨âӤ릳¤jÃBªº¶i³f¤ñ¸û¯S®í) ¥[¤W«Ø³ìªk»¡¸ê®ÆÅã¥Ü¤W¥b¦~¾P°âÃB¤´¦³¦¨ªø ¬G¤p§Ì²q´ú¦b¥¼¨Ó3Ӥ뤺À³¸Ó·|¦³¤@¦¸ªº´¶Àù¨O¶i³f.... |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/10 ¤U¤È 08:18:18²Ä 85 ½g¦^À³
|
DOTA §Ú¬d¨ì¤F¡AÁÂÁ¡C À³¸Ó¬O¥X³fµ¹Áú°êªºÅã¼v¾¯ì®ÆÃÄ¡Cì¤å¦p¤U¡C ¥X³B: ¦]µØ¤½¶}»¡©ú®Ñ 105 ¦~¥Dn¾P°â²£«~¬°¿¯S¹ç¡B´¶Àù¨O(Bendamustine)¡AÀç·~¦¬¤J¤ñ«¤À§O¬°¿¯S¹ç 4.31%¡B´¶Àù¨O (Bendamustine) 88.41%¡A ¥Dn¾P°â¦a°Ï¬°°ê¤º¥«³õ¡F¨ä¥L¦¬¤J«Y¨Ó¦ÛÅã¼v¾¯¬ÛÃö²£«~¤§Ã±¬ùª÷¡A ¦ûÀç·~¦¬¤J¤ñ«¬ù¬°5.55%¡A¥Dn¾P°â¦a°Ï¬°¥[®³¤j¤Î¤¤ªF¦a°Ï¡C106¦~¤W ¥b¦~°£¤F¿¯S¹ç¤Î´¶Àù¨O(Bendamustine)ªº°ê¤º¾P°â¥~¡AÀç·~¦¬¤J¤ñ«¤À§O ¬°5.32%¤Î75.23%¡AÅã¼v¾¯ì®ÆÃĦûÀç·~¦¬¤J¤ñ«16.82%¡A¥Dn¾P°â¦a°Ï ¬°Áú°ê¡F¾P°âÅv§Qª÷¦ûÀç·~¦¬¤J¤ñ«¬°2.62%¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/10 ¤U¤È 08:11:39²Ä 84 ½g¦^À³
|
Hi ¦Ì¤j 6¤ë¥÷À禬¼W¥[ì¦]¬° DOTA ¾P°â¼W¥[°Ý¨ì¸ò¬d¨ìªº¦ü¥G¬OÅã¼v¾¯ªºì®Æ??¤£ª¾³o³¡¤ÀÀ禬¥¼¨Ó¬O§_¥¼¨Ó¤´¦³¾÷·|»{¦C?? ½Ð°Ý DOTA ¾P°â¼W¥[ «üªº¬O¤°»ò?? ÁÂÁ±z¡C 2016/12;2017/1 À禬¤j¼W¬O´¶Àù¨Oªº¥X³f¡A©Ò¥H¸Ó²£«~³£¶°¤¤¦b´XÓ¤ë¥X³f¶Ü?? ÁÂÁ±z¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/10 ¤U¤È 08:06:15²Ä 83 ½g¦^À³
|
Æ[¹î¥»©PÄw½X¡A¤d±i¥H¤W¤j¤á¥u±¼¤F 18 ±i¡A800-1000±i ±¼¤F 10 ±i¡C¥Dn½æÀ£¶°¤¤¦b 50-200 ±i³oӯŶZ¡A¦@½æ¤F 150 ±i¥ª¥k¡AÄw½XÅé½èºCºC§ïµ½¤¤¡C ¤U¬P´Á«ùÄò°lÂÜ 1. ¯q±o¤WÂd¼f¬d (12/11)¡A¥Í§Þ¤½¥q¤WÂd·¦V²y¡A¤×¨ä¬O¦b°·¥Ã/±d³ß °h¥X«á¡C 2. ¦]µØ¤WÂd¥Ó½Ð (³oÀ³¸Ó¬Oµu´Á³Ì«nªº¨Æ¤F) 3. ¤º´ò¬O§_°±¤â¡C 4. ®³Ó±M§Q¤£ª¾¹D·|¤£·|µoÓ·s»D...... µ¥µ¥¬Ý¹Æ!! |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/10 ¤U¤È 05:11:04²Ä 82 ½g¦^À³
|
§ó¥¿«e±ªº¤å¦r ´¶Àù¨O¦¨ªø13.96% «Y°·³ì¤µ¦~¤W¥b¦~ªº¼Æ¦r ì¤å»~µ¬°ºI¦ÜQ3ªº¼Æ¾Ú |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/10 ¤W¤È 09:24:40²Ä 81 ½g¦^À³
|
Mogwai¤j·PÁ¤À¨É ±zÁ¿ªº½×ÂI¤p§Ì²`¦³¦P·P ¤£¹L¤µ¦~¦]¸¿ÕÀ禬n¤j´T¦¨ªø¥i¯à·|¦³ÂIÃø«× µu´Á¦]¸¿ÕÀ禬n¤j´T¦¨ªøn¬Ý¤g¦Õ¨ä¥«³õ ¦Ó¤g¦Õ¨ä¬F©²n¨Dªº¬O¥²¶·n¥H¸¨¦a²£ªº¤è¦¡¥Í²£ ¬G¦b¤g¦Õ¨ä¦X§@¹Ù¦ñºV©w«en¤j¶q¥X³f¥i¯à·|¦³ÂIÃø«×? ¤£¹L´N12¤ë~2¤ëªºÀ禬¦¨ªø¶Ü?¤p§Ì¬O«ù¼ÖÆ[ªº¬Ýªk ¦]¬°¥H°·³ìQ3ªº©u³øÁÙ¦³ªñ´Áªºªk»¡¸ê®Æ¨Ó¬Ý ´¶Àù¨OºI¦ÜQ3À禬¦¨ªø13.96% ¦Ó¸Ó²£«~¦Û±q¥h¦~12¤ë~¤µ¦~1¤ë¶i³f¬ù4000¸U¥ª¥k«á ¨´¤µ©|¥¼¦³·sªº¶i³f ¬Gºâ¤@ºâ®Éµ{À³¸Ó¤]§Ön¦³¤U¦~«×ªº¶i³f¤F¡K. ¥u¬O¤µ¦~¥d¦b¦³¤WÂdªº³oÓÅܼÆ,´N¬Ý°·³ìn§âÀ禬°µ¦bþÓ¤ë¤À¤F... (¤p§Ì¨ä¹ê¦³ÂI¦n©_ªº¬O6¤ë¥÷À禬¼W¥[ì¦]¬°DOTA¾P°â¼W¥[°Ý¨ì¸ò¬d¨ìªº¦ü¥G¬OÅã¼v¾¯ªºì®Æ??¤£ª¾³o³¡¤ÀÀ禬¥¼¨Ó¬O§_¥¼¨Ó¤´¦³¾÷·|»{¦C??) |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/12/9 ¤U¤È 11:19:23²Ä 80 ½g¦^À³
|
¦]µØ¬Q¤Ñ 12¤ë7¸¹¤S®³¨ì¤@Ó¬ü°ê±M§Q¤F Metronomic oral gemcitabine for cancer therapy ¤W¤@Ó¬ü°ê±M§Q¬O¦³ÃöOralPas§Þ³N¥»¨,³o¤@Ó±M§Q¬Ý°_¨Ó¬OOralPas§@¥Î©óÀù¯g¤W¤èªk. ¸Ü»¡¦]µØ³Ìªñªº¦n®ø®§³£¥u¦³¤@¤é¦æ±¡´N¶^¦^18¶ô¦h. ³Ìªñ¦³´X«h¦³Ãöªº·s»D¸ò¤j®a¤À¨É 1. °·³ìªá3ÂI¦h»õÁʶR´º¼wªºÃÄÃÒ©MÀ³¦¬½ã´Ú,ªí¥Ü¦]µØ¥À¤½¥q¨S¨º»ò½a¶Ü? 2. 12¤ë11¸¹¯q±o¥Ó½Ð¤WÂd®×±N¦³¨Mij(¥i¥HÆ[¹î¥S§Ì¤½¥q¤WÂd¦¨¥\©Î¥¢±Ñ³y¦¨ªº¼vÅT) 3. °·¥Ã©M³ß±dºM¾P¿³Âd,³oµ´¹ï¬O¹ï¥xÆW¥Í§ÞÄw¸êª¬ªpªº§Üij¦æ¬°,¤§«á¬F©²©Î¥Á¶¡·|§ó«µø¥Ø«eÁÙ¦b¿³Âdªº¥Í§Þ¤½¥q¶Ü? µu´Á¶¡¤º¦]µØÀ³¸Ó·| 1. ¦b¬ü°ê¦¬²Ä¤@ÓD07001-F4 ¤G´ÁÁ{§Éªº¯f¤H(·PÁ§ë¸êªÌ¤jªº®ø®§) 2. À³¸Ó·|¥Ó½Ð¤WÂd(»°¦b12¤ë23¤é¬ì§Þ¨ç¦³®Ä´Á¶¡¤º),¤£¹L§Ú»{¬°¯q±oªº¤WÂd¦¨¥\»P§_À³¸Ó·|¼vÅT³o¥ó¨Æ. ¥t¥~¦]µØ¤½¥¬11¤ëÀ禬,1~11¤ë²Öp¬ù0.43»õ¤¸,¤ñ°_¥h¦~¥þ¦~0.457»õ(¥]§t¨â¦Ê¦h¸Uªº±ÂÅvª÷),¬Û®t¤£»·. ¤£¹L°O±o¤µ¦~¦]µØÀ³¸Ó·|¦³¦]¸¿Õ²£«~ªº¦¨ªø,¦pªG12¤ë¨S¦³¤ñ¸û¤jªºÀ禬¶i®i,´N·|ÁÙÆZÅý¤H¥¢±æªº |
|
|
·|û¡G®ÇÆ[ªÌ10141545 µoªí®É¶¡:2017/12/6 ¤W¤È 07:44:15²Ä 79 ½g¦^À³
|
Ó¤H·Qªk ¨SÀò§Q¥Í§Þ·sÃĪѷÀI¤[¤[99%...ÁaµM¦³¤d¸Un·V¤§...°ª»ùªÌ¥u¦ÊªÑ½m¥\¡A§C»ù¤p°u¥H§Þ³N±Æ[¹î¶R½æ¡A²ßºD°ò¥»«ù¦³¥u1±i·í±m¨é¬Ý«Ý¡A¦]¬°¨SÀò§Q¨S¤°¤j®ø®§¡A@¤ßµ¥«Ý¤½¥q§V¤O³á¡I!! ¤½¥qÁ«¤j¿úÁaµM¶B¬Ý¦³±M·~¦ý¥¼¦³¹ê½èÀò§Q¦p¥_·¥¬Pn·V¤§¡A¤£ª¾¤S®M¦í¦h¤ÖÁo©ú¤Hªº¸êª÷???¼F®`ªÌº¦¶^³£ÁÈÃz§Q¡A¦ý¤Ö¤§¤S¤Ö¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/5 ¤U¤È 06:28:28²Ä 78 ½g¦^À³
|
¤µ¤Ñ¬OÓ¬ö©À¤é¡A¤º´ò¥S§Ì¨S¦³¥X9±i¡Aµ¥¤Ñ¤W±¼®ø®§~ |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2017/12/4 ¤U¤È 06:49:24²Ä 77 ½g¦^À³
|
¤µ¤Ñ¦]µØ¨«¶Õð·¡A¥[ªo! |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2017/12/4 ¤W¤È 07:52:53²Ä 76 ½g¦^À³
|
ª©¥D±z¦n¡A¤H§äı±o12/3§Úªºµo¨¥¤º®e¤£¾A·í¡A½ÐÀ°§Ú§R°£¡AÁÂÁª©¥D¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/3 ¤U¤È 07:29:14²Ä 75 ½g¦^À³
|
«K©y¡A¬Y¾ãµ{«×¤]¬O¦]¬°¤½¥q¸gÀçªÌ¤£¤Óµ½©ó¸gÀç¸ê¥»¥«³õ¡A¸Ó¥´§¾ªÑ¡CÀ³¸Ó«Øij¤½¥q¦h°Ñ¥[ªk»¡¡AÅý§ë¸ê¤j²³¤F¸Ñ¤½¥q¦b°µ¤°»ò¡A¼Æ¾Ú¡A¶i«×³£Åu¶}¨Ó¡A§ë¸ê¤j²³¤]´N¤ñ¸û¤£·|®`©È¤F¡C¥u¯à»¡³\Á`¤£³ßÅw»¡ÁÙ¨Sµo¥Íªº¨Æ±¡¡A§C½Õ¦æ¨Æ¡C °ª¿vÀð¡A¼s¿n³¡A½wºÙ¤ý¡C¤½¥q¿ú°÷¥Îªº®ÉÔ¬O¦n¡A¦ý¥H²{¦b¥Í§Þ¥«ªp¿½·æ¡A¼W¸ê§xÃø¡AÁÙ¬O§â´¤ªí²{¾÷·|¡A§O¤Ó²M°ª¬°¦n¡C |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2017/12/3 ¤U¤È 12:08:59²Ä 74 ½g¦^À³
|
¤j¥ß¥ú8O±i´N¥i®³¤U¡A¯uªº¦]µØ¤Ó«K©y¤F |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2017/12/3 ¤W¤È 11:54:21²Ä 73 ½g¦^À³
|
¥~¸ê½æ¤j¥ß¥ú¥i®³¤U¦]µØ¸gÀçÅv¡A¤Ó´Î¤F¡C¤j¥Í§Þ¤j¦ÑÁó¤p¤ß°Ú!¦U¦ì¤j¤j¤ÀªRªº¤Ó´Î¤F¡C |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2017/12/3 ¤W¤È 10:08:00²Ä 72 ½g¦^À³
|
¦U¦ì¤j¤j, ¤p§Ìı±o¨ä¹ê¦]µØ¦b²£«~¬ãµo¤Î±M§Q¤W³£¬O¦³¤j¤j¦³«e´º,Á`¸g²z¤]¬O«D±`±M·~,©Ò¥H¦b¤½¥qªº°ò¥»±¤W¬O¨S°ÝÃD¦Ó¥B¨ã¦³»·´º¥i§ë¸ê©Êªº,ªø´Á«ù¦³¬O¤@©w¯à¦³«D±`¤jªº¦^³ø,¥H²{¦æªÑ»ù¨Ó»¡,¤£¨ì19¤¸,¤@±iÃÄÃÒ¥i¥H¤ä¼µ¦h¤Ö¤¸? 38¤¸? ¨º¥i¬O§ë¸êÀò§Q100%.... ¦p¦U¦ì¤j¤j©Ò¨¥,¦³¤jªÑªF¨C¤Ñ½æ¥X9±i(¥i¥H¤£¥Î¥Ó³ø),©Î³\¬O¥L¯uªº¬O¦]¬°nÅý¼W¸ê¦¨¥\¶i¦Ó¦Y±¼Äw½X,µM«á¦^¦R¨ì¥«³õ¤W,µ¥©ó¬OÅܬÛ¶¸ô¼W¸ê¦¨¥\,©Ò¥H18.1¤¸¬OÓ©³½u,¤]¯uªº´X¥G¨S¦³¦¨¥æ, ¤£¹L¥O¤H®`©Èªº¬O,¦]µØ¤jªÑªF¦³¨S·Q¹L§CªÑ»ù±a¨Ó±j¤jªº·ÀI¬O¤°»ò?§CªÑ»ù¬O¤½¥q³y¦¨ªºÁÙ¬O¦³¤ß¤H¤h³y¦¨ªº?ÀHµÛ¤½¥qªº¬ãµo¶}©ln¶}ªáµ²ªG¤§®É,ªÑ»ù«o¶V¨Ó¶V§C,¦³¤WÂdªº¥´ºâ«o¿E¤£°_ªÑ»ù................... ¤C»õªº¤½¥q,¥«È¤£¨ì14»õ, ¶W¹L60%¥H¤Wªº¦b¥~¬y°ÊªÑÅv,30%ªÑÅv§C»ùÁʤJ¥u»Ýn4»õ,µM«á¤½¥q¥Ø«eªº¬ãµo¦¨ªG³£¥ô¤H¬V«ü¤F..........³o¬O¤½¥q°]°Èªø¤£¯à¦A¤£¥h·Qªº¨Æ±¡¤F,,,¤£¥i¥H¦A¥Î³Ì²³æ¤èªk¨ÓÄw¸ê |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/2 ¤U¤È 10:25:58²Ä 71 ½g¦^À³
|
°w¹ï¤jªÑªF½æªÑ¤A®×¤p§Ì¬Ýªk¸òmogwai¤j¬Ûªñ ¸Ü»¡°·³ì¨Ã¤£¬O®a°]¸U³eªº´Iª¨ª¨ ¦Û¤vªº¥»·~¬ùºû«ù¤pÁ«¤p¬Õ¥ª¥k °¾°¾¨âÓ¨à¤l¾Ç¾ú¤S°áªº°ª¨C¦~³£»Ýnª¨ª¨¸ê§U¬ã¨s©Ò¾Ç¶O¡K. §ó³ÓµÛ¨ä¤¤¤@ӵئr½úªº¥S§Ì ¥æ¤F¤@¦ì¤C©h®Q »Ýnª¨ª¨¥X7»õ¥ª¥kªº¸uª÷¡K. ¥[¤W¤jÀô¹Ò¤S·¥«×¿½±ø¡K¡K. ¬G½æªÑÄw¿ú¤]¬OµL¥i©`¦ó ¥t¥~¦A¤À¨É¤@¤UªÑªF·|ªº¹êªp ªÑªF·|¨º¤@¤Ñ¥¿¦n¬O²Ä¤G¦¸²{ª÷¼W¸êªº³Ì«á¤@¤Ñ ¨º°}¤l±Á{¤F³Ð§ë¥S§Ì ¥[¤W¤g«°¥S ¤TxÁp¦Xªº§¨À» ¥[¤W³\¦h¹ï©ó¥Í§Þ¤Î¤½¥q¥¢±æ©Êªº½æÀ£ ¦Ñ¹ê»¡¤G¦¸²{¼W¥i§_¦¨¥\?©|¦b¥¼©w¤§¼Æ¡K.. ·í®ÉªÑªF·|¦³¤@¦ìªÑªF°_¨Óµo¨¥§Æ±æªL¸³¥i¥H½T«O²{ª÷¼W¸ê¶¶§Q§¹¦¨ ªL¸³·í®É¦^µª»¡ ²{¼W¤j®a¤£nªº ¤jªÑªF·|t³d¡K. ¦Ñ¹ê»¡¤p§Ì·í®É·Q»¡³o³¡¤ÀÀ³¸Ó·|§ä¯S©w¤H»{ÁʤF¤£°_¦h»{ÁÊ1000¦h±i ¨S·Q»¡³Ì«á°·³ì©~µM¤@Ó¤H¦Y¤F4000¦h±i.... (¦pªG¤¸´I-«°ªF ¯uªº¦p²q´ú¬O¤jªÑªFªº¤Íx¤Í±¡ÃÙ§Uªº¸Ü¨º´N¬ù5000±i¤F) ¥t¥~¨ä¹ê±q6¤ë¨ì²{¦bªÑ»ù«Ü¦h®É¶¡³£¦b18¤¸¥ª¥k½L±Û ¦©±¼¤âÄò¶O¸òµ| ¨ä¹ê®Ú¥»Àò§Q·¥·L ¥H«_ªº·ÀI¸ò®É¶¡¦¨¥»¨Ó¬Ý»¡¥L̦bª£ªÑ¯uªº¬O¦³ÂI¨I«¡K ¦^¨ì¦]µØ¥»¨¤p§Ìı±oÄw½X¼vÅTªº¬O¤½¥qµu¤¤´Áªº¨«¶Õ ªø´Á«h¬O¬Ý¤½¥qªº°ò¥»± ¥H¤p§Ì¹L©¹§ë¸ê¤¤¸Î¦³ªº§ë¸ê¸g¾ú¦Ó¨¥ ´¿¸g¾ú¤F¥~¸ê¤jªÑªFgenentech ¥Dn¬ì¾Ç®a ÁÙ¦³®üôªº¤j½æªÑ ¨C¦¸½æªÑ®ÉªÑ»ù¤£¥i§_»{ªºªÑ»ù·|¨ü¨ìÀ£§í ¦ý¦p±N®É¶¡©Ôªø¨Ó¬Ý¥un¤½¥q«ùÄòªº«e¶i ªÑ»ù²×¨s·|¦^¨ì¥¦À³¦³ªº»ùÈ¡K (·íµM¨âÀɪѲ¼¥»½è¦³©Ò®t²§ ¤£¹L¥L±Á{ªº½æÀ£¤Î¼Æ¶q¤]®t§O¬Û·í¤j¡K.) ¦Ó¥H¦]µØ¥Ø«eªº¥«È¨Ó¬Ý ¥L³Ì¤jªº·ÀI¤£¦A©ó¥Lªº²£«~½u¦Ó¬O¦b©ó°]°È± ¥H²£«~½u¦Ó¨¥¤¤´Á¦³¾÷·|µo´§ªº¤T¤j²£«~½u 1.¤fªA§ÜÀùÃÄ 2.°ª¦åÀ£ÃÄ 3.Åã¼v¾¯¤Î¦]¸¿Õµ¥ ¥un¦³¤@¶µ¯à¦b¬ü°êµ¥¥Dn¥«³õ¤WÀ³¸Ó´N¥i¥HÅý¤½¥q¦³Ã©wªºÀò§Q¤F (°ò¥»¤W3¤w¸g¦b£¸¨Ç°ê®a¤W¥«¤F 1.¸ò2.¦]¬°ÃĪ«¥D¦¨¤À¨S¦³§ó°Ê¬Ý¨Ó¦¨¥\¾÷²v¤]¤£¤p....) ¥u¬O³o¨Ç»Ýn1~3¦~ªº®É¶¡ÁÙ¦³¤@©wªº¸êª÷³v¤@¥h§¹¦¨FDAªº¦U¶µn¨D.... ¥H¥Ø«e¨Ó¬Ý¤½¥q¿n·¥¿ì²z¤WÂd¥Ó½Ð ¥[¤W´¶Àù¨O©¹«e±À¶i¨ì¤@½uÀøªk °]°È±¬O¦³¾÷·|µy·L§ïµ½ªº¡K.. ³Ì«á´Á¬ß¤½¥q¯à°÷³vº¥®³¥XÀ³¦³ªº¦¨ÁZ ¥H§K¶dt²³®a¥S§Ìªø´Á±¡¸q¬Û®¼¤F¡K.. |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/2 ¤U¤È 09:51:27²Ä 70 ½g¦^À³
|
¨ä¹ê³Ìªñ¬Ý¤@¥»Âø»x¼g±o«Ü¦n¡A§ë¸ê¥Í§Þ´N¬OnÅý¦Û¤v±q«ùªÑµLÄß (®£Äß) ¨ì«ùªÑ¦³¾Ú (¨Ì¾Ú)¡C·íµM°ò¥»±¬O¤@¦^¨Æ¡AÄw½X¤S¬O¥t¥~¤@¦^¨Æ¡C ª¾¹DÄw½X¨Ó·½¥H¤Î¶R¶i/½æ¥Xªº¤ßºA¡A·f°t¤½¥q¤£Â_«e¶iªº¶i«×¡A¨ä¥Lªº¤]´N¨S¦³¬Æ»ò¤F¡CªÑ»ù°ª°ª§C§C¤]´N¬O¤ß±¡°_¥ñ½}¤F¡C¤jªÑªF½æªÑ¡A¤]¥u¬O³zÅSªÑ»ùªø´Á©³³¡ªº¦ì¸m½}¤F¡C ¦]µØ¦³©¯¡A´c·N½æªÑªºÄw½X¨Ó·½¤w¸g´X¥G¨S¦³¶i¥X¤F¡C³Ñ¤UÁÙ¬Oµ¥¤Ñ¤Wªº®ø®§¤F¡C |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2017/12/2 ¤U¤È 08:28:14²Ä 69 ½g¦^À³
|
ÁÂÁ¦ÌÄ_¤j¤j¤Î¦U¦ì¤j¤j¤~¹ï¡C(¹ï¤£°_¡A¥´¿ù¦r¤F) |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2017/12/2 ¤U¤È 07:46:54²Ä 68 ½g¦^À³
|
¦U¦ì¤j¤j¡AÁÂÁ±z̸ԲӪº¸Ñ´b¡A¥u¬O¥xÆW§ë¸ê¥Í§ÞªÑªº¤H¡A¤@¦A¨ü¶Ë¡A§ë¤Jªºª÷¿ú©¹©¹¦¨¥´¤ôº}¡A¨C®a¤½¥q¤L¥G¬OÁ«¥»¡A¤S®³¤£¥X¸Ó¦³ªº¶i«×¡A¤j®a¶Ì¥Ê·í¤[¤F¡A¤pªÑªF¤£·Q°Ñ»P»{ªÑ¤]«Ü¥¿±`¡A¤j®a¹ï¥Í§ÞªÑªº§Nºz³è±ó¡A²{¶¥¬q¥u¦³¥Í§Þ¤½¥q¦Û¥ß¦Û±j¡A®³¥X¦nªº¦¨ÁZ³æ¡A¤~¯à«·sÅý§ë¸ê¤H»{¦P¡C¦]µØ¦b§Ú¤ß¤¤¬O¤@®a¦n¤½¥q¡A¦ýªÑ»ù²_¸¨¨ì18¤¸¡A¥s¤H¤ß»Ä¤SµL©`¡CÁÂÁºôbªÌ¤j¤jªº»¡©ú¤Î¦U¦ì¤j¤jªº¨£¸Ñ¤À¨É¡C |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/12/2 ¤U¤È 07:12:28²Ä 67 ½g¦^À³
|
¥Ñ¾ú¦~¨Ó¤d±i¤j¤á¤Î°·³ìªº«ùªÑ¤ñ¨Ò¨Ó¬Ý,¤jªÑªF¤Î¥À¤½¥qªº½T¤@ª½¦³¦b¥X²æªÑ²¼ °Ñ¦Ò¦~³ø °·³ì«ùªÑ¤ñ¨Ò 103 25.76% 104 21.5% 105 18.45% 106 17.3% (¥H¤W¥ÎªÑªF·|¥l¶}¦~¨Ó¬Ý) ½æ¤E±i³oºØ¦æ¬°«Ü¦«e´Nµo¥Í¤F,¤£¹L§Ú¬O¸ÑÄÀ¦¨°·³ì¨Ã¤£¬O°]¤O¶¯«pªº¤½¥q,¤S¦³¨âÓ¿N¿úªº¤l¤½¥q,½æªÑÄw¿ú¤]¬OµL¥i«p«D. ¦]µØªºÄw½X±«Ü®t,¦ý®ø®§±¬Ý¨Ó¤S¤£¿ù,´N¬Ý¥«³õºÝ«ç»ò¬ÝÅo! |
|
|
·|û¡GªL§Ó³Í10143927 µoªí®É¶¡:2017/12/2 ¤U¤È 05:23:56²Ä 66 ½g¦^À³
|
·PÁ¦ÌÄ_¤j¤À¨É¡A¦ýÓ¤H¤£Ä±±o¬O¦p¦¹¡C »¡¦nÅ¥¬O±¡¸q¬Û®¼¡AÁ¿ÃøÅ¥ÂI¡AÁÙ¬OÁÈ»ù®t¡C °£«D¤jªÑªF«Ü¯Ê¿ú¡A§_«h¨Ì¥Ø«eªºªÑ»ù¡A¤´µM«ùÄò¤p¶q½Õ¸`¡A¹ê¦b¦³ÂI¥t¤Hê¦i©Ò«ä¡C ¸Ó¤£·|¬O¦Û¤v¤]¤£¬Ý¦n¶Ü¡H ªP¶O§Ú©ê¨º»ò¤[¡A¤]°Ñ¥[¤G¦¸¼W¸ê¡C ¥t¥~¡A¦pªG§Ú¨S§Ë¿ùªº¸Ü¡AÅã¼v¾¯¦b¥xÆW¤£¬O¤w¸g¨ú±oÃÄÃÒ¤F¶Ü¡H¬°¦ó¤]³£¨S¦³¾P¶q¡H |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/2 ¤U¤È 04:44:13²Ä 65 ½g¦^À³
|
Hi ¦Ì¤j ¤F¸Ñ¤§«á¤Ï¦Óı±oÁŵM¶}®Ô¡C¤jªÑªFªº¤ä«ù»P§ÔÅý¤]¬OÅý¤H´Ü¨Ø¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/2 ¤U¤È 03:34:11²Ä 64 ½g¦^À³
|
³o¤@¦¸¤p§Ìn¬°³o¦ì©Ò¿×ªºÀ³¸Ó²`¨è·\ª¹ÀË°Qªº¤jªÑªF»¡¤@¥y¸Ü ·íµM¤jªÑªF¤£½æªÑ ¬Æ¦Ü¬O¤j¤O¶R¶i¬O³Ì²z·Qªºª¬ªp ¦ý¦U¦ì¥i¥H¥h¬d¬d¸Ó¤jªÑªFªº¤µ¦~¥H¨Ó±K¶°©Ê¨C¤Ñ¥X²{ªº½æ½L¬O¥X²{¦b¤°»ò®ÉÔ? ·í¤½¥q¤í¯Ê¬ãµo¸êª÷»Ýn²{ª÷¼W¸ê®É¦U¦ìª¾¹D²Ä¤@ªiÄ@·N±Ç¿ú¥X¨Óªº¤j¤pªÑªF¦³´X¦ì¶Ü? µª®×:²Ä¤@¦¸²{ª÷¼W¸ê»ù®æ©w¦b23¤¸»{Áʪº¦³202¤H(¤½¥qªÑªFÁ`¼Æ¬ù2800¤H) §Ú·Q·í®É¤½¥q¬Ý¨ì³oºØ»{Áʱ¡ªp¤j·§«Ü¶Ì²´ ¬G·í®É¤@¨Ç«nªº¤½§iÁÙ¥X¤F¤@¨Ç®t¿ù.... ½Õ°»ù®æ«á²{ª÷¼W¸ê»ù®æ©w¦b18¤¸ »{Áʪº¤Hµy·L¦h¤@ÂI ¦L¶H¤¤ ¬ù260¦h¤H.... ¥H²{¦b³o¼Ë§NÄBÄBªº¥«ªp¨Ó»¡ n¤£¬O¸Ó¤jªÑªF«Ü»¨®ðªº¤@Ó¤H¦Y¤U¤F2/3 ¬ù4000¦h±iªº²{¼WÃB«× ²{¦b¤½¥q¥i¯à²{ª÷¼W¸êÁÙ¨S¦³§¹¦¨...... ¤µ¦~¥H¨Ó¦]µØ½æÀ£¥Dn«e¤»¤j¨Ó·½ ¤À§O¬° ¥üÂ×-ªFªù ¤¸¤j-«n¨Ê ¤¸¤j-¤º´ò ¤¸´I-«°ªF ¥ÃÂת÷-¤º´ò ¤é²±-¤g«° ¨ä¤¤«e¨â¤j¬°¦P¤@¹Ùªº³Ð§ë¥S§Ì ¦b¤µ¦~²{ª÷¼W¸ê«nÃöÁ䪺¤@¨Ç¤é¤l¤¤¸ò¤£ª¾þ¸Ì¨Óªº ¤g«°¥S Áp¤â§âªÑ»ù¥´ªº¦nµL©Û¬[¤§¤O ²{¦b³o¤@¨âÓ¤ë³o¤T¦ì¤¯¥S¤w¸g¤ñ¸û¤Ö¶i¥X¤F.... ¤¸´I-«°ªF«Ü¥i¯à¬O¤jªÑªF¬°¤F³o¦¸²{ª÷¼W¸ê¦¨¥\½Ð¨Ó¨ó§Uªº¤pÀ°¤â ¤â¤¤ªº³f¦b²{¼WªÑµo©ñ«á¤@¤f®ðË¥X500¦h±i¨S·N¥~ªº¸ÜÀ³¸Ó³f¤£¦h¤F.... ³Ñ¤Uªº¨âÓ±b¤á´N¬O³o¤@¦¸¤j®a°Q½×¼ö¯Pªº¤jªÑªF¤F ¸Ó¤jªÑªF¬°¤F²{¼W¦¨¥\¤@¥i®ð§â§O¤H¤£nªº³Ñµæ³Ñ¶º¦Y§¹¦Y¤Ó¹¡¦Y¨ì©Ô¨{¤l ¥u¦n¨C¤Ñ¥XÓ9±i.... ÀY¤@¦¸¤p§Ì¬Ý¨ì¤jªÑªF¦b½æªÑµo²{¦Û¤v¥Í®ð¤£°_¨Ó..... |
|
|
·|û¡GJacK10145269 µoªí®É¶¡:2017/12/2 ¤U¤È 01:38:43²Ä 63 ½g¦^À³
|
¦U¦ì¤j¤j¦n¡A¤£¨ì20¤¸ªºªÑ»ù¡A¤jªÑªFÁÙ¨C¤Ñ½æ§r?¬O¯uªº¶Ü¡H¤£·|·\ª¹§ë¸êªÌ¶Ü¡H¬O¤£¬O¤jªÑªFÀ³¸Ó¦³¦³³d¥ôÂI¡A¥þ¤O¶R¶i¤~¹ï§r¡H²{¦b¥Í§ÞªÑÅý¤H³è±ó¡A³o¨Ç¤jªÑªF¬O¸Ó²`¨è·\ª¹ÀË°Q§r¡I |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2017/12/2 ¤W¤È 07:48:27²Ä 62 ½g¦^À³
|
¦]¬°¤jªÑªF¨C¤Ñ½æ9±i¡]§t¡^¡A§K¥Ó³ø¡A¤½§i§r¡A©Ò¥H¤~·|¦³¸³ºÊ«ùªÑ¨C¤ë¤U°¡K¡K¡K¡K¡K |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/12/1 ¤U¤È 08:49:25²Ä 61 ½g¦^À³
|
Àù¯g·sÃÄ¡A§ÜÀù¾÷Âà½T©w (Àù¯gªvÀø½Ö¤£ª¾¹D Gemcitabine ¯à§ÜÀù)¡A©t¨àÃÄ (ÁxºÞÀù)¡A¦h°ê¦h¤¤¤ß¤G´ÁÁ{§É¡C ªÑ»ù¥uÈ20¤¸¥H¤U?? ¬ö¿ý Inno-Go-03¡A¶}©lªº³o¤Ñ¡A¥xÆW¥«³õ¬O«ç¼Ëªº¹«¥Ø¤o¥ú¡C ¤¸¤j¤º´ò/¥ÃÂת÷¤º´ò¡A¥S§ÌÀÉ¡A¨C¤Ñ¦X§@µL¶¡¦@½æ9±i¡A¯u¬O¦³·N«ä¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/12/1 ¤U¤È 07:53:16²Ä 60 ½g¦^À³
|
¥»¤½¥q¬ãµo¤¤ Gemcitabine¤fªA·sÃÄÀò±o½Ã¥ÍºÖ§Q³¡³q¹L ¤HÅéÁ{§É¸ÕÅç¼f¬d¡A®Öã¦P·N¦]µØ¥Í§Þ°õ¦æÁx¹DÀù¤HÅéÀø®Ä¡B ÃĪ«°Ê¤O¾Ç¤Î¦w¥þ©ÊÁ{§É¸ÕÅç¡C 1.¨Æ¹êµo¥Í¤é:106/12/01 2.¤½¥q¦WºÙ:¦]µØ¥Í§Þ»sÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GD07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) ¤G¡B¥Î³~¡GªvÀøÁx¹DÀùªº Gemcitabine¤fªA·sÃÄ ¤T¡B¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¤G´ÁÁ{§É¸ÕÅç ¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (¤@)´£¥X¥Ó½Ð¡þ³q¹L®Öã¡þ¤£³q¹L®Öã¡G½Ã¥ÍºÖ§Q³¡®Öã¦h°ê¦h¤¤¤ßÃÄ«~¸ÕÅç¼f ¬dµ{§Ç¦P·N¶i¦æÁx¹DÀù¤HÅéÁ{§É¸ÕÅç(pµe½s¸¹¡GInno-GO-03)¡A¸Ó¸ÕÅç©ó 106¦~8¤ë1¤é¤wÀò¬ü°ê¹«~ÃĪ«ºÊ·þºÞ²z§½¥Ó½Ð¦h°ê¦h¤¤¤ßªºÁx¹DÀù¤HÅéÁ{ §É¸ÕÅç(IND No.¡G129288)®Öã³q¹L¡C (¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î (¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G§ÜÀù·sÃĤG´ÁÁ{§É¸ÕÅç«á¡A ±Nµø¨u¨£Àù¯g¤§Á{§ÉªvÀøµ²ªG¡A¨Ó¨M©wÂX¤jªvÀø¤H¼Æ©Î¦Ò¼{¦V¬ü°ê¹«~ÃĪ«ºÊ ·þºÞ²z§½´£¥X·sÃĥӽСC (¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¦]¯A¤Î¥¼¨Ó°ê»Ú±ÂÅv½Í§P¸ê°T¡A¬°ÁקK¼vÅT±ÂÅvª÷ÃB ¡A¥H«O»Ù§ë¸ê¤HÅv¯q¡A¼È¤£´¦ÅS¡C ¤¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G (¤@)¹wp§¹¦¨®É¶¡¡GY¤@¤Á¶¶§Q§¹¦¨¡A¹wp¦b108¦~2¤ë§¹¦¨¦¬®×¡C (¤G)¹wpÀ³t¾á¤§¸q°È¡G¸Ó¤p¤À¤l·sÃÄ«Y¦]µØ¥Í§Þ¿W¥ß¬ãµo¡A¾Ö¦³100%±M§QÅv¡A«Ý §¹¦¨¨Ã³q¹L¬ü°ê¹«~ÃĪ«ºÊ·þºÞ²z§½n¨D¤§¬ÛÃöÁ{§É¸ÕÅç§Y¥i¥Ó½Ð¤W¥«¡C 6.¦]À³±¹¬I:µL¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A §ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C ±µ¤U¨Ó´N´«³oÓ¤ë¬ü°ê¦¬¶i²Ä¤@¦ì¯f¤H¤F,¥[ªo¥[ªo!! |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/30 ¤U¤È 10:02:12²Ä 59 ½g¦^À³
|
·PÁ¦̤j§iª¾¡C ¦ÛÀç°Ó³sÄò¶R¤T¤Ñ(¬ÝÄw½XÀ³¸Ó¬O¤j®iÃÒ¨é (505T))¡A¯u¬OÃø±oªº²{¶H¡C¬O·Q°Ñ¥[±ÀÂ˨é°Ó¶Ü? ²{¦b¥u¯à«Ì®§¥H«Ý¡Aµ¥¤Ñ¤W±¼¤U¤@Ó®ø®§¨Ó¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/29 ¤W¤È 08:56:05²Ä 58 ½g¦^À³
|
¥DnÀø®Ä«ü¼Ð±Ä¥ÎOSÁÙ¦³¥ý¶i¦æ¤G´ÁÁ{§É«Y¦]¬Ý¦~³ø°w¹ïÁxºÞÀù³W¹ºªº¼gªk¸òªk»¡ì©l³W¹ºªº¦ü¥G¦³©Ò¤£¦P¬GªÑªF·|®É¸ß°Ý¤½¥q±o¨ìªº¦^´_,¥t¥~ÁxºÞÀù©M¨ÅÀùµ¥¯e¯f¤£¤Ó¤@¼Ë,¬O¬Û·í´c©Êªº¯e¯f©Ò¥H±Ä¥ÎOSÀ³¸Ó¤]¤£¦Ü©ó¹³¨ÅÀùÁ{§É¨º¼Ë»ÝnÆ[¹î¨ì¤Ñ¯î¦a¦Ñ...¤£¹L¬ÛÃöÁ{§Éªº³WµeÁÙ¬O«Ý¤½¥q¤½§i¬°·Ç,¥H¤U¸`¿ý¤½¥q¦~³ø°w¹ïÁxºÞÀù¤¶²Ð¨Ñ°Ñ: ÁxºÞÀù¤§¤Æ¾ÇªvÀøªº¦¨®Ä¬Û·í¤£¨Î¡A¥Ø«e¼Ú¬ü¥Dn¥«³õ¤]©|¥¼¦³ÃĪ« ³q¹LÁ{§É¸ÕÅç¨Ã¥¿¦¡¨ú±oªvÀø¦¹¯e¯f¡C5-FU ¬O³Ì¥ý¨Ï¥Î©ó§ÜÁxºÞÀùªºÃÄ ª«¡A³æ¿W¨Ï¥Î®É¶È¦³ 10%ªº®ÄªG¡F¤§«á¦X¨Ö¨Ï¥Î leucovorin¡Binterferon-£\¡A cisplatin ¤Î oxaliplatin «á¥i±o¦³ªº®ÄªG¥Ñ 25%¼W¦Ü 50%¡A¦Ó¤¤¦ì¼Æ¦s¬¡´Á (median survival)¥Ñ 6 Ó¤ë¨ì 12 Ó¤ë¡C¦X¨Ö¨Ï¥Î capecitabine ¤Î cisplatin ¥i ´î»´¬r©Ê¡A¨Ã¦³ 41%ªº®ÄªG¡A¤¤¦ì¼Æ¦s¬¡´Á¬° 12 Ó¤ë¡C³Ìªñ gemcitabine ³æ¤@¨Ï¥Î¦³®Ä¹F 30%¡F¦X¨Ö gemcitabine¡Bcisplatin¡Bcapecitabine ¤Î oxaliplatin ¦³®Ä²v¹F 36%¡A¤¤¦ì¼Æ¦s¬¡´Á¬° 10 ¨ì 15 Ó¤ë¡Aºî¦X¤wµoªíªº½×¤å¡AÁ`µ² ¬° gemcitabine ¦X¨Ö cisplatin ©Î oxaliplatin ¥i¥H±o¨ì³Ì¨ÎªºªvÀø®ÄªG¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/28 ¤U¤È 10:27:17²Ä 57 ½g¦^À³
|
Hi ¦ÌÄ_ ÁxºÞÀù¤G´Áªº¥Dn²×ÂIÀ³¸Ó¬O PFS §a? ®Ú¾Ú 2016 ¦~ªk»¡¡C³Ìªñ«Ü¦h·sÃÄÁ{§É³£¥Î ORR ·í¦¨¥Dn²×ÂI¡AÁYµuÁ{§É®É¶¡¡A«D±`¸r¼}¡C(¨Ò¦p ¥_·¥¬Pªº¨xÀù/¶¡¥ÖÀù II/III ´Á; ASLAN ÁxºÞÀù pivital exp.)¡A¤£¹L¡A³q±`·|³Qn¨D¸É°µ¤T´Á´N¬O¤F¡C ¤£¹L¥H gemcitabine ©ú½Tªº§ÜÀù¬¡©Ê¨Ó»¡¡A©Î³\¤ã¹êªº OS ¼Æ¾Ú¡A¤~¬O¤G´Á¨úÃÒªº«O»Ù§a¡A«e´£¬O¼Æ¾Ún¦n¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/28 ¤U¤È 09:32:23²Ä 56 ½g¦^À³
|
Hi mogwai¤j¦³ÃöÁxºÞÀù¹êÅç¾Ú¤p§Ì¤F¸Ñ¨Ã°Ñ°u¤½¥q¢·¤ë¢°¤éªº¤½§i³Ì«á¸ò¢Ô¢Ò¢Ï½Í©wªºµ²ªG¬O¥Ø«e¥ý°õ¦æÁ{§É¤G´Á¹êÅç¥DnÀø®Ä«ü¼Ð¬°¢Ý¢á¡AÁ{§É¹êÅçµ²ªG¥X¨Ó«á¬Ý¬Ý¢ø¢÷£@¢í¢ú°÷¤£°÷¡A¦pªG®i²{¥Xªº®Ä¤O«Ü©ú½T¤½¥q·|¦Ò¼{¥H²{¦³µ²ªG¥Ó½Ð¢Ü¢Ò¢Ï¡A¦p¬Ý±o¥XÁͶզý¥i¯à®Ä¤OÁÙ¥¼¹F¢Ü¢Ò¢Ïªº±ø¥ó«hÂX¤j¦¬®×¤H¼ÆÂন¢±/3´Á¡A·íµM¦pªG¬ÛÃöª¬ªp¥¼¦p¹w´Á«h´N¦b³]p¥¿³Wªº¤T´ÁÁ{§É¤F¡A·íµM¦³Ãö¬ÛÃöÁ{§Éªº³]pÁÙ¦³¦¬®×±ø¥óµ¥ÁÙ¬Oµ¥¤½¥q³Ì«á¤½¥¬¤~¯à§¹¥þ©ú¦¡K. |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/11/28 ¤U¤È 08:00:41²Ä 55 ½g¦^À³
|
·PÁ§ë¸êªÌ¤j¤j±a¨Óªº¦n®ø®§, ®Ú¾Ú¥h¦~©³ªk»¡·|¤º®e,¬Ý°_¨ÓD07001·|°µ§¹¦w¥þ©Ê¹êÅç«á¤G¤T´Á¤@°_°µ,¦]¬°¦³©t¨àÃÄn¯À,©Ò¥HÁ{§É®É¶¡©M³W¼Ò³£¥i¥H´î¤Ö. Phase II/III¸ÕÅç (ÁxºÞÀù¸ÕÅçpµe·§n) ®Ú¾Ú»P¬ü°êFDA©ó2016¦~pre-IND·|ijµ²½×, ©e°U°ê»ÚCRO ¦Ê·çºë¹©³]p¡A±N©óÁxºÞÀù¦w¥þ©Ê½T»{«á¶i¦æ¥H¤U¸ÕÅç¡G „«Âùª¼¸ÕÅç¡A68¦ì¨ü¸ÕªÌ¥H 1:1ÀH¾÷¤À°t¡A¥H¯e¯fµL´c¤Æ¦s¬¡´Á(Progress Free Survival, PFS)°µ¬°Àø®Äµû¦ô«ü¼Ð „«Âùª¼¸ÕÅç¡A¦A¥[136¦ì¨ü¸ÕªÌ¥H 1:1ÀH¾÷¤À°t¡A¦X¨Ö©Ò¦³µ²ªG¥H¾ãÅé¦s¬¡´Á(Overall Survival, OS)°µ¬°Àø®Äµû¦ô«ü¼Ð ¥t¥~¤½¥q¨C¦¸ªk»¡©Î¨ü³X³£·|»¡´XÓ¤jÃĤw¸g¦³®³¨ìterm sheet©Îñ¤FCDA,¦ý¨ì¥Ø«e¬°¤î³£¨S¦³¥O¤H®¶¾Äªº±ÂÅv±ø¥ó¥X¨Ó,¤£ª¾¹D¬O¤½¥qªºn¨D¤Ó°ªÁÙ¬O¦³¨ä¥Lì¦]. ©Ò¥H©êµÛ³oÀɪѲ¼¯uªº¸ò¦bצæ¤@¼Ë,§Æ±æ¦³¤@¤Ñ¯à¥\¼w¶êº¡ |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/28 ¤U¤È 04:50:28²Ä 54 ½g¦^À³
|
11/20 ¦V TFDA ´£¥X·sªºÁ{§É¥Ó½Ð®× (¤½¤å¤å¸¹: 1066063867/CDE ®×¸¹¡G106IND11260)¡A¤µ¤Ñ¶i«×¬d¸ß¤w¸g¼f¬d§e§P³q¹L¹Æ!! ¥t¥~¡AÁxºÞÀùªº³¡¤À¤½¥q 11/28 ¦^À³¡A¤UÓ¤ë¦b¬ü°ê±N¦¬²Ä¤@Ó¯f¤H¤F¡Ainsulin oral ªº³¡¤À¥Ø«e¦³´XÓ¥~°ê¤½¥q¬¢½Í term sheet ¤Î¦X¬ù¤¤¡C ~~צ椤¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/27 ¤U¤È 12:52:17²Ä 53 ½g¦^À³
|
ÁÂÁ¦ÌÄ_ªº¦^À³¡A«D±`·PÁ±z¡C ²{¦b¨C¤Ñ³£ÀRÀRªº¡AÆZ¦nªº¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/27 ¤W¤È 09:19:16²Ä 52 ½g¦^À³
|
¦Ü©ó¦³Ãö«áÄò°ÝÃD¤À¨É¦p¤U: 2.¤C¬P³¡¤À¥h¦~¬O¦]¬°¤C¬P«ù¦³ªº¤g¦a«ÜÈ¿ú¡A¶°¹Î¥Î«K©yªº»ù®æ¦Y¤U¤C¬P©Ò¥H¦b·|p±b±¤W¥h¦~¥i»{¦C·G»ùªºÁʶR§Q¯q¡A¦ý¥Ø«e°Ñ°u«Ø¹´ªº¦~³ø¥Ø«e¤C¬Pªº¥»·~¬O¤p´TÁ«·lªº¡A©Ò¥H¤µ¦~À³¸Ó¬O¨S¦³¬ÛÃöªº§Q±o¥i¥H»{¦C¡A¥Ø«e¤C¬P°£¤Fì¥ý¬J¦³²£«~½u¥~¥Dn³W¹º¨ÑÀ³¦]µØÅã¼v¾¯¸ò¦]¸¿Õµ¥«~¶µ¡A¬G¤C¬PÀò§Qn¤j´T´£ª@¥i¯àn¦^Âk¦]µØ¬ÛÃö«~¶µ¦ó®É¨ú±o¬ü°êÃįg¡A¦p¨ú±oÃÄÃÒ©¡®É°£¤F¥i¥H»{¦C¦¨«~¾P°â¬ü°êªº¾P³f¦¬¤J¥~¡A¦b¤C¬Pªº³¡¤À¤]¥i¥H»{¦C¦]¨ÑÀ³¬ÛÃöì®ÆÃÄÀ禬Á«Âà¬Õªº§ë¸ê¦¬¯q¡A¥i¥H»¡¬OÂùÀYÁȪΤô¤£º|¥~¤H²¢¡A¤£¹L¦b¬ÛÃö«~¶µÁÙ¨S¦³¨ú±oÃÄÃÒ¤§«e¤C¬P³¡¤À¥i¯à´N¨C¦~n´£¦C¤@¤p³¡¤Àªº§ë¸êÁ«·l¤F¡K. 3. N11001 (ªvÀø«e¦C¸¢ªÎ¤j)³¡¤À¦L¶H¤¤³oÓ«~¶µ¦n¹³´X¦~«e´N¼g»¡npÂà¬ÛÃö¼t°Ó¤F¡A¦]¬°¦]µØ¥Lªº²£«~½u¯uªº«Ü¦h¡A³o¤@¶µÀ³¸Óºâ¬O¤ñ¸û¤pªº²£«~½u¡A¤p§Ì³o¤@³¡¤ÀÁÙ¨S¦³¬ÛÃöªº°T®§¤£¦n·N«ä¡A±z¦p¦³±oª¾¬ÛÃö°T®§ÁٽФÀ¨É ÁÂÁ 4.¦³Ãö¹Å¦h©ú³¡¤À³o¤@¤äÃÄ·íªì°e¥ó®Éè¦n¾A¥Îªº¼f¬d¾÷¨î¬O¨®É¬ü°êFDA¤â¤¤¦³Ãö¾Ç¦WÃÄ¥Ó½ÐANDA®×¥ó¤j¶ë¨®¡A°O±o´¿¸g¬Ý¹L¬ü°ê¦X§@¹Ù¦ñAkronªk»¡·|¸ê®Æ¥§¡¼f¬d´Á¶¡¤j¬ù3¦~¦h¡K..¸ÓÃÄ«~2014¦~5¤ë°e¥ó¡AFDA©ó¥h¦~4¤ë¥÷«e©¹¤C¬P¬d¼t(¬d¼t®É¤Sè¦n¬O¤C¬PìªÑªF¤£°µ¤F¡A°·¹´¶°¹Îè±µ¤â«C¶À¤£±µªº®ÉÔ¡K¡K)¤§«áFDA³qª¾¸É¥ó¡A¤½¥q©ó3Ó¤ë«e§¹¦¨¸É¥ó¡A²{¦bÀR«ÝFDA¼f®Ö¤¤¡A¤£¹L¦n®ø®§¬O²{¦bFDA¼f®Ö¾Ç¦WÃĪº³t«×¤w¸g¤j´T´£¤É¤F¡A²z½×¤W¨ÓÁ¿°e¥ó«á¥b¦~¤@¦~¤ºÀ³¸Ó·|¦³µ²ªG¡A¥u¯à´Á«Ý³o¤@¦¸¯à°÷¶¶§Q¤F©ÎªÌ¦pªG»Ýn¦A¸É¥óªº¸Ü¤£n¤ÓÃø¤F¡K.. |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/27 ¤W¤È 08:51:55²Ä 51 ½g¦^À³
|
Hi §ë¸êªÌ¤j¦³Ãö´¶Àù¨Oªº³¡¤À°Ñ¦Ò¤é¥»¦X§@¹Ù¦ñSymbio ©xºôªº¤¶²Ð¤Î¦³Ãö´¶Àù¨Oªºì¥é³æ¤º®e: ¥é³æ³¡¤Àì¾A¥Î¯f±w¬°: 1.Binet¤ÀÃþstage B¤ÎC¤§ºC©Ê²O¤Ú²y¥Õ¦å¯f(chronic lymphocytic leukemia,CLL)¡C 2.´¿±µ¨ü¦Ü¤Ö¤@ºØ¤ÆÀø¤§©M½w©Ê«D¦óªNª÷¤ó²O¤Ú½F¡A¤»Ó¤ë¤º´¿¥HrituximabªvÀø¥¢±Ñ¤§³æ¤@ªvÀø¡C 3.Bendamustine¦X¨ÖRituximab¾A¥Î©ó¥ý«e¥¼´¿±µ¨üªvÀøªºCD20¶§©Ê¡B²Ä III / IV ´Á©M½w©Ê«D¦óªNª÷¤ó²O¤ÚÀù(non-hodgkin lymphoma, NHL)¡CBendamustine¦X¨ÖRituximab¾A¥Î©ó¥ý«e¥¼´¿±µ¨üªvÀø¥B¤£¾A¦X¦ÛÅé·F²ÓM²¾´Óªº²Ä III / IV ´Á³Q®M²ÓM²O¤ÚÀù(mantle cell lymphoma, MCL)¡C ¥t¥~Symbio¦³Ãö´¶Àù¨O¤¶²Ð³¡¤À¦p¤U TREAKISYM® has become an essential drug (standard drug) in the treatment of refractory/relapsed low-grade NHL and MCL, since its October 2010 approval, and following its December 2016 approval for the additional indication of first-line treatment of low-grade NHL and MCL, is expected to become widely used for this treatment.(¬Ý¨Ó·sªº¾AÀ³¯g¬O°w¹ï¥é³æ¤¤²Ä3Ãþªº¯f¤H©¹«e©Ý®i¬°¤@½uÀøªk¡A¥Ñ¨â®a¤½¥qªº¦~³ø¤Î»¡©ú¤¤¬Ý¨ÓÀ³¸Ó¹ï©óÀ禬ªº¼Wªø»á¦³À°§U^^) Moreover, we initiated a phase 3 study for the indication of relapsed/refractory diffuse large B-cell lymphoma, or r/r DLBCL, in August 2017.(«ÂI¨Ó¤FSymbio¤½¥q¦b¤µ¦~8¤ë¤S°w¹ï´¶Àù¨O¤S¶}¤F·s¾AÀ³¯gªºÁ{§É¡A«¢«¢¬Ý¨Ó³oÓÃÄ¥¼¨Ó¼Æ¦~¤¤¨â®a¤½¥q¥i¥H¾a¦o¦b¬ÛÃö»â°ì¤¤©Ý®i¥«³õ^^^) |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/26 ¤U¤È 10:07:50²Ä 50 ½g¦^À³
|
¦ÌÄ_¤j ±z¯u¬O²Ó¤ß¡A¬dªº¦n¥J²Ó³á!!·P´n¥Í§ÞªÑ¶W¶^¶Wº¦¡A³£¬O¦]¬°¤½¥q¨S¦³¦b²Ä¤@®É¶¡¡A²M·¡»¡©ú¶i«×¡A³y¦¨§ë¸ê¤H¾á¤ß®`©È¡C ©Î³\³o¤]¬O§ë¸ê¥Í§ÞªÑ©À®Ñ·|¦³¥Îªºì¦]¤§¤@§a!!²Ó¸`¦Û¤v¾ÇµÛªá®É¶¡¬d¡AºCºCªº´x´¤«×´N¤ñ¦W¼L©M©Ò¿×¦Ñ®v¨Óªº¦h¤F¡C§Æ±æ¬O©³³¡¶i³õ¹Æ! ¦^Âk¦]µØ¡A½Ð±Ð¦ÌÄ_: 1. Bendamustine ¥i¯àªº·s¾AÀ³¯g¥i¯à¬O¤°»ò©O? ¦~³ø¤W»¡¯f±w¤H¼Æ·|¦³¨â¦ì¼Æ¥H¤Wªº¦¨ªø©O!µu´Á°^ÄmÀ禬¤£®e¤pòó©O!! 2. ¤C¬P¤Æ¾Ç«ùªÑ¬O¤£¬O¤]¦³¥¼¹ê²{Àò§Q¥i¥H»{¦C? 3. N11001 (ªvÀø«e¦C¸¢ªÎ¤j)¡A ¤½¥q¤]³W¹º 2017¦~§ÞÂ൹¬ÛÃö¦X§@¼t°Ó¡A³o³¡¤À±z¦³°lÂܶÜ? 4. ¹Å¦h©úÃÄÃÒ2014 ¦~¥Ó½Ð³£²{¦b¤]3¦~¤F¡A±z¦³¸ß°Ý¹L¤½¥q¶i«×¶Ü? ¥H¤W¡AÁÂÁ±z! |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/26 ¤U¤È 03:45:04²Ä 49 ½g¦^À³
|
Hi ¦U¦ì¤j¤j³o¨â¤Ñ°µ¤F¤@¨Ç¥\½Ò ¤p§Ìn×¥¿¤@¤U¤§«eªº»¡ªk §Q¥Îºô¸ô¸ê·½¬d¸ß¤µ¦~¨´¤µ¤½¥q¸òTFDA ¥Ó½ÐIND ªº®×¥ó¤p§Ì¦@¬d±o2®× ¨ä¤¤¤@®×¬°¤µ¦~6¤ë¥Ó½Ðªº¸Ó®×¤w©ó¤W¤ë©³¸gTFDA¦P·N³Æ¬d (¦]¸Ó®×©óCDE®×¸¹¬°101¦~ªº¬ÛÃö®×¸¹)¬G¤p§Ì¤£¦¨¼ôªº±À´ú«Ü¥i¯à¬OÁxºÞÀù¤G´ÁªºÁ{§É..... ¦pªG¤Wz¬OÁxºÞÀù¤G´ÁªºÁ{§Éªº¸Ü¨º§ë¸êªÌ¤j»¡ªºªñ´Á¥Ó½ÐªºÁ{§É«Ü¦³¥i¯à´N¬O¤d©I¸U³êªºOral Insulin 1´Á¤F ¹ï·Óaaps¤¤¹ï¤½¥qªº¤¶²ÐOral Insulin: will be into phase 1 study in 2018, TFDA¼f¬d´Á¶¡§ì3~6Ó¤ë¬Ý°_¨Ó®Éµ{¦ü¥G»á¬°§k¦X...... ¥t¥~¤½¥q¦~³ø¤¤¦³´£¤Î¦³Ãö´¶Àù¨O¦b2017¦~¸g¤é¥»SymBio¤½¥q¦X§@¹Ù¦ñ¨ó§U¡A¤w¸g©ó¤T¤ë¥÷¦V¥xÆW½Ã¥Í¸p¥Ó½Ð·sªº¾AÀ³¯g¤¤ 襩¤p§Ì¥ç¬d±o¦b¤µ¦~3¤ë24¤é¦³¤@¥óNDAªº®×¤l ¸Ó®×¶i«×©O?¤w¸g¨«¹L¤F¥é³æ¼f¬d¤Î10¤ë¥÷ªºCDE³Ì²×¼f¬d ¥Ø«e®×¥óª¬ªp¬°¤wµ²®×µ²½×¬°¦P·NÅܧó®i©µ....·f°t´¶Àù¨O1~3Ӥ뤺À³¸Ó·|¦³ªº¤U¦~«×§å¦¸¶i³f..... ®¦,¦pªG¥H¤W±À½×²Å¦X¹w´Áªº¸Ü¥¼¨Ó1¦~¶¡¤½¥qÀ³¸Ó·|»á¬°¦£¸L..... |
|
|
·|û¡G¤Ñ¦æ10138985 µoªí®É¶¡:2017/11/24 ¤U¤È 03:10:57²Ä 48 ½g¦^À³
|
ÁÂÁ§iª¾ |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/24 ¤U¤È 01:34:51²Ä 47 ½g¦^À³
|
´N¤½¶}¸ê°TÆ[´ú¯¸ªü «e´X¤Ñ¦³¤½¥q¬°¤F·Ç³Æ¤WÂd¨ú±o¤º³¡±±¨î³ø§iªº¤½§i ¥t¥~Áö»¡«e°}¤l¦³¤j¤j¹ï©ó¤jªÑªF½æªÑ»á¦³·Lµü ¤£¹L¦b¸g¾ú¤F¯E¹©®×¹L«á³o¨â¦~¨Óªº²{ª÷¼W¸ê¤]¦hÁ«¤F°·³ìªL¸³ªº¤ä«ù¤F ¤×¨ä¬O¤µ¦~³o¤@¦¸ªº²{ª÷¼W¸êªL¸³¬°¤FªÑªF·|¹ï©óªÑªFªº©Ó¿Õ¤@Ó¤H¦Y¤F2/3ªº²{¼W´Ú¤]¯u¦hÁ«¥L¤F ¸Ó¤ÀÂI³o¨â¦~¨Óªº¾Þ§@²ß©Ê¤jP³£³o¼Ë¡A·í°ò¥»±¨S¦³¤j¶i®iªÑ»ù¤j´T´¤É®É½æ¥X«ùªÑ±NªÑ»ùÀ£¤U¨Ó ¤j´T¤U¶^®É«h¬O¶i³õ¶R¶i«ùªÑ ¾ãÅé¦Ó¨¥³o¨â¦~«ùªÑ¬O³vº¥¼W¥[ªº ¬Û¤Ïªº·í¤½¥q°ò¥»±¦³¶i®i®É«hªGÂ_¤j¶qªº¶R¶i(¹³7¤ë®É¨º¼Ë¡A«Ü¥i±¤¤½¥q«á¨ÓÀ禬¨S¦³Ä~Äò¦¨ªø ¥[¤W¹J¨ì²{¼WÄw½X´²¥X ©Ò¥HªÑ»ù¤S¦^´ú18¤¸¦h¦¸¤@ª½¨ì²{¦b) ¥u¯à´Á¬ß¤½¥q¯à¦h¥[§V¤O¤F ²¦³º¥un¯à®³¥X¦n¦¨ÁZ¤£©È¨S¦³§B¼Öªü¡K¡K |
|
|
·|û¡G¤Ñ¦æ10138985 µoªí®É¶¡:2017/11/24 ¤U¤È 01:11:08²Ä 46 ½g¦^À³
|
½Ð°Ý¦]µØn·Ç³Æ¤WÂd³oÓ®ø®§¬O±qþ¸Ì±oª¾? ¯à§_§iª¾¤@¤U, ÁÂÁÂ! |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/24 ¤W¤È 11:14:44²Ä 45 ½g¦^À³
|
Hi ¦ÌÄ_ OK!! ÁÂÁ±z¡A¥u¬Oı±o¥¦³Ìªñ¦ü¥G¦³·N¤£ÅýªÑ»ù©¹¤W¨«¡A©Ò¥H°Ý°Ý¡C °·³ì«H ¤]¬O«Ü°÷·N«ä¡A±q8¤ëªº¤½¶}»¡©ú®Ñ¬Ý¨Ó¡A106/6 ¤ë¦o´X¥G¦Y¤F4300±i²{¼W¡A³o¨â¦~³£¬O¥L¥]¿ì¥«³õ¤W¤£¨¬ªº²{¼W¾lÃB¡C¤]ºâ¬O¤p±dª¨ª¨¤F¡C ÁÂÁ±z¤À¨É¡A´Á«Ý¤WÂd«e·~ÁZµoªí·|¯à¬Ý¨ì±z¡A«¢¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/24 ¤W¤È 09:28:46²Ä 44 ½g¦^À³
|
Hi §ë¸êªÌ¤j ¦b³o¥Í§Þ¦Bªe´Á¤¤¤p§Ìı±oI«á¦³´Iª¨ª¨(¦p¼íX©Î¬O X¶ì)¤ä«ùÄ@·N¦b¤½¥q»Ýn¸êª÷²{ª÷¼W¸ê®É±Ç¿ú¥X¨Ó¤ä«ù¤½¥qªº·|¤ñ³æ¯Â°]°È¾Þ§@ªº¥«³õ¬£¥D¤O¨Óªº¦³·N¸q¡A¦Ü©ó±z´£ªº¸Ó±b¤á¨ì©³¬O¦ó¤è¯«¸t?´¿¦b´XÓ³õ¦X¶¢²á®ÉµL·N¶¡¤F¸Ñ¬Y¤è¶Õ¤O¦³¬£¥Nªí¥X®u¡A¸Ó¶Õ¤Oªñ¦~¨ÓµÛ¾¥¥Í§Þ§ë¸ê»á²`¡A¬Æ¦Ü¦b¬Y¥Í§Þ¤½¥q¤¤¦û¤F«nªº¦ì¸m¡K¡K¦Ü©ó±z´£ªº±b¤á¨s³º¬O§_¬O¸Ó¶Õ¤O¶i¥X±b¤á¤§¤@?¤p§Ì¥\¤O©|²L¥B¤£¬O100%ªÖ©w©|¤£´±¦b³o¤½¶}ªººô¯¸¤¤Ár´úÁٽШ£½Ì¡K¡K |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/23 ¤U¤È 10:12:58²Ä 43 ½g¦^À³
|
¦ÌÄ_¤j §Ú¹ê¦b«Ü¦n©_ ²Î¤@-·s¥x¤¤ ¨ì©³¬O½Ö¡A§A¥i¥Hµ¹ÂI´£¥Ü¶Ü? ÁÂÁ±z¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/23 ¤U¤È 02:19:10²Ä 42 ½g¦^À³
|
cstang ¤j ·|¦³¦n®ø®§ªº¡A©ñ¨ì©ú¦~§Ú·Q´Á«Ýªº¬O¥ý¦^¨ì 4X¡A¦pªG³£¬O°µÁxºÞÀù¤G´Á¡A§ì¥ÍµØªÑ»ù¤@¥b¤£¹L¤À§a!! ´Nºâ¬O³Q¤jªÑªF½æªÑªº ASLAN¤]¦³§Ö 40¡C(³o¤]¬O¤Ó©e©}¡A¨âÓ¤T´Á¡AªÑ»ù³o¼Ë....) 5 ¦~«e¦]µØ¡A3X ¤W¿³Âd¡A²{¦b·sÃÄ¡B±ÂÅvªº¶i«×³£©¹«e¶i¤£¤Ö¡AÁÙ®³¤FÓ FDA ©t¨àÃÄ¡A¥Î§C©ó 30 ¤WÂd¡A§Ú»{¬°¤Ó©e©}¡C µ¥«Ý§a!¦³¥y¸Ü»¡±o¦n:§ë¸ê¬O¤@ºØצæ¡C |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2017/11/23 ¤U¤È 01:14:32²Ä 41 ½g¦^À³
|
¦U¦ì¤j¤j,¦]µØ·Ç³Æ¥Ó½Ð¤WÂd¬O¥ó¤j¨Æ,¦p§ë¸êªÌ¤j¤j»¡©ú ¦]µØ ¬ì§Þ¨Æ·~³\¥iÃÒ¬O2017/12/23 ¨ì´Á,¨º¤½¥q¯uªº«æ»Ý¦n®ø®§¨Ó¤ä«ù¤W¥«....... ¦b106¦~²{ª÷¼W¸ê¤½¶}®ÑP57~P58,(106/107¦~¤½¥q²{ª÷¦¬¤ä¹w´úªí)´£¥X107¦~1¤ë¤½¥q²{ª÷±b±N·|p³]©w³Ì§C¦w¥þ²{ª÷¬y°Ê¶q,·|pªºpµe¬O¦A¼W¸ê¥H´£¨Ñ107¦~«×²{ª÷©PÂà,¥Ø¼Ð¬O3»õ,¨Ñ107¦~¦U¶µ¬ãµo¤Î¥Ó½Ð³W¶O¨Ï¥Î,¦pªGªÑ»ù¦A¦p¦¹§CÁS±N³y¦¨¼W¸êªº§xÃø....... ´Á«Ý¦³¦n®ø®§¯à¤ä¼µªÑ»ù |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/22 ¤W¤È 11:25:05²Ä 40 ½g¦^À³
|
¦ÌÄ_¤j ¬Ý³oºA¶Õ¡A·íµM¬O¶R¶R¶R¡Aµ¥®ø®§¹Æ¡I |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/22 ¤W¤È 09:33:12²Ä 39 ½g¦^À³
|
Áp¥ÍÃĨú±o¤º±±³ø§i®É¶¡¶ZÂ÷¬ì§Þ¨Æ·~·N¨£®Ñ¨ì´Á¶È¦³1Ó¦h§«ô®É¶¡ ®Éµ{¬Û·íºò¢¡A ¦]µØ«h©|¦³1Ӥ륪¥kªº®É¶¡¡A¥t¥~¥Ñªñ¦~¨Óªº¤@¨Ç®Éµ{(²{¼W ¬ì§Þ¨Æ·~·N¨£®Ñ ¤º±±³ø§iµ¥) ¦]µØ ¯q±o¥i»¡¬O¥ç¨B¥çÁÍ¡A ¥[¤W¨ä¹ê¤½¥q¦¦b³\¤[¥H«e´N³°Äò®i¶}¤WÂd·Ç³Æ§@·~¡A¤p§Ì¬O¤ñ¸û¶É¦V»{¬°¤½¥q¦b´Á«e§¹¦¨°e¥óªº¾÷·|¤j¨Ç ¥t¥~¦³ÃöIND³¡¤À¤p§Ì¤]ı±o¬OÁxºÞÀùªºÁ{§É¾÷·|¤j¨Ç(¶Â°¨Oral Insulin) ³Ìªñèµ²§ôªºaaps¦~·|°w¹ï¦]µØ¤¶²Ð»á¬°@¤H´M¨ý: Oral Gemcitabine: will be into Phase 2/3 study the second half in 2017, it was developed based on OralPAS platform. Oral Insulin: will be into phase 1 study in 2018, it was developed based on OralPAS Pro platform. |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/21 ¤U¤È 08:34:11²Ä 38 ½g¦^À³
|
mogwai ¤j ¤]¬O¦³¨Ò¥~ªº¨Ò¤l³á¡A¹³¬O¤WÓ¤ëÁp¥ÍÃÄ¡A´N¬O¦]¬°¬ì§Þ¨Æ·~³\¥iÃÒ¹O´Á¡A¥u¦n«·s¥Ó½Ð (¤TÓ¤ë¶]¤£±¼)¡C ¦]µØ ¬ì§Þ¨Æ·~³\¥iÃÒ¬O2017/12/23 ¨ì´Á¡A¥i¥HÆ[¹î¡C¦ý¬O¦pªG°Ñ·Ó ¯q±o ¼Ò¦¡¡A²z½×¤W³o§«ô´£¤º±±¡A¤U¬P´Á´N´£¤WÂd¥Ó½Ð¡C³ÌªñÄw½XÆZáAÃÄ«~±ÂÅv¤]´X¥G§¹¦¨¡A11/20 ¤]¦V TFDA ´£¥X·sªºÁ{§É¥Ó½Ð®× (¤½¤å¤å¸¹: 1066063867/CDE ®×¸¹¡G106IND11260)¡A²q±o¨S¿ùÀ³¸Ó¬OÁxºÞÀù¤G´Á(ÁÙ¬Onµ¥¤½¥q¤½§i)¡C¤£¨ì 20 ªºªÑ»ù¡A§Ú¬O»{¬°È±oµ¥«Ý¡AÀ³¸Ó¤]¤£¥Îµ¥¤Ó¤[¡C |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/11/21 ¤U¤È 08:07:57²Ä 37 ½g¦^À³
|
¦]À³¥»¤½¥q¤WÂd¥Ó½Ð§@·~»Ý¨D¡A©e½ÐñÃÒ·|p®v¥X¨ã ¡u¤º³¡±±¨î¨î«×¼f¬d³ø§i¡v ²Å¦X±ø´Ú ²Ä 25 ´Ú ¨Æ¹êµo¥Í¤é 106/11/21 »¡©ú 1.¨ú±o·|p®v¡u¤º³¡±±¨î±M®×¼f¬d³ø§i¡v¤é´Á:106/11/21 2.©e½Ð·|p®v°õ¦æ¤º³¡±±¨î±M®×¼f¬d¤é´Á:105/10/01¡ã106/09/30 3.©e½Ð·|p®v°õ¦æ¤º³¡±±¨î±M®×¼f¬d¤§½t¥Ñ:¦]À³¥»¤½¥q¤WÂd¥Ó½Ð»Ýn 4.¥Ó³ø¤½§i¡u¤º³¡±±¨î±M®×¼f¬d³ø§i¡v¤º®e¤§¤é´Á:106/11/21 5.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL ¬Ý¤F´X®a¤½¥q¡A°õ¦æ¦¹¤@¨BÆJªº¤½¥q³Ì§Ö¥b¦~¦h¤@ÂI´N¥i¥H¤W¥«Âd¡A§Æ±æ¤½¥q¥i¥H¶¶«KÄÀ©ñ¤@¨Ç¦n®ø®§¥H§Q¤WÂd |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/8 ¤W¤È 07:49:36²Ä 36 ½g¦^À³
|
«¢«¢ cstang¤j¥¢·q¥¢·q «e°}¤l¬Ý¨ì¤j¤j ¤p¤pªº°Ê¤F¤@¤U ¥iÅý·Q¤p½¼¦Ìªº§Ú¾á¤ß¤F¤@°}¤l.... ¬Ý¨ì¤j¤j³o¼ËÁ¿ ¥i¯u¬O¦w¤ß¤F³\¦h ¦³ªÅ°O±o¦^¨Ó§¤§¤^^ ¸Ü»¡¤½¥q§Y±N°Ê¨«e©¹°Ñ¥[AAPS¦~·| ¥[¤Wºâ¤@ºâ®Éµ{¤]®t¤£¦h¶}©ln®i¶}¤WÂd¬ÛÃö§@·~¤F §Æ±æ¤½¥q³o´XÓ¤ë ¦Ü¤Ö¤]¯à¦p¦Pªùªº¯q±o¨º¼Ë °µ¥X¤@ÂI¦¨ÁZ ²¦³º¤£ºÞ쥻¸ê¦â«ç¼Ë ¤£¦n¦n¤W§©ªº¸Ü «ç»ò§äªº¨ì¦n¤H®a¶ù©O? |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/7 ¤U¤È 10:41:04²Ä 35 ½g¦^À³
|
cstang «e½ú¡A¤pªº¸ê¾ú©|²L¡A¯Zªù§Ë©ò¡A¥H«áY¦³¦nªº¥Í§Þ¼Ðªº¡AÁٽФ£§[½ç±Ð¡C |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2017/11/7 ¤U¤È 10:01:42²Ä 34 ½g¦^À³
|
«¢«¢«¢.......¥S¥x½Õ¬dªº¯u²M·¡.....¤£·|¦A¥X¤F,¸êª÷½Õ¥Î,·|¦^¸Éªº |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/7 ¤U¤È 09:24:57²Ä 33 ½g¦^À³
|
¤µ¤Ñ¤S¤p¤p¥[½X¤F¦]µØ¡A¬°¦U¦ì¾ã²z¤µ¤ÑÄw½XÅܤơA·«B¥Í«H¤ß¡A¦nªÑ¤£±I¹æ¡C 11/7 ½æÀ£°lÂÜ 10 ±i¥H¤W¨é°Ó¡C(±ÀÂ˨é°Ó°£¥~¡A«ö·Ó 11/7 ½æ¥X±i¼Æ±Æ¦C) 1. µØ«n¥Ã©÷-]®ß¡A 11/6¶R¡A¥þ³¡½æ¥ú¡C 2. §»»·-®ç¶é¡A2016/1 ¥H¨Ó¶R¶Wªñ 170 ±i¡A§¡»ù 25.8¡A¤£¤Ó¥i¯à½ß¿ú¥þ¥X§a!!§Æ±æ§O¨Ó¶Ã¡C 3. ³Í°ò-¤T¦h ¡A11/6 ¶R 42±i¡A³Ñ¤U 20 ±i¥ª¥k¡A³oÓÄw½XÅܤÆÆZ¦³½ìªº¡C¥xºÍ°hªºº}«G¡A¦ý¦]µØ¥i¯à¨S¦³ÁȨì¡C 4. ´I¨¹-¶é°Ï¡A11/6 ¶R ¡A¥þ³¡½æ¥ú¡C 5. ¥ÃÂת÷-³Õ·R¡A11/6¶R¡A¥þ³¡½æ¥ú¡C 6. ´I¨¹-·s¦ËµØ«H¡A11/6¶R¡A¥þ³¡½æ¥ú¡C 7. ¤é²±-ÀY¥÷¡A11/6 ¶R 17±i¡A³Ñ¤U5±i¡C ¥H¤WÀ³¸Ó¤£Ãø¬Ý¥X¤µ¤Ñ¬O®£·W©Ê½æÀ£¡A¨â¤j³Ð§ë¨ÌµM¨S¦³¥X³f¡A³Ñ¤Uªº·W±iÄw½X¤]¤£¦h¤F¡Cµyµy¾ã²z¤@¤U¡A§Ú¬Oı±oÆZ°·±dªº¡Cȱoµ¥«Ý搂!! |
|
|
·|û¡Geagle10134960 µoªí®É¶¡:2017/11/6 ¤U¤È 09:45:35²Ä 32 ½g¦^À³
|
¤µ¤Ñ¿³Âd¦¨¥æ¶q«e10¦W¥Í§Þ´N¦û¤F¤CÀÉ¡A«Ü¤[¨S¬Ý¨ì³oºØ´ºªp¤F¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/6 ¤U¤È 08:27:23²Ä 31 ½g¦^À³
|
¤µ¤Ñ³Ð§ë¥S§Ì¨ÌµM¨S¦³¥á¥XÄw½X¡A±q 2016/1 ¥H¨Ó¡A¤¸¤j-¤º´ò¡A¥üÂ×-ªFªù¡A¤¸¤j-«n¨Ê¡Aµ}ù¼M°ÕˤF 3500 ¦h±i¡C ¤Ö¤F³o¨Ç½æÀ£´N¬O³Ì¤jªºÄw½X§Q¦h¡C«ùÄòÆ[¹î¶W¯Å§C¦ôªºªÑ²¼¨ì©³¥i¥H¼u¦h°ª¡Cµu½u«È©M¨é°Ó«ùÄò´£¨ÑÄw½X¡AªÑ»ùªmÄˤ¤¡C |
|
|
·|û¡Gªö®f10138830 µoªí®É¶¡:2017/11/6 ¤W¤È 09:25:41²Ä 30 ½g¦^À³
|
½Ð°Ý¦³¤Hª¾¹Dªñ¨Ó¥i¦³¦n¤°»ò®ø®§¶Ü¡H |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/6 ¤W¤È 09:15:00²Ä 29 ½g¦^À³
|
»ù¶q³£©Ç©Çªº¡C¤w»´¸Ë¤W°¨¡Aµ¥«Ý¤ÏÀ³¯u¹ê»ùÈ¡C |
|
|
·|û¡G®ÇÆ[ªÌ10141545 µoªí®É¶¡:2017/11/5 ¤U¤È 10:12:18²Ä 28 ½g¦^À³
|
Ó¤H·Qªk ¥un¤½¥q¦b!«ùÄò§V¤O·|¦³¾÷·|¤Ï¼u ¥Í§ÞÁ`¬Oº©º©ªø¸ô..1±i¶R¤F¦n¦h¦~«ùÄòµ¥«Ý....¨SÀò§Q«ù¦³¤@±i·í±mú³ °ò¨È¦³°Ñ»P...è±¾¿³Âd14¤¸¶^¦¨Ó¦ì¼Æ¦Aº¦¨ìµLªk·Q¹³...¯E¹©¤]¬O¦^¥x®É¶R¶i«ù¦³ °Ñ»P¹Lµ{º©ªø¤£©ö...´Á«Ý¤½¥q§V¤O¤F¡C |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/5 ¤U¤È 09:03:01²Ä 27 ½g¦^À³
|
·PÁ¦ÌÄ_¤jªº¦^ÂСA§Ú¤]¬Oª`·N¨ì¥üÂ×-ªFªù¡A¤¸¤j-«n¨Ê¡A¨â¤j¨é°Ó¦b 10/30~11/3 ³o©P¨S¦³¨S½æ¶W¡A¤~ı±o©_©Ç¡A¦n©_°Ý°ÝÄw½X¡C³o¨â®a¥un¤£¦A¨ÑÄw½X¡A¦]µØ«Ü§Ö´N¥i¥H¦^Âk¸Ó¦³ªº»ù®æ¤F¡C ¤£»¡§Oªº¡A2014/5 ²Î¤@§ëÅUµ¹ªº°Ñ¦Ò»ù¬O 96; ²Ä¤@°]¸gµ¹ 19X; ¤é²±§ó¬Oµ¹ 200 ¦h; ¥u¬O¸g¹LX¨È¡B¯EX ·¼É«á¡A¥Í§ÞªÑ»ù³Q¥´À£¨ì³Ì§C±µªñ 18 ¤¸¡A¦ý¬O¤½¥qµL½×¬O±ÂÅv¡BÁ{§É¡B¤WÂd¥Ó½Ð¶i«× (2016/12 ¨ú±o¬ì§Þ¨Æ·~³\¥iÃÒ) ³£©¹«e±À¶i¤£¤Ö¡AªÑ»ù¹ê¦b¸¨«á¤½¥q»ùȤӦh¡C·P¹Ä~~ |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/11/5 ¤W¤È 08:47:53²Ä 26 ½g¦^À³
|
³o¥i¦³ÂIÃø˧ڤF ¦pªG¬O¯Â·sÃĪºÁ{§É¹êÅ窺¸Ü ¬ü°êªº¸ê®Æ¥i¥H¦b¤U±ªººô§}¬d¸ß clinicaltrials.gov/ ¥xÆWªº©O¥i¥H¦b¥xÆWÃÄ«~Á{§É¹êÅçºô¬d¸ß www1.cde.org.tw/ct_taiwan/knowledge.html ¦ý¬Oc08001¯S®íªº¤@ÂI¬O¥L«e´X¦~¸gfda®Ö¥i ÄÝ505(b2)·sÃÄ¡A¨Ã¥iÂǥѹê¬I¥ÍÅé¬Ûµ¥©Ê¸ÕÅç¶i¦æÃĪ«¥Ó½Ð¨úÃÒ¡C ¦Ü©ó¤½¥q¹ê¬I¥ÍÅé¬Ûµ¥©Ê¹êÅ窺¶i«×¬O§_¦³¤½¶}ªººô¯¸¬d¸ß ¦]¤p§Ì«D¥Í§Þ±q·~¤Hû¤]¤£¬O«Ü²M·¡ ¤£ª¾¬O§_¦³±Mºëªº¤j¤j¥i§iª¾? ¦Ü©ó·§²¤ªº¶i«×©O ¤p§Ì¬ù¤TÓ¤ë«e¸ò¤½¥q¸ß°Ý¥Ø«e¥¿¶i¦æ¸Õ»s§å¥Í²£¤¤ ¨C¤@§å¦¸ªº®Éµ{¶¶§Qªº¸Ü¬ù6Ó¤ë »Ý¶i¦æ3§å¦¸ªº¥Í²£ ¥Ø«e target §¹¦¨ªº®Éµ{¬ù¬°©ú¦~Q3 Q4 ±À´ú²{À³¤w§¹¦¨1§å¦¸ªº¸Õ»s§å¥Í²£¤F ¤£¹L³o¸Ìn¥ý»¡©úªº¬O¨Ì¾Ú¥H©¹§ë¸ê¥Í§ÞªÑªº¸gÅç¥Í§Þ¤½¥qªº¤@¨Ç®Éµ{ ±`·|¦³©ÒÅÜ°Ê ¤pªÑªF¯à°µªº´N¬O±Òë®Éµ{¯à°÷¶¶§Q¤F¡K¡K..^^ ¦Ü©ó¤½¥qªºÄw½X¶Ü ..¡K¡K ¤p§Ìı±o¦b³oºØ¤½¶}ªººô¯¸Á¿±o¤Ó¥Õ¤£¤@©w¬O¦nªº¡K¡K ¦]µØ³o¤@¦~¨Ó¿n®z¤£®¶ªº¨«¶Õ°£¤F¤jÀô¹Ò¤£¨Î¥~ ¾É¦]©ó¨â¤j³Ð§ë¥S§ÌˤF¬ù1800±i¶i¦Ó¤Þµo¤Fªñ´Á§ë¸ê¤H¶¡ªº¦h±þ¦h¡K.. ¤£¹L³o¤@¬P´Á¦h¥H¨Ó¤×¨ä¬O¬P´Á¤ªºÃz¶q¤Wº¦ ³Ð§ë¥S§Ì©~µM¨S¦³¥X³f ºâ¬O¦³¹H¥H©¹¥L̪ººD©Ê¤F ´NÅý§ÚÌ«ùÄòªºÆ[¹î¤U¥hºO¡K.. |
|
|
·|û¡G§ë¸êªÌ10141485 µoªí®É¶¡:2017/11/4 ¤U¤È 10:57:34²Ä 25 ½g¦^À³
|
½Ð°ÝÃö©ó C08001 (carvedilol CR) ¤½¥q¦b¬ü°ê°µªº Pivotal ¦³Á{§É¸ê°T¥i¥H¬d¸ß¶Ü?? ¶i«×³¡¤À½Ð°Ý¦ÌÄ_¤j¦³´x´¤¶Ü? ³Ì«á½Ð±ÐÄw½X³¡¤À¡A²Î¤@-·s¥x¤¤³Ìªñ¶i¥X¥Ác¡A¤jÅé¦Ó¨¥¬O¶R¶W¡A½Ð°Ý¦³¤j¼wª¾¹D³oI«á¥i¯à¬OþÓ¤j©@¶Ü?? ÁÂÁ¡C |
|
|
·|û¡G¤Ñ¦æ10138985 µoªí®É¶¡:2017/10/26 ¤U¤È 01:37:21²Ä 24 ½g¦^À³
|
ÁÂÁ¤À¨É³á! |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/10/26 ¤U¤È 01:08:17²Ä 23 ½g¦^À³
|
¦]µØªºÃĪ«¦pªG¦³¤w¸g¨ú±o¬ü°êÃÄÃÒªº´N¤£·|¬O²{¦b³oºØ³nwwªºªÑ»ù¤F ¥Ø«e¥L¯Ê¤Öªº´N¬O¬Y¤@ÓÃĪ«¯à°÷¦b¬ü°ê¥«³õ¨ú±oÃÄÃÒ°^ÄmÀò§Q´£¤É§ë¸ê«H¤ß ´N¤p§Ì©Òª¾ ¥Ø«eÅã¼v¾¯ ¹Å¦h©ú¦b2014¦~¤w¥Ó½ÐÃÄÃÒ 2016¦~¬d¼t «á¨Ón¨D¸É¥ó¦b¤µ¦~¦~¤¤®É§¹¦¨¸É¥ó¥Ø«eÀR«Ýfda¼f®Ö¤¤ ¥t¥~°ª¦åÀ£ÃÄ ¸ò ¦]¸¿Õ «h¬O¶i¦æ¥Ó½ÐÃÄÃÒ«eªº¤@¨Ç¥Í²£¸Õ»s§åªº°Ê§@ ´N¤pªÑªFªºÓ¤H¤ßÄ@ªº¸Ü §Æ±æ®Éµ{¶¶§Qªº¸Ü ¥i¥H¦bªñ1~2¦~¤º¥Ó½ÐÃÄÃÒ©Ô |
|
|
·|û¡G¤Ñ¦æ10138985 µoªí®É¶¡:2017/10/26 ¤U¤È 12:41:54²Ä 22 ½g¦^À³
|
½Ð°Ý¦³¤Hª¾¹D¦]µØªºÃĪ«,þ¤@Ó¦³¨ú±o¬ü°êÃÄÃÒªº?? |
|
|
·|û¡GSam Lee10136780 µoªí®É¶¡:2017/10/25 ¤U¤È 02:11:50²Ä 21 ½g¦^À³
|
¨C¦¸ªÑ»ù¨Ç³\´¤É¡AÁÙ¬O¦³¤H¤£¬Ý¦n¡A»ù¦ì¤@ª½§C¸¨¡A¯uªº¨º»ò¨S«H¤ß¶Ü¡H |
|
|
·|û¡Gªö®f10138830 µoªí®É¶¡:2017/10/24 ¤U¤È 01:25:51²Ä 20 ½g¦^À³
|
ªÑ»ùª½¸¨,¤£ª¾¦ó®É¤~·|¦³¦nªº±¶³ø¶Ç¥X¨Ó |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/10/7 ¤W¤È 08:35:12²Ä 19 ½g¦^À³
|
¦]¸¿Õ¥Ø«e¦b¬ü°ê¥«³õ¸òGlenmark Pharmaceuticals Inc.ñªº¬ONon-binding term sheet ©|¤£¬O¥¿¦¡ªº¦X¬ù ¾Ú¤p§ÌÁA¸Ñ°£¤FGlenmark¥~À³¸Ó¦³¸ò¨ä¥LÃļt¦³¿³½ì.... ¥u¬O¬°Ãøªº´N¬O±ÂÅv³oªF¦è«ÜÃøÁ¿¨ì©³¦ó®Én½Í¦¨¤£®e©ö¤S¤@Ó©ú½Tªº®É¶¡ªí ¥u¬O´N¦]µØ²£«~½u¨ÓÁ¿¤p§Ìı±oµu´Á¸û¦³¾÷·|¥B¥²¶·½ÍªºÀ³¸Ó¬O ¦]¸¿Õ ¸ò °ª¦åÀ£ÃÄ ²¦³º¦pªG¨Ì¾Ú²£«~ªº®Éµ{±ÀÂ_ªº¸ÜÀ³¸Ó1~2¦~¤º´N¦³¾÷·|°e¥ó¥Ó½ÐÃÄÃÒ ¦Ó¨ä¤¤¦]¸¿ÕÁÙ¥i¯à±Á{¬ÛÃöªº±M§Q¶D³^... ¥t¥~¸êª÷°ÝÃD¤]¬O¤p§Ì¤ñ¸û¾á¤ßªº¤@ÂI §Æ±æ¤½¥q¦U¶µ²£«~½u¦Ü¤Öªñ´Á¦³¤@¨â¶µ¯à¶}ªáµ²ªG ©Î¬O§â³¡¤À¥Dn²£«~°Ï°ì±ÂÅv¦p¤fªA§ÜÀùÃĤ饻¥«³õµ¥¥ý¨ú±o¤@¨Çªº¸êª÷ ÁöµM²{¦bñ±ÂÅv±ø¥ó¥i¯à¤£¬O³Ì¦nªº ¦ý¦Ü¤Ö¦b³o¥Í§Þ¦Bªe´Áªº¶¥¬q¥iѺª`¤½¥qÀç¹B¸êª÷¨Ã´£¤É§ë¸ê¤H«H¤ß..... |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/10/7 ¤W¤È 12:20:51²Ä 18 ½g¦^À³
|
·PÁ¦ÌÄ_¤jªº¤À¨É, ¤£¹L¤§«e¤½¥q¦³³o«h·s»D (4172)¦]µØ-¤½§i¥»¤½¥q»P¬ü°êGlenmark Pharmaceuticals Inc.ñq¦]¸¿Õ(BH4)¤§²£«~±ÂÅv¤Î¨Ñ³fNon-binding term sheet §Ú·Q¦]¸¿Õ¬ü°êÃÄÃÒªº§G§½ÁÙ¬O¦³, §Æ±æ¤½¥q³o»ò¦h²£«~½u,¦Ü¤Ö¦³¤@¨âӺɧֶ}ªáµ²ªG,§Ú¹ê¦b¦³ÂI©È¤½¥q¦]¬°¸êª÷°ÝÃD¦Ó¼µ¤£¤U¥h. |
|
|
·|û¡Gbio man10142285 µoªí®É¶¡:2017/10/6 ¤U¤È 10:54:36²Ä 17 ½g¦^À³
|
ÁÂÁ¤À¨É ^^ |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/10/6 ¤U¤È 10:45:19²Ä 16 ½g¦^À³
|
mogwai¤jÁÂÁ§Aªº¤À¨É ¦b¥Í§ÞªÑµ¥«Ý¾¤©ú¨ì¨Óªº¦P®É «Ü»Ýn¦U¦ì¤j¤j̱M·~ªº¤À¨É.... ¤p§Ì¤]¤À¨É¤@¤U³Ìªñ¬ÝBioMarin°]³øªº¤ß±o ¦pªG¦³¯d·N¦]µØªº·s»D¥i¥Hª¾¹D¤½¥q¦³·Nµo®i¦]¸¿Õ¬ü°ê¥«³õ ¦ÓBioMarin ªºKuvan¥¿¬O¦]¸¿Õ¹ï·ÓªºÃĪ« 2017¦~¤W¥b¦~½æ¤F1.943E¬üª÷¸û¥h¦~¦P´Á¦¨ªø¢°¢µ¢H¡]¢±¢¯¢°¢µ¦~¾ã¦~½æ¤F3.48E) ¥Ø«e¸ÓÃıM§Q©|¥¼¨ì´Á¬ÛÃö¢Þ¢³ªºÄvª§ªÌ¦³¡GPar¡@¸ò¡@DRL ¨ä¤¤ì¼t°£¤F¸ò¢Ò¢à¢ÚÁÙ¦³¤@¥ó®×¥ó¦b¶D³^¥~¨ä¾l¬Ò¤w©M¸Ñ ´N©M¸Ñ¤º®e¨Ì¤p§Ì²Ê²Lªº¤F¸Ñ¨Ó¬Ý ¢Þ¢é¢ú ¸òDRL¬Ý¨Ó³Ì§Ön¨ì2020¦~¬ÛÃö²£«~¤~¦³¾÷·|¤W¥« ¸Ó¤½¥q¦~³ø°£¤F´£¤Î¤w¸g¥Ó½ÐP4ªº2®a¼t°Ó¤§¥~¥t¥~´£¤Î: We also face potential generic competition for Kuvan in certain foreign countries, including, without limitation, Russia, South Korea, Taiwan, and Turkey(Ó¤Hı±o³o¸Ì«üªº¬O¦]µØªº¦]¸¿Õ.....) ¬JµM¦]¸¿Õ¦b¬ü°ê¥«³õ¥¼¨Ó¬O¨«P4ªº¤è¦¡ ì¼t±Ä¥Î±M§Q¶D³^ªº¤è¦¡¤zÂZ±À¿ðÃÄÃÒªº¥Ó½Ð¬O·¥¦³¥i¯àªºµ¦²¤ ¦Ó´N¤p¸êªº¦]µØ¨ÓÁ¿À³¸Ó¬O¨S¦³¯à¤O¸ò°]¤O¥h¸ò³oÃþªº¤jD¤l¥´¬[..... ¬G¥¼¨Ó¦]¸¿Õ¦p¯u¹³¤§«e³ø¾ÉÁ¿ªº¥B¦U¶µÁ{§É¸ò¥Í²£«Ü©¯¹B¥i¥H¦b©ú¦~§¹¦¨ªº¸Ü ¤p§Ìı±o±N¦]¸¿Õ¬ü°ê¥«³õ±ÂÅv¥X¥h Åý¤ñ¸û¤j¤@ÂI¥B¤ñ¸û¦³¸gÅ窺¼t°Ó±µ¤â«áÄòªº¦æ¾P¸ò¶D³^¾÷·|«Ü¤j ¥t¥~¹ï·Óªñ´Á¤t´¶¤@¨t¦C¥[³t¾Ç¦WÃĤW¥«ªº·s¬F ¤p§Ìı±o³o¹ï¦]µØ¬O¾÷·|¤]¬O¬D¾Ô ²¦³º¥L¥D§ðªº¾Ç¦WÃĹ³¬OÅã¼v¾¯¸ò¦]¸¿Õµ¥¬ÛÃö¥Í²£»sµ{Ãø«×·¥°ª ¬ÛÃöDMFÀɮפ£¬O¨S¦³´N¬O¶È¦³¤@¨â®a ¦p¦]¸¿Õ¯à°÷»°¦b¥t¥~¨â®aÃļt¤§«e¤W¥«¹ï¤@®a¥«È¤£¨ì14»õªº¤pÃļt¨Ó»¡¬Û«HÀ°§U¬O«Ü¤jªº.... |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/10/6 ¤U¤È 01:39:48²Ä 15 ½g¦^À³
|
¤½¥q§Y±N¦bAAPS(¤Q¤@¤ë¤¤)µoªíªº¨âÓ±MÃD 1. T3036 - Development and Optimization of Softgel Capsule Containing Hydrophilic Fill Formulation ¥Dn¬O®i¥Ü¤½¥q¶}µoªº³n½¦Ånªº§Þ³N,²¨¤ô©Ê¤ñ¥«±¤Wªº²£«~¦n(contact angle ¤j10«×) 2.T1062 - Investigation of Oral Rapid-acting Insulin Formulation (N11005-F5) on Postprandial Glucose Response, Hemoglobin A1c (HbA1c) and Weight Variation in STZ-induced Diabetic Mice ¥Dn´yzN11005ªº³t®Ä©Ê(¥b¤p®É«á´ú¶q¸²µå¿}ªº§t¶q),´Ý¯d®É¶¡µu(¨â¤p®É«á¦A´ú¸Õ¤@¦¸) ÁÙ¦³¹ï ¿}¤Æ¦å¦â¯À(HbA1c)Ȫº¼vÅT ¤§«e·s»D³ø¾É¦³´£°_¤fªA¯Ø®q¯À¥¿¦b´M¨D±ÂÅv,§Æ±æ¦b³o¦¸·|ij¤W¥i¥H¶¶§Q§ä¨ì¦X§@¼t°Ó. ps. §Ú¥u¬O²¤¬°¾ã²z,¦³¿³½ìªº¤H¥i¥ÎAAPS+innopharmax google¥þ¤å |
|
|
·|û¡GªL§Ó³Í10143927 µoªí®É¶¡:2017/10/1 ¤U¤È 07:11:35²Ä 14 ½g¦^À³
|
§Ö¨S±Ïªº¤½¥q¤F¡A¤°»ò³£¨S®ø¨S®§ªº¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/8/21 ¤W¤È 08:17:57²Ä 13 ½g¦^À³
|
¦³¬ÛÃö¦]µØªº³ø¾É¤F ¦]µØÃĪ«±ÂÅv ³ø¨Îµ money.udn.com/money/story/10162/2654066 ¤j³¡¤Àªº³ø¾É¸ò¤p§Ì¤F¸Ñ¬ÛÃöªº°ò¥»±¬Ûªñ °£¤F¦]¸¿Õ¬ü°ê¥«³õÀ³¸Ó¬O¤O«÷©ú¦~¥Ó½ÐÃÄÃÒ¥~(¦Ñ¹êÁ¿n©ú¦~¨ú±oÃÄÃҨö}½æ¦³ÂIÃø«×.....) ´Á¬ß¦]µØ¥i¥H¿v¹Ú½ñ¹ê¤@¨B¤@¸}¦L¦a§¹¦¨¦U¶µ²£«~ªº¶}µo.... |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/8/20 ¤U¤È 10:23:27²Ä 12 ½g¦^À³
|
¥t¥~´NÅã¼v¾¯¨ÓÁ¿ ¹Å¦h©ú¥Ø«e¶È¦³¤C¬Pµù¥U¬ü°ê¢Ò¢Û¢ÔÀÉ®× ¦p¸ÓÃĪ«¦p´Á¤W¥«¦b¬ü°ê¥«³õ¬OÄÝ©ófirst generic ¸Ó²£«~°e¥ó¥Ó½Ð®Éµ{¥¿¦n¾î¸ó¤F¬ü°ê¾Ç¦WÃļf¬dÅܲªº·s¨î®Éµ{ 2014¦~®É·í®É¥¿¦n¬O¾A¥ÎÂÂ¨î °O±o·í®É¬Ý¨ìªº¸ê®Æ¤@ӾǦWÃÄ¥§¡n¼f¢²¢µ¡ã¢³¢¯Ó¤ë ¬G¤½¥q°e¥ó«á¤@ª½µ¥¨ì¥h¦~¢³¤ëfda¤~¦w±Æ¬d¼t ¬d¼t«á¦³n¨D¤½¥q¸É¥ó ¨Ì¾ÚªÑªF·|®É¤½¥q»¡ªk¸Ó¸É¥ó¤w¸g§¹¦¨ «e°}¤l¨Ã¥Ñ¬ü°ê¦X§@¼t°Ó¦Vfda»¼¥æ¸É¥ó¸ê®Æ ¦]¬°²{¦b¤t´¶·s¬F¾Ç¦WÃÄ°e¥ó«á¢î¢ì¢é·|©ó¤@¦~¤º¼f§¹ ©Ò¥Hì«h¤W¶¶§Qªº¸Ü¤@¦~¤º´N·|¦³µ²ªG¡]¬Ý¬O®ÖµoÃÄÃҩάOn¨D¸É¥óµ¥¡^ ¤£¹L·íµM¦pªGfdan¨D¦b¸É¤@¨Ç¸ê®Æªº¸Ü®Éµ{´N·|¦A¦³©Ò±À©µ ©Ò¥H´N¦bµ¥µ¥§a¡@¦pªG©ú¦~ªÑªF·|ÁÙ¨S¦³ÃÄÃÒªº®ø®§®É «¥Ì¦A¨Ó°Ý°Ý¬Ý¬O§_¢î¢ì¢é¦³n¨D¸É¥ó¡K¡K |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/8/20 ¤U¤È 10:08:24²Ä 11 ½g¦^À³
|
Hi ¦U¦ì¤j¤j ¤fªA¯Ø®q¯À´N¤p§Ì¤F¸Ñ¶}µoÃø«×«D±`ªº°ª ¦]¬°¤£ºÞ¬O¦å¿}¹L§C©Î¹L°ª¨Åé³£¨S¿ìªkt²ü ¥[¤W¨CÓ¤H¨Å骬ªp³£¤£¤Ó¤@¼Ë ©Ò¥H¶}µoÃø«×¥i»¡¬O·¥°ª ¥Ø«e³o¤@°Ï¶ôì¥ý»â¥ý¦b¦]µØ«e±ªº¦³ ì¯Ø®q¯À¤@¤èÅQ¥DNovo Nordisk¸ò¥H¦â¦C¤½¥qOramed Pharmaceuticals¡]ORMP¡^ ¤£¹L´N¦b«e¤£¤[Novo Nordisk¤]«Å§i¥¢±Ñ©ñ±ó¤F ¦Ó¬Û¸ûOramed Pharmaceuticals¶}µoªº¤fªA¯Ø®q¯À¦Ó¨¥ ¦]µØªº¯Ø®q¯À¨ãQuick Onset & Fast Working-BestªºÀu¶Õ¡]¸Ô¨£¥h¦~9¤ë¥÷ªk»¡¸ê®ÆP21¡^ ¤]¦]¬°ORMP¤½¥qªº¤fªA¯Ø®q¯À¤´§ïµ½ªºªÅ¶¡¬G¥Ø«e°ê¥~¤ÀªR®v¹w¦ô ORMD-0801 won¡¦t replace insulin injections, but could delay the need for them ¡]¸Ó²£«~ÁöµMµLªk¨ú¥N¥Ø«eª`®g«¬ªº¯Ø®q¯À¦ý¦o¥i¥H©µ½w¨Ï¥Îªº»Ý¨D¡^ The major difference between diabetes and almost any other niche market in healthcare is that the diabetes market can be changed fundamentally just by altering the insulin administration route.¡]¿}§¿¯f¥«³õ©M¨ä¥Lªº¯e¯f¬Û¸û¤U·|¦]¬°ª`®gÀW²vªºÅܧó¦Ó¨Ï¾ãÓ¥«³õ¦³¤Ñ½¦aÂЪº§ïÅÜ¡^ Generally speaking, making an injectable therapy orally available increases sales, patient compliance, outcomes, etc. But with diabetes, if an oral route to insulin administration makes it to market, it could change things in a much more fundamental way.¡]¤fªA¯Ø®q¯Àªº²£¥Í¤£¶È¥i¼W¥[¾P°âÃB¤]¥i¼W¥[¯f±wªº¨Ì±q©Ê¶i¦Ó¼vÅTªvÀø®ÄªGµ¥µ¥±N¨Ï¾ãÓ¥«³õ²£¥Í¤Ñ½¦aÂЪºÅܤơ^ ¸Ó¤ÀªR®v¬Ý¦n¢Ý¢à¢Û¢Þ¤½¥q·sÃĦp¯à¦¨¥\¥i¥H¦b¬ü°ê¢¶¢¯¢¯¢Ð¥«³õ¤¤¨ú±o¤@®u¤§¦a¡K¡K ¥Ø«eORMP¤½¥q±N¦b¢·/31©Mfda¶}·|°Q½×¤T´Áªºprotocol °w¹ï¦]µØªº¤fªA¯Ø®q¯À¦Ó¨¥¤p§Ì¬O¥H¬°¦p¯à¦¨¥\¶}µo±N¬O¦]µØªº¯µ±KªZ¾¹ ²¦³º¸Ó¥«³õ«D±`¥¨¤j¥B¥Ø«e«e±¶È¦³ORMP¤½¥qªº¤fªA¯Ø®q¯À ¦Ó¸Ó¤fªA¯Ø®q¯À¤´¦³¬Û·í¤j§ï¶iªÅ¶¡¡]±q¤fªA¨ìµo´§®Ä¥Î®É¶¡ªøµ¥µ¥¡K.¡^ ¤£¹L¦]¤fªA¯Ø®q¯À¤´³B©óÁ{§É«e Â÷ÃĪ«¤W¥«ÁÙ¦³«D±`¦h¦~ªº®É¶¡ ¬G¥Ø«e¤p§Ì¶È¬OÃöª`¦ý¦Û¦æ¦b°µ¦]µØªºµû»ù®É¨Ã¥¼§â³o¤@¶ô¦ô¶i¥h¡K.. ¦Ü©óÃĪ«¶i¤@´Áªº®Éµ{¶Ü¡K..ªÑªF·|±o¨ìªº°T®§¬O©ú¦~¶i¤@´Á¡K. ¤£¹L¨ä¹ê·sÃĶ}µoÅܼƫܤj¥[¤W¸ÓÃĪ«ªºÃø«×«D±`ªº°ª ©Ò¥H¥¼¨ÓÁ{§É«e¶¥¬q¦p»Ý¥[¤J§ó¦hªº§ï¨}¾ÉP®Éµ{¦³©Ò±À©µ ¤p§Ì¬Oı±oÁÙ¦nÁ`¤ñ¯{¤j¿ú¤U¥hµo²{ÃĪ«³]p¦³°ÝÃD©Î¬OÁ{§É³]p¦³°ÝÃD¨Óªº¦n¡K¡K. |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2017/8/19 ¤W¤È 10:41:16²Ä 10 ½g¦^À³
|
COMPANY OVERVIEW Can provide in the development of a specified oral pharmaceutical product involving the Drug delivery system service based on the OralPas and OralPas Pro platform. Product Name: oral gemcitabine, oral insulin, carvedilol CR Product Description: Oral Gemcitabine: will be into Phase 2/3 study the second half in 2017, it was developed based on OralPAS platform. Oral Insulin: will be into phase 1 study in 2018, it was developed based on OralPAS Pro platform. ¤µ¦~AAPSªºÂ²¤¶¡A¤fªA¯Ø®q¯À¹wp©ú¦~¶iphase1,¦ü¥G¬O²Ä¤@¦¸§ì¥X¹w¦ôªº®É¶¡ÂI¡A§Æ±æOralPAS Pro¯à¸Ñ¨M¤§«e¹J¨ìªº§xÃø ¥t¥~¦³¤Hª¾¹DÅã¼v¾¯ªºª¬ªp¶Ü¡HÃÄÃҥӽЦn¹³¤ñ¤@¯ë¾Ç¦WÃĪº¥§¡®É¶¡¨Ó±oªø¤F |
|
|
·|û¡GSam Lee10136780 µoªí®É¶¡:2017/8/18 ¤U¤È 02:51:28²Ä 9 ½g¦^À³
|
µ¥³oªi¼W¸êªÑ¶}©l¥æ©ö¶R½æ«á,ªÑ»ù·|¶}©l¦^öÜ? |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2017/8/16 ¤U¤È 01:37:36²Ä 8 ½g¦^À³
|
¤@¡B¿³ÂdªÑ²¼¥N¸¹¡G4172¡C ¤G¡B¿³ÂdªÑ²¼ºØÃþ¤Î¼Æ¶q¡G´¶³qªÑ6,388,000ªÑ¡C¡]§tû¤u¹S³ÒÂà¼W¸ê 0 ªÑ¡^¡C ¤T¡B¿³ÂdªÑ²¼¶}©l¶R½æ¤é´Á¡G¥Á°ê 106 ¦~ 08 ¤ë 17 ¤é¡C ¥|¡B¿³ÂdªÑ²¼Åv§Q¸q°È¡G»Pì¤wµo¦æ¤§ªÑ¥÷¬Û¦P¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/8/13 ¤U¤È 02:38:42²Ä 7 ½g¦^À³
|
Hi cstang¤j ªì¬Ý¨ì¦¹¤½§i®É¤p§Ì¤]¬O«Ü¶Ì²´ ¾Ú¤p§Ì¤F¸Ñ¸ÓºM¥ó¨Ã«DÃĪ«¥»¨¤§°ÝÃD¥ç«D¦]µØ¤½¥q¤§ì¦]©Ò¾ÉP ¥u¯à»¡¤½¥q¦³ÂIµL¶d¨ü¨ìªi¤Î...... ¥Ø«eCarvedilol CR¦b¬ü°ê¥«³õ¤§¶i«×¡B¥«³õ¤Î©w»ù¾Ú»DÀ³¸Ó¤£·|¨ü¦¹¤@¨Æ¥ó¤§¼vÅT ¹ï¤½¥q¥i¯à¤§¼vÅTÀ³¸Ó´NÄÝ¥xÆW°ÏªºCarvedilol CR¤W¥«®Éµ{¥i¯à·|¨ü¼vÅT ¤£¹L¦]¥»¨Ó¥xÆW¥«³õ´N¤£¤j¥[¤W¤½¥q쥻´N¶È¯à©â¨ú¤@©w¤ñ²vªºÅv§Qª÷¦Ó¤w ©Ò¥H¹ï¤½¥q¹ê½èÀ禬¼vÅT¤WÀ³¸Ó¤£¤j..... |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2017/8/13 ¤U¤È 02:07:14²Ä 6 ½g¦^À³
|
ªF¥ÍµØºM¾P¤ß¦åºÞ°ª¦åÀ£·sÃÄCRTA04(¦]µØ¶}µoªF¥ÍµØ¥xÆW¤T´Á§¹¦¨¨Ã©ó¥h¦~©³¥Ó½Ð¥xÆWÃÄÃÒ¡^¡A»¡¬O¦]¬°°Ó·~¦X§@²z¥ÑºM®×¡H¬°¦ó¡K¡K«ç¸Ñ¡A¤j¤jÌ©ú¥Õ¶Ü¡H |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/8/1 ¤W¤È 10:42:54²Ä 5 ½g¦^À³
|
¤½¥q¥Dn²£«~Gemcitabine¤fªA·sÃĶi¤JÁ{§É¤G´Á¤F.... ¥[ªo¦b¥[ªo! ¥»¤½¥q¬ãµo¤¤ Gemcitabine¤fªA·sÃÄÀò±o¬ü°ê¹«~ÃĪ«ºÞ ²z§½ (US FDA) ³q¹L¤HÅéÁ{§É¸ÕÅç¼f¬d(IND)¡A ®Öã¦P·N¦]µØ¥Í§Þ°õ¦æÁxºÞÀù¤HÅéÀø®Ä¡BÃĪ«°Ê¤O¾Ç¤Î¦w¥þ©ÊÁ{§É¸ÕÅç¡C »¡©ú 1.¨Æ¹êµo¥Í¤é:106/08/01 2.¤½¥q¦WºÙ:¦]µØ¥Í§Þ»sÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GD07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) ¤G¡B¥Î³~¡GªvÀøÁxºÞÀùªº Gemcitabine¤fªA·sÃÄ ¤T¡B¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¤G´ÁÁ{§É¸ÕÅç ¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G¤w§¹¦¨¬ü°ê¤HÅéPK¸ÕÅç»P¥xÆW¤@´ÁÁ{§É¸ÕÅç (¤@)´£¥X¥Ó½Ð¡þ³q¹L®Öã¡þ¤£³q¹L®Öã¡G³q¹L¬ü°ê¹«~ÃĪ«ºÊ·þºÞ²z§½¥Ó½Ð¦h°ê¦h¤¤ ¤ßªºÁxºÞÀù¤HÅéÁ{§É¸ÕÅç(IND No.¡G129288)®Öã (¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î (¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G§ÜÀù·sÃĤG´ÁÁ{§É¸ÕÅç«á¡A±N µø¨u¨£Àù¯g¤§Á{§ÉªvÀøµ²ªG¡A¨Ó¨M©wÂX¤jªvÀø¤H¼Æ©Î¦Ò¼{¦V¬ü°ê¹«~ÃĪ«ºÊ·þºÞ ²z§½´£¥X·sÃĥӽСC (¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¦]¯A¤Î¥¼¨Ó°ê»Ú±ÂÅv½Í§P¸ê°T¡A¬°ÁקK¼vÅT±ÂÅvª÷ÃB¡A ¥H«O»Ù§ë¸ê¤HÅv¯q¡A¼È¤£´¦ÅS¡C ¤¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G (¤@)¹wp§¹¦¨®É¶¡¡GY¤@¤Á¶¶§Q§¹¦¨¡A¹wp¦b108¦~2¤ë§¹¦¨¦¬®×¡C (¤G)¹wpÀ³t¾á¤§¸q°È¡G¸Ó¤p¤À¤l·sÃÄ«Y¦]µØ¥Í§Þ¿W¥ß¬ãµo¡A¾Ö¦³100%±M§QÅv¡A«Ý§¹ ¦¨¨Ã³q¹L¬ü°ê¹«~ÃĪ«ºÊ·þºÞ²z§½n¨D¤§¬ÛÃöÁ{§É¸ÕÅç§Y¥i¥Ó½Ð¤W¥«¡C 6.¦]À³±¹¬I:µL¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A§ë ¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/7/22 ¤U¤È 11:28:12²Ä 4 ½g¦^À³
|
°w¹ï¦]µØ¤p§Ìı±o¥L¦b·sÃĪѤ¤ºâ¬O·ÀI¸ò³ø¹S¤ñ¸û§¡¿Åªº ¦]µØ¦b³Ð¥ß®É§Y¦Ò¶q¨ì·sÃĵo®i·ÀI¤j©Ò¥H±Ä§xÃø¾Ç¦WÃÄÁÙ¦³ ¥Hµo®i¤fªA§Þ³N¥¥x¨«505 b2ªº¤è¦¡¨Óµo®i·sÃĦhºÞ»ô¤U¨Ó°§C·ÀI (¤p§Ì¬Û·í»{¦P«¼CµL¾W«e½ú©ÒÁ¿ªº:°ª§Q¼í = °ª·ÀI ©Ò¥H¦b¯A¤J·¥²`¤ô°Ï(·¥°ª·ÀI)ªº·sÃĪѮɡA ¤p§Ì¤]¬O°¾¦n¿ï¾Ü¤@¨Ç·ÀIȬ۹ï¤W¤ñ¸û¥i¥H±±¨îªº·sÃĪÑ)¡A °w¹ï¦]µØ¤p§Ìı±o¥LªºÀu¯ÊÂI¦p¤U: ÀuÂI: 1.²£«~½u¦h¥B§¹¾ã:µu´Á°ò¥»½L¦³¤w¸g¦b¥xÆW¤W¥«ªº·sÃÄ¡B¥Ó½Ð¥xÆWÃÄÃÒ¤¤ªº·sÃÄ¡B ¤w¦b¥@¬É¦h°ê¤W¥«ÄÝ©ófirst genericªº§xÃø¾Ç¦WÃÄ¡A ¤¤´Á¦³¤w¸g¦b¬ü°ê¥Ó½ÐÃÄÃÒÄÝfirst genericªºÅã¼v¾¯ ÁÙ¦³§Y±N¶i¤J30~40¤H¼Ï¯Ã©Ê¹êÅ窺505b2·sÃÄ(¥xÆW¤w¥Ó½ÐÃÄÃÒ)¡A ªø´Á«h¦³oral Gemcitabine¸ò¤fªA¯Ø®q¯À³o¨â¶µ505b2·sÃÄ¥¬§½¬Û·íªº§¹¾ã 2.¤½¥q¥«È¶È¬ù17»õ¤£¶È³sÂi±¤W¤@½u¥Í§Þ¤½¥q¥«È¹sÀY³£¤£¨ì¡A ´N³s¦b¿³Âd¤¤¦h¼Æ¤G½uªº¥Í§ÞªÑ¥«È¤]¬O¥Lªº¦n´X¿¡K¡K (well¦]µØÁöµMµu´Á¤º¤£¤Ó¥i¯à¦¨¬°¤H¤HºÙ¸rªº©ú¬P¿ï¤â¡A¦ý¥Lªº¤T¤j¥D¤O²£«~: 1.§xÃø¾Ç¦WÃÄ 2.°ª¦åÀ£ÃÄ 3. oral Gemcitabine ¥un¦³¤@¶µ¦bªk³W¥«³õ¯à°÷¤W¥«¥i³Ð³yªºÀ禬À³¸Ó»·°ª©ó¥Ø«e¥«È«D±`«D±`¦hªº (¥Ø«e1¸ò2¤w¸g¨«¨ìºâº¡«á±ªº¶¥¬q¤F¡A¦Ó¥B¦¨¥\¾÷²vÀ³¸Ó«Ü°ª¡A 3.ÁöµM¥Ø«e¥u¬O±N¶i¤J2´Á¶¥¬q¦ý°²¥H®É¤é¦¨¥\²v¬Û¸û¤@¯ë¨ä¥L¤½¥q·sÃĦ¨¥\²vÀ³¸Óºâ°ªªº) 3.¥D¨ÆªÌªº¸gÅç¤Î§Þ³N¡F¬Û¸û©ó¨ä¥L¤½¥q¦]µØ¥Dn§Þ³N¨Ó¦Û©ó¤½¥q¬ãµoªø°q³Õ¤h ¡A¦]¬°§Þ³N¬O¦Û¤vªº¥[¤W¹L¥h¦bÃħޤ¤¤ß¦h¦~ªº¸gÅç Åý¤½¥q¥i¥H¤£Â_¦a¬ãµo·sªº§Þ³N(¤ñ¦p»¡¤fªA¯Ø®q¯À´N¬O¤fªA§Þ³N¥¥x·s¤@¥Nªº§ï¨})¡A ¥t¥~Á`¸g²z³\³Õ¤h«h¦³¦h¦~°ê¥~Ãļt¤u§@¸gÅç¡A ¬Û¸û©ó¨ä¥L¥Í§Þ¤½¥q¦]µØ³o´X¦~¸ò³\¦hÃļt¤w¸gñ¤F³\¦hªº±ÂÅv¦X¬ùºâ¬O¸gÅç¬Û·íÂ×´Iªº¡C 4.¤½¥q¦U¶µ·~°È·~°È°õ¦æ¤O¤Î¦U¶µ©Ó¿Õ¨Æ¶µ¤§°õ¦æ¡G ¤½¥qªº°õ¦æ¤O¸ò¸Û«H§Ú·Q¬O§ë¸ê¤@®a¤½¥q³Ì«nªº¶µ¥Ø¡A¦Ó³o¤@ÂI»Ýnªø®É¶¡ªºÆ[¹î¡A §ë¸ê¨â¦~¦h¥H¨Ó¥Ø«e¬Ý°_¨Ó¬OÁöµM¦³¨Ç¶i«×µy¦³¿ð©µ¤£¹L¦b·sÃĪѤ¤À³¸ÓÁٺ⤣¿ùªº (°O±o¥h¦~ªÑªF·|¦³ªÑªF°Ý¨ì°ª¦åÀ£ÃÄ¥xÆWªº¶i«×¡A ·í®É¤½¥qªí¥Ü¤w±µªñ§¹¦¨À³¸Ó¦~©³¥i¥H¥Ó½ÐÃÄÃÒ¡A µ²ªG©~µM¯uªº¦p´Á¦b¦~©³¥Ó½ÐÃÄÃÒ¡A¯uªº¬O«Ü¶^¯}²´Ãè¡A ¦Ñ¹êÁ¿¦b§ë¸ê¥Í§Þªº³o6~7¦~¡A¬ü°ê¤½¥q¬O¦³³¡¤À¯uªº¯àon schedule ¦Ó¦b¥xÆW«h¦]¬°·sÃĬãµo°ª«×ªº¤£½T©w©Ê¸ò±M·~©Ê¥[¤W¤S¬OÄÝ©óèµÞªÞ¶¥¬q¡A ´N³s¤p§Ì¦h¦~«e§ëªº¤½»{¬O¥Í§ÞÁZÀu¥Íªº¤¤¸Î¤]¬O±`¦³¶i«×¿ð©µªº°ÝÃD 2.¥t¥~¥»¦¸²{ª÷¼W¸ê¤jªÑªF¤]«H¦uªÑªF·|©Ó¿Õ½T«O²{¼Wªº¦¨¥\¡A ¥Ø«e¬Ý¨Ó¦b³o¤@³¡¤ÀÀ³¸Ó¤]ºâ¬OÁÙ¥i¥Hªº) ¯ÊÂI³¡¤À 1.¸êª÷°ÝÃD:¦]µØ¬Û¸û¤W¨S¦³¦W¤H¥úÀôI«á¤]¨S¦³¤j°]¹Îªº¤ä«ù¡A ©Ò¥H¬Û¸û¤W¶Ò¸ê¬O¤ñ¸û§xÃøªº¡A³o¤]¬O¤@ª½¥H¨Ó¤p§Ì¤ñ¸û¾á¤ßªº¤@ÂI¡A ¤£¹LªÑªF·|«á¸ò¤½¥q²á¹L¡A¤½¥q¹ï©ó¦U¶µ²£«~ªº±ÂÅv©Î¬O°Ï°ì±ÂÅv±Ä¨ú¶}©ñªººA«× ¥[¤W¦³³W¹º¤WÂdªº¥´ºâ¡A¦pªG³o¨â¶µ¦³¨ä¤¤¤@¶µ¦¨¥\À³¸Ó¥i¼È¸Ñ¸êª÷ªº°ÝÃD¡C 2.¤½¥qµu´Á¤º¨S¦³¶i¤JÁ{§É«á´Áªº©ú¬P²£«~¡G ¬Û¸û©ó¦h¼Æ¥Í§Þ¤½¥q²£«~¸¹ºÙ¥«³õ¼Æ¤Q»õ©Î¬O¦Ê»õ¬üª÷ªº¡A ¤½¥qªºµ¦²¤¬O¨«niche marketªº¤è¦¡¡A©Ò¥H¬Û¸û¤W¦W®ð¸û¤£ÅT«G (¨ä¹ê¤fªA¯Ø®q¯À¥«³õ·¥¤j¡A¤£¹LÂ÷¤W¥«ÁÙ¦³10¦~¥H¤W´N²¤¹L¤£´£¡K¡K)¡A ³oÂI¤p§ÌˬOı±oÁÙ¦n ¦]¬°¥Lªº¥«È¶È¦³¤H®aªº¹sÀY¡A ¦pªG§â¥«È¦]¯À¯Ç¤J¦Ò¶q»¡¤£©w¥L¥¼¨Ó¤Wº¦²L¤O¤£¿é¥i³\¦h¤@½u¥Í§Þ¤½¥q? 3.Äw½X°ÝÃD¡G §ë¸ê¦]µØªº³Ð§ë·~ªÌ¦]¬°³Ð§ëªº¨î(¦~7¦~)©Ò¥H¦b«e°}¤l¥²¶·¥X²æ«ùªÑ¶¡±µ³y¦¨«e°}¤lªº½æÀ£¡C ¨ä¥L¯ÊÂI³¡¥÷¦U¦ìª©¤Í¦pªG¦³·Q¨ìªº¸ÜÅwªï¸É¥R¤F (¤p§Ì§ë¸ê¥Í§Þ¤@¦V¬O¥ý±q§ä¥Lªº¯ÊÂI¶}©l: ¦]¬°¥Í§Þ¹ï©ó§Ú̧ë¸ê¤H¨ÓÁ¿¯uªº¤Ó±M·~¤F¡A¶È¤@¬N¦a¬Ý¨ì¤½¥q¦nªº³¡¤À¨ä¹ê®e©ö¦³°¾¨£ªº²£¥Í¡A¶¡±µ³y¦¨§ë¸êªº¥¢§Q¡K¡K) |
|
|
·|û¡Gcstang10139565 µoªí®É¶¡:2017/7/22 ¤U¤È 03:31:01²Ä 3 ½g¦^À³
|
¦n¤½¥q ´Nȱo§Ú̵¥«Ý.............ªáÁ`¬O·|¶},¶X§C¥¬§½,®i±æ¥¼¨Ó ¯E¹©®×«á ¥xÆW¥Í§ÞÃþªÑ¶i¤J¥V¯v´Á 2017/07/22 10:08 ¤¤¥¡ªÀ ¡]¤¤¥¡ªÀ°OªÌÁú´@´@¥x¥_2017¦~7¤ë22¤é¹q¡^2014¦~°ò¨È¨Æ¥óÅý¥Í§ÞªÑ±q¶³ºÝ¶^¸¨¨¦©³¡A§ë¸ê¤H¾l±ªµS¦s¡F2016¦~¦A«×Ãzµo¯E¹©¨Æ¥ó¡A¼É·°é§óÂX¤Î¨ì¬F°Ó¼h±¡A§ë¸ê¤H«H¤ß¥Ë¸Ñ¡A¤]Åý¥Í§ÞÃþªÑªº¤H®ð«æá¡B¶i¤Jº©ªøªº¥V¯v´Á¡C ªñ¨Ó¤£¤Ö¥Í§Þ·~¥D³´¤JµJ¼{ª¬ºA¡A·P¹Ä¥x¥_ªÑ¥«¯¸¤W¸UÂI¡A°ß¿W¥Í§ÞªÑÁÙw¦b¦a¤W¡Cªñ4Ó¤ëÂdÂi¶R½æ¤¤¤ß¥ÍÂå«ü¼ÆÁÙ°±¯d¦b¤µ¦~¥H¨Ó§CÀÉ°Ï130¦Ü140ÂI¶¡¾_Àú¡A¬Û¸û2014¦~ªº°ªÂI245.4ÂI´Xªñ¸y±Ùª¬ºA¡F³æ¤éÃþªÑ¦¨¥æ¶q§ó¬O°¨ì·s¥x¹ô20»õ¤¸¥H¤U¡A¦¨¥æ¥e¤ñ°¨ì10%¥H¤U¡A¬Û¸û2015¦~®Éªº36%¾ú¥v°ª®p¦³¦p¤ÑÄ[¤§§O¡C ¡u¥Í§ÞªÑ¨ì©³«ç»ò¤F¡H¡v¡B¡u¨ì©³n«ç»ò±Ï¥Í§ÞªÑ¤~¯à°_¦º¦^¥Í¡H¡v¡B¡u¥Í§ÞªÑÁÙ¦³±Ï¶Ü¡H¡v¤j·§¬O³Ìªñ¥Í§Þ¬É¨£±®É³Ì±`Å¥¨ìªº¶}³õ¡C¥¢¥h¤F¥«³õ¥úÀô¡A¥Í§Þ¤½¥qº¥ý±Á{ªº¬OÄw¸ê§xÃøªº°ÝÃD¡C ¥Í§ÞªÑ±q¹L¥h§ë¸ê¥«³õªº·í¬õ¬µ¤lÂû¡AºtÅܦ¨¦p¤µªº¡uÄF§½¡v»¡¡A§ë¸ê¤H«H¤ß±Y½L¡B§N²H¥H¹ï¡A¹ï¥Í§ÞªÑÁפ§¬°®£¤£¤Î¡C §Y¨Ï¤µ¦~¥H¨Ó¤£¤Ö¥Í§Þ·~ªÌ§¤¾Ö§Q¦h¡A¦b·sÃĬãµo¤WÀò±o«¤j¶i®i¡A¥«³õ¨Ì¡uµL·P¡v¡AªÑ»ù¤´µM¤£°Ê¦p¤s¡A§ó¦³¤£¤ÖӪѪѻù¸y±Ù¦A¸y±Ù¡A¯}©³¦A¯}©³¡A¥O¤H¦³¡u²`¤£¨£©³¡vªº®£·W¡F¤£¤Ö¤HÂk©S¬O¡u°ò¨È©M¯E¹©·Sªºº×¡v¡B¡u¥«³õª£§@¹LÀY¡v¡A§â§ë¸ê¤HÀ~Ãa¤F¡A¤]À~¶]¤F¡C ¡u²z·Q«ÜÂ׺¡¡B²{¹ê«Ü°©·P¡v¡A¯«¶©³Ð¿ì¤Hº[«eÁ`¸g²z¡B¥Ø«e¬O¬ü°êºû±ï¸ê¥»¡]Vivo Capital¡^³Ð¿ì¦X¹Ù¤H°¨®ü©ÉÂI¥X¤F¥Í§ÞªÑªº¯S©Ê¡C °¨®ü©É´¿«ü¥X¡A¥Í§Þ²£·~¦³«Ü¤j¤@³¡¤À¬O¬ì¾Ç¡A¦³¤Ó¦h¥¼ª¾¡A¥²¶·ªø®É¶¡¦LÃÒ§ä¨ì¹ïªºµª®×¡A¤£¦P©ó¹q¤l·~¡F¥xÆW¥Í§Þ²£·~µo®i¤£¹L´X¤Q¦~¡A»P°ê»Ú³Ì¦¨¥\ªº¨Ò¤lÁÙ¦³¤£¤p¶ZÂ÷¡A¤£¯à¦³¤Û·Q¡A·Qn¤@¨Bµn¤Ñ³£¬O§@¹Ú¡C ªÀ¹Îªk¤H°ê®a¥Í§ÞÂåÀø²£·~µ¦¶i·|·|ªø±iµ½¬F¤]»{¬°¡A·sÃĬãµo¸Ñª¼µL½×¦¨¥\©Î¥¢±Ñ³£¬O¥¿±`¡A¯à±q¥¢±Ñ¤¤§ä¨ì¹ïªº¤è¦V¤~¬OÃöÁä¡C ¥LÁ|¬ü°ê¥Í§ÞÀsÀYAmgen¬°¨Ò¡A¦b¬õ¦å²y¥Í¦¨¯À(EPO) ¦¨¥\¤W¥««e¡A¤]¦³«Ü¦h¼Ðªº¦b¬ãµo¤¤³~´N¥¢±Ñ¤F¡A¨S¦³¤§«eªº¥¢±Ñ¡A´N¨S¦³«á¨ÓÁȶi¤W¦Ê»õ¬ü¤¸ªº¾÷·|¡C¯E¹©¨Æ¥ó¤Þ°_²³¤HÆf¥Ø¡A¥Dn¬O¦]¬°¦b·sÃÄÁÙ¨S¦³¤W¥««eªÑ»ù¹L¼ö©ÒP¡C ±Á{²{¶¥¬q¥«³õ«H¤ß±Y½Lªº³B¹Ò¡A¥Í§Þ·~ªÌªí¥Ü¡A¦b¿E±¡¹L«á¦^Âk°ò¥»±¨S¤°»ò¤£¦n¡AÁ`¬O¦b°h¼é«á¤~¯àµo²{¬O½Ö¦b»rªa¡A³o¬O¥Í§Þ²£·~¥²¸gªº¹Lµ{¡A¤]¬O¥«³õ¾÷¨î¥²¸gªº¸ô¡C ·~ªÌ»{¬°¡A¥ø·~¤@¨B¤@¸}¦L§â¨Æ±¡°µ¦n¡A¥«³õ«H¤ß¦ÛµM·|¦^¨Ó¡A¥Í§Þ·~¤£»Ýn±Ï¡A¥u¯à¾a¦Û¤v§â¼Æ¦rú¥X¨Ó¡A¦¨¥\¤~·|°Á{¡F¤£¹L¡A¥Í§Þ·~½T¹ê¤£¦P©ó¨ä¥L²£·~¡A«D2¡B3¦~´N¯à¬Ý¨ì¦¨ªG¡A¡u¤Q¦~¿i¤@¼C¡v¬O°ò¥»ªº¡A§ë¸ê¤Hn¦³¤@©wªº»{ª¾¡AÁ`¤£¯à¸Ñª¼¥¢±Ñ´N§ì°_¨ÓÃö¡A³o¬O¤£¹ïªº¡C ¿E±¡¹L«á¡A§ë¸ê¤H¥á¤F«H¤ß¡B¦ý¦h¤F²z©Ê¡A¬Û«H¹ï¥Í§ÞªÑÀ³¸Ó¥H¡u²z©Ê¬Ý«Ý¡v¡BÁÙ¬O¡u·P©Ê´Á«Ý¡v¡A¤ß²z¤w¦³¤@§â¤Ø¡C¶Ë²ª²Ö²Öªº¥Í§ÞªÑ¦ó®É¤~¯à¨Ó¨ìÀG¹DºÉÀY¡B¨£¨ìÀÆ¥ú¡H¨S¤Hµ¹±o¥Xµª®×¡F¤£¹L¡A´H¥V¹L«á±µµÛ´N¬O¬K¤Ñ¡A¬O¤£Åܪº©w«ß¡C |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/7/15 ¤U¤È 02:21:26²Ä 2 ½g¦^À³
|
1.§xÃø¾Ç¦WÃij¡¤À:¦]µØªºÅã¼v¾¯³¡ªù(¹Å¦h©ú ¹Å¦hµø«Ø¤Î¬ãµo¤¤ªº¨ä¥LÃÄ«~) ¥H¤Î¨u¨£¯e¯f¦]¸¿Õµ¥³o¨ÇÃÄ«~¨ä¹ê¦b³¡¤À°ê®a³£¤w¤W¥«¡A ¨ä¤¤¹Å¦h©ú·~¤w¥Ó½Ð¬ü°êÃÄÃҨéó¥h¦~±µ¨üFDA¬d¼t¨Ã§¹¦¨¬d¼t«áªº¸É¥ó (¥Ø«eì¼tÃĦb¬ü°ê¾P°âÃB¬ù8000¸U)¦b¬ü°ê¦X§@¼t°Ó¬°NASDAQ±¾µP¤½¥qAkorn(Fresenius) ³o¨Ç¾Ç¦WÃĩΦ]¦³¥Í²£¤Wªº°ª¬r©Ê¡B¥[¤W»sµ{»P®Æ·½¨ú±o¤WªºÃø«×¥Ø«e³£¬OFirst Generic ¨S¦³·N¥~ªº¸Ü¤W¥««á¨ú±o¤@©wªº¥«¥eÀ³Äݤ¹·í¥i´Á (¥Ø«e¥þ²yì¼tÃľP°âÃB:¹Å¦h©ú¬ù3»õ¬üª÷ ¦]¸¿Õ3.46»õ¬üª÷) 2.·s¾¯«¬·sÃij¡¤À: Carvedilol CR¦b104¦~8¤ë±µÀòfda¨Ó¨ç¦P·N¥i¥HÂÇ¥Ñ505(b2)³~®|¡A ¹ê¬I¥ÍÅé¬Ûµ¥©Ê¸ÕÅç¡]§Y¬°24-48¤H¤§¤fªA«á48¤p®É¤º¦å ¤¤¿@«×´ú©w¤§¥ÍÅé¬Ûµ¥©Ê¸ÕÅç¡^«á¡A§Y¥i¶i¦æ¬ü°ê¥Ó½Ð·sÃĨúÃÒ¡C ¦¹¥~¦b¥xÆW³¡¤ÀªF¥ÍµØ«h¬O¥H·sÃijW®æ¨Ó°µÁ{§É¸ÕÅç·~¤w¦b105¦~12¤ë¥Ó½Ð¥xÆWÃÄÃÒ ¥Ø«e¬ü°ê¥«³õ³¡¤À¶i«×¨ì¤FÁ{§É¸ÕÅçÃĪ«ªº¥Í²£¡A¨S·N¥~ªº¸Ü¨úÃÒ¾÷²vÀ³¸Ó¬O«Ü°ªªº ¸ÓÃĪ«²L¦b»ùȨ̾ڤ½¥q©e°U¥«½Õ¾÷ºc¬ã¨s¦³2»õ¬üª÷¥ª¥k Gemcitabine Oral¬O¤ÆÀøÃÄGemcitabineªº¤fªA¾¯«¬¡A¸ÓÃĪ«¤w¸g§¹¦¨Á{§É¤@´Áªº¹êÅç ¥B¤w¨ú±o©t¨àÃĸê®æªº»{ÃÒ¡A§Y±N¶i¤J¤G´ÁÁ{§É¹êÅç¡A¦]Gemcitabine¤w¦³¤Q¦h¦~ªºÁ{§É ¨Ï¥Î¸gÅç¥[¤W¤@´ÁÁ{§É¹êÅç¦w¥þ©ÊÀu©ó¹w´Á¡A¦bÃĪ«¦¨¤À¬Û¦Pªº«e´£¤U¡A ¥¼¨ÓÁ{§É¦¨¥\¾÷²vÀ³¸Ó¤]»á¤j¡A¥t¥~Gemcitabine³o¤äÃĬ۫H¥xÆW³\¦h¥Í§Þ§ë¸ê¤HÀ³·í³£¤£¯¥Í ¦]¬°¥Ø«e³\¦h¶i¦æ¤¤ªºÁ{§É¹êÅç³£¦³¨Ö¥Î³o¤äÃÄ¡A¸ò¦UÃļt¨Ã¤£¥þµM¬OÄvª§Ãö«Y ¸ÓÃĪ«ªº¥«³õ»ùȨ̾ڤ½¥q©e°UIMS ªº½Õ¬d¬ù¦³15»õ¬üª÷..... |
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2017/7/15 ¤U¤È 01:43:20²Ä 1 ½g¦^À³
|
ªñ¦~¨Ó¤½¥qÀ禬¦h¥b¨Ó¦Û©ó´¶Àù¨O¥xÆW¥«³õ°^Äm ¸ÓÃĪ«¦b¤µ¦~3¤ë·~¤w¦V¥DºÞ¾÷Ãö¥Ó½Ð·s¾AÀ³¯g ¨S·N¥~ªº¸ÜÀ³¸Ó©ú¦~·s¾AÀ³¯g´N¥i¥H¶}©l°^ÄmÀ禬 ¥[¤WCarvedilol CRÀ³¸Ó¦³¾÷·|©ó¤µ¦~¦~©³©Î©ú¦~¨ú±o¥xÆW°ÏÃÄÃÒ ¥[¤W³o¤@¦~¦h¨Ó·~¤w©MAvir Pharma ²`¦`¥«Ã¹¯ÀÂåÃĦ³¤½¥q¤ÎÁú°êBL&H¤½¥q ñq¦U¼Ë§xÃø¾Ç¦WÃĪº¸g¾P¦X¬ù ³æ¥H¥Ø«e´x´¤ªº¸ê°T¥¼¨Ó´X¦~À禬«ùÄò¦¨ªøªº¹w´ÁÀ³©|Äݤ¹·í.... ¦ý¨ä¹ê¦]µØ²L¤O»·¤£¥u¥Ø«e¥«³õ¬Ý¨ìªº³o¨Ç..... ¥¼¨Ó¦]µØÀ禬¤j´T¸õ¤ÉªºÃöÁä¦b©óªk³W¥«³õªº¨úÃÒ, ºX¤Uȱo´Á«Ýªº²£«~¥i¥H¤À¦¨¤U¦C¨â¤j³¡¤À¨Ó¬Ý 1.§xÃø¾Ç¦WÃÄ:Åã¼v¾¯ ¨u¨£¯e¯f¥ÎÃÄ 2.·s¾¯«¬·sÃÄ: Carvedilol CR¤ÎGemcitabine Oral |
|
|
|